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Introduction and Research Purpose 
Breast cancer is the most commonly diagnosed cancer in North America and the second 
most common cause of cancer death in women. For early stage breast cancer (ESBC), it is 
well established that breast conservation therapy (BCT) and mastectomy are equivalent 
treatments for survival. Treatment for ESBC can therefore be viewed as preference 
sensitive care, where decision-making between treatment options should vary according to 
patient preferences. In Canada, interprovincial mastectomy rates vary greatly from 25% to 
68% between provinces with a national average of 38%. Saskatchewan has consistently 
reported the nation’s second highest mastectomy rate with the latest report showing 63% . 
There has been international research investigating why women choose mastectomy versus 
BCT, but there is limited data within Canada to explain these provincial variations. The aim 
of my thesis is to better understand Saskatchewan women’s choice between mastectomy 
and BCT in ESBC. In this dissertation, I have addressed the research objectives through four 
manuscripts outlined below 
 
Manuscript 1: 
To assess the current evidence, we conducted the first systematic review on the factors 
influencing women’s choice of mastectomy versus BCT in ESBC. 
 
Manuscript 2: 
To identify the factors that influence Saskatchewan women’s choice between BCT or 
mastectomy in ESBC, we conducted a province-based qualitative study which identified 
themes and subthemes influencing therapy choice. This was the first part of an exploratory 
mixed methods study. 
 
Manuscript 3: 
To help improve our understanding and organize our research, we created a conceptual 
framework of why women choose mastectomy versus BCT in ESBC. This framework was 
important in organizing our systematic review and guiding our survey. 
 
Manuscript 4: 
Finally, to understand decision-making influences of Saskatchewan women with ESBC, we 
conducted a province wide survey. Creation of this survey was grounded on our previous 
work and the second portion of our mixed methods study. 
 
Results and Conclusion 
Our research demonstrates treatment choices for Saskatchewan women with ESBC were 
primarily influenced by disease stage and individual belief factors. These findings would 
suggest that women are making their treatment choices predominantly based on individual 
values and preferences. The use of mastectomy and BCT rates as an indicator of quality of 
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 1 
CHAPTER 1: INTRODUCTION 
1.1 Research Problem 
In North America, breast cancer is the most commonly diagnosed cancer as well as 
the second most common cause of cancer death in women.(1) For early stage breast cancer 
(ESBC), it is well established that breast conservation therapy (BCT) and mastectomy offer 
equivalent rates of survival.(2–9) However, since the seminal National Institute of Health 
(NIH) Consensus Conference in 1991, the surgical literature has consistently recommended 
BCT as preferable to mastectomy.(10) A recent Canadian Partnership Against Cancer 
(CPAC) system performance report lays down similar guidelines: “BCT is therefore 
generally recommended for most women with Stage I or II breast cancer.”(11) In 
Saskatchewan, however, from 2007 to 2010, 65% of newly diagnosed breast cancer 
patients underwent mastectomy – the second highest mastectomy rate in Canada.(12) The 
choice of mastectomy versus BCT is a complicated decision-making process influenced by 
many factors.(13) The literature focused on identification of these factors with a view to 
treating ESBC exhibits heterogenous study design and offers only limited experimental or 
prospective evidence.(13–18) Accordingly, it is unknown whether the factors highlighted in 
the literature are generalizable to the Saskatchewan population. The aim of this thesis is to 
better understand Saskatchewan women’s choice between mastectomy versus BCT in ESBC, 
improving understandings of this complicated decision-making process and supplying 
physicians and administrators with a basis for future policy review and quality 




1.2 Objectives  
The objectives of this research are as follows: 
1. To assess the evidence related to women’s choice between BCT and mastectomy 
through a systematic review. 
2. To identify factors that influence Saskatchewan women’s choice between BCT 
and mastectomy in cases of ESBC. 
3. To compare and contrast underlying reasons behind the choice between 
mastectomy and BCT in cases of ESBC. 
4. To quantitatively examine the significance and weight of factors influencing 
Saskatchewan women’s choice between BCT and mastectomy in cases of ESBC. 
5. To understand the appropriateness of Saskatchewan’s surgical variation in 
mastectomy rates relative to the rest of Canada.      
1.3 Dissertation Organization 
This dissertation is a manuscript-based thesis structured around four manuscripts 
with accompanying introduction, background, transition, and conclusion chapters. The 
manuscripts include a systematic review, the creation of a framework, and a sequential 
mixed-methods study. No other systematic reviews have been published on this topic, so 
such an approach is important for synthesis of the literature and to inform our survey 
development. In the interest of time efficiency, we began our mixed methods study 
concurrent with the later stages of the systematic review. The mixed methods study began 
with an exploratory qualitative study, in which we identified influencing factors in decision-
making and their relationships with the choice between mastectomy and BCT in cases of 
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ESBC. As the initial research from the qualitative study and the review evolved alongside 
each other, the complexity of women’s reason for choosing mastectomy over BCT became 
clear, revealing the need for a guiding structure to help frame this work. During this time, I 
developed a conceptual framework to examine why women choose mastectomy versus BCT 
in cases of ESBC. This framework, in turn, helped guide the organization and analysis of 
both the systematic review and the subsequent survey. As a by-product of this 
interconnected process, the framework manuscript, after having been initially introduced 
in the systematic review, in chapter 2, is not is presented until chapter 6. The final 
component of this dissertation, representing the second phase of our mixed methods study, 
is a province-wide survey capturing a much larger sample of the population. Creation of this 
survey was grounded in the work of the systematic review, the initial qualitative research, 





CHAPTER 2: BACKGROUND LITERATURE 
 
2.1 Early Stage Breast Cancer Equivalent Survival 
 
 In 1991, the NIH Consensus Conference published recommendations on the 
Treatment of Early-Stage Breast Cancer.(10) The conference, which took place June 18 to 
June 21, 1990, brought together representatives of the American College of Surgeons, the 
American College of Radiology, the College of American Pathologists, the American Cancer 
Society, and the Society of Surgical Oncology. This was the first consensus panel to 
recommend breast conservation treatment as equivalent therapy to mastectomy for women 
who have ESBC. In fact, BCT was recommended as the ‘preferable’ primary therapy in the 
report: ‘Breast conservation treatment is an appropriate method of primary therapy for the 
majority of women with stage I and II breast cancer and is preferable because it provides 
survival rates equivalent to those of total mastectomy and axillary dissection while 
preserving the breast’.(10)  
The report defined breast conservation treatment as ‘excision of the primary tumor 
and adjacent breast tissue (also known as lumpectomy, segmental mastectomy, or partial 
mastectomy), followed by radiation therapy’. The report continued to state total 
mastectomy is an appropriate primary therapy when BCT is not indicated or selected. Both 
surgical therapies are accompanied by axillary dissection, which provides important 
prognostic information. These recommendations, and the distribution of the landmark 
studies, have radically changed breast cancer practice and generally align with the current 




 Six prospective randomized control trials that have examined mastectomy versus 
breast conservation therapy and radiation for early stage breast cancer. Whole breast 
irradiation was used in each of the trials and varied from 45 to 50 Gy.(4–8,21,22) Five of the 
six trials also employed a boost to the primary cancer site, whereas the National Surgical 
Adjuvant Breast and Bowel Project (NSABP) B-06 trial delivered a dose of 50 Gy to the 
entire breast without a primary site boost. No significant differences in survival rates were 
seen between the two treatments in any of the trials. This survival equivalence has been 
further confirmed in a meta-analysis of the prospective randomized trials.(9) In an update 
of guidelines for ‘Standard for Breast Conservation Therapy in the Management of Invasive 
Breast Carcinoma’, Morrow summarized the results of these trials, as shown in Tables 2.1 
and 2.2.(3)  
Table 2.1: Prospective randomized trials comparing conservative surgery and 












Milan I 1973-1980 701 I Q, RM CMF 
Institut 
Gustave-Roussy 















EORTC 1980-1986 868 I-II LE, MRM CMF 
Danish Breast 
Cancer Group 





5FU = 5-fluorouracil. 
AC = Doxorubicin, Cyclophosphamide. 
CMF = Cyclophosphamide, Methotrexate, 5-fluorouracil. 
EORTC = European Organization for Research and Treatment of Cancer. 
LE = Local Excision. 
MRM = Modified radical mastectomy. 
Q = Quandrantectomy 
RM = Radical Mastectomy 
WE = Wide Excision 
Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, et al. Standard for breast conservation therapy in the management 




Table 2.2: Survival comparison for conservative surgery and radiation (CS and 
RT) versus mastectomy in prospective randomized t rials 
Trial Endpoint 
Overall Survival % 
CS and RT/Mastectomy 
Disease-free Survival % 
CS and RT/Mastectomy 




73 (0.19) 65 
 




77 (0.89) 75 72 (0.93) 69 




79 (NS) 82 
70 (NS) 66 
( ) = p-value 
EORTC = European Organization for Research and Treatment of Cancer 
NS = Not Significant 
Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, et al. Standard for breast conservation therapy in the management 
of invasive breast carcinoma. CA Cancer J Clin. 2002 Oct;52(5):277–300 
 
 However, some uncertainty remains in the literature about whether there is 
increased local recurrence risk in the treated breast or chest wall with BCT compared to 
mastectomy. This uncertainty arises chiefly from heterogeneity in the study populations 
and from inconsistency in the studies’ definitions of local recurrence.  Depending on the 
publication, local recurrence has included nodal recurrence, skin recurrence, all 
recurrences in the ipsilateral breast, or selective ipsilateral breast recurrences. Table 2.3 
summarizes the data from the prospective randomized trials. Overall, the incidence of local 
recurrence ranges from 3% - 20% in the BCT group compared with 4% - 14% in the 
mastectomy group and four of the six randomized trials showed no significant difference in 
local recurrence. A significantly higher local failure rate observed in the National Cancer 
Institute (NCI) trial, but only gross tumor removal was required for study entry, as they did 
not mandate microscopically negative margins – microscopically positive margins being 
strongly associated with increased risk of local recurrence.(23,24) Similarly, in the 
European Organization for Research and Treatment of Cancer (EORTC) trial, 48% of the 
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patients had microscopically positive resection margins and 81% of the patients in the BCT 
arm had T2 tumors – a relatively high percentage. 
Table 2.3: Comparisons of local recurrence following conservative surgery and 
radiation (CS and RT) or mastectomy in prospective randomized t rials 
Trial Endpoint CS and RT Mastectomy 
Milan I Cumulative incidence at 
18 years 
7% (NS)              4% 
Institut  
Gustave-Roussy 
Cumulative incidence at  
15 years 
9% (NS) 14% 
NSABP B-06 Cumulative Incidence 10% 8% 
National Cancer 
Institute 
Crude incidence median 
follow-up at 10.1 years 
19% (0.01) 6% 
EORTC Actuarial at 10 years 20% (0.01) 12% 
Danish Breast 
Cancer Group 
Crude Incidence median 
follow-up at 3.3 years 
3% (NS) 4% 
( ) = p-value 
EORTC = European Organization for Research and Treatment of Cancer 
NS = Not Significant 
Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Giuliano A, et al. Standard for breast conservation therapy in the management 
of invasive breast carcinoma. CA Cancer J Clin. 2002 Oct;52(5):277–300 
2.2 Mastectomy Rates in Canada 
2.2.1 Breast Cancer Surgery in Canada, 2007-2008 to 2009-2010 
In 2012, an estimated 22,700 Canadian women were diagnosed with invasive breast 
cancer, 5,100 of whom died of the disease.(1) In October of 2012, the Canadian Institute for 
Health Information (CIHI) and the Canadian Partnership Against Cancer (CPAC) published a 
report from a pan-Canadian perspective on patterns in surgical care named ‘Breast Cancer 
Surgery in Canada, 2007-2008 to 2009-2010’.(12) It was the first report of such scope and 
magnitude to examine invasive breast cancer in Canada. This report is important to 
understanding measurers of quality of care while examining variations in clinical practice. 
The key findings from this report are outlined hereafter. 
 The study cohort covered a three-year period from 2007-2008 to 2009-2010.   
During this time 65,067 women, or roughly 22,000 per year, were treated surgically for 
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breast cancer. The majority of these women (57,840; 89%) were treated for invasive 
disease, and almost all were treated for unilateral disease (56,892; 98%). A relatively small 
portion of the cohort was treated for ductal carcinoma in situ (DCIS) (7,227; 11%). A small 
fraction of those originally treated for DCIS were subsequently treated surgically for a 
diagnosis of invasive breast cancer within one year (548; 8%).(12) 
Significant variation in mastectomy rates were seen among this group of women 
across the country. The crude mastectomy rate for invasive breast cancer nationally was 
39%, but the figure varied by province, from 26% in Quebec to 69% in Newfoundland and 
Labrador. Saskatchewan had the second highest reported rate of mastectomy in Canada, 
with a crude rate of 65% (1,094 of 1,686). Figure 2.1 below shows the rates of mastectomy 
among women who had unilateral invasive breast cancer and DCIS. Because the graph is 
sourced from the Breast Cancer Surgery in Canada report, it includes figures for DCIS.(12)  
Figure 2.1: Crude mastectomy rates among women with unilateral invasive 
breast cancer versus DCIS only, whose first s urgery took place between 2007-




Canadian Institute for Health Information. Breast Cancer Surgery in Canada 2007-2008 to 2009-2010 [Internet]. Canadian Institute for 
Health Information; 2012 Oct. Available from: https://secure.cihi.ca/estore/productFamily.htm?locale=en&amp;pf=PFC1936 
 
 Three  data sources were used to identify all inpatient and outpatient surgical 
procedures that took place between 2006-2007 and 2010-2011: the Hospital Morbidity 
Database, CIHI; the National Ambulatory Care Reporting System, CIHI; and the Alberta 
Ambulatory Care Reporting System, Alberta Health and Wellness. A woman’s first known 
index surgical procedure for breast cancer was based on the first discharge meeting the 
inclusion/exclusion criteria, with no recorded history of breast cancer. Appendix A gives 
the full patient selection criteria. Data from 2006-2007 were included to all exclusion of 
patients who had a record of surgical treatment of breast cancer within the past year. From 
the index surgery, a treatment window of one year was established. All surgical 
interventions during this one-year period were identified. The surgical procedures were 
coded hierarchically, so that if a woman underwent breast conserving surgery (BCS) for 
primary breast cancer in the left breast and within 365 days had the breast surgically 
removed, she was coded for analytical purposes as having had a mastectomy. 
Re-excision rates after BCS also demonstrated significant provincial variation. (12) 
Re-excision is usually indicated if positive margins are present in the initial resection.(25) 
The subsequent re-excision procedure may be further BCS with a wider excision or 
conversion to mastectomy. The relatively high rates of re-excision in some provinces may 
explain and influence geographical variation in provincial mastectomy rates. If a patient 
who initially underwent BCS had subsequent mastectomy at any point during the next year, 
she would be coded as undergoing mastectomy in their final procedure. Eleven percent of 
women who had unilateral invasive breast cancer and who initially had BCS subsequently 
underwent mastectomy within a year of their initial procedure, increasing the national rate 
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of mastectomy from an initial figure of 32% to 39% within a year of the initial diagnosis. In 
Saskatchewan, the mastectomy rate rose from 53% initially to 65% as the final procedure, 
for a 12% conversion to mastectomy – which is higher than the national average. The rates 
of re-excision for women who underwent BCS as their index procedure, as well as the index 
and final mastectomy rates across the country for unilateral invasive breast cancer are 
displayed in the Figure 2.2 and Table 2.4. (12) 
Figure 2.2: Rates of re-excision among women who underwent BCS for invasive 
breast cancer as their index procedure, by p rovince, 2007-2008 to 2009-2010 
 
Canadian Institute for Health Information. Breast Cancer Surgery in Canada 2007-2008 to 2009-2010 [Internet]. Canadian Institute for 
Health Information; 2012 Oct. Available from: https://secure.cihi.ca/estore/productFamily.htm?locale=en&amp;pf=PFC1936 
 
Table 2.4: Mastectomy and BCS among women with u nilateral invasive breast 
cancer, index versus final procedure 
Index Procedure 
 B.C. Atla. Sask. Man. Ont. Que. N.B. N.S. P.E.I. N.L. Canada 
BCS 4,877 2,490 790 1,396 14,738 11,792 837 928 133 481 38,517 
Mastectomy 2,596 2,482 896 607 6,719 3,138 521 843 107 406 18,375 
Total 7,473 4,972 1,686 2,003 21,457 14,930 1,358 1,771 240 887 56,892 
Final Procedure 
 B.C. Atla. Sask. Man. Ont. Que. N.B. N.S. P.E.I. N.L. Canada 
BCS 4,040 2,204 592 1,282 13,413 10,979 719 794 100 277 34,439 
 
 11 
Mastectomy 3,433 2,767 1,094 721 8,045 3,951 639 977 141 609 22,453 
Total 7,473 4,971 1,686 2,003 21,458 14,930 1,358 1,771 241 868 56,892 
Note 
Small differences between the totals for the index and final procedures for selected provinces are due to women moving to 
another province during the treatment period. 
  
Data for a few other important factors expected to influence mastectomy rates – age 
group, neighbourhood income quintile, and travel time to the closest cancer centre – were 
included in the logistic regression model to provide adjusted mastectomy rates. Consistent 
with some U.S. population-based studies, mastectomy rates were higher among women of 
younger age (<50) and those of older age (70+).(13,26) Women living in the least affluent 
neighbourhoods by quintile were more likely to undergo mastectomy than women living in 
the most affluent neighbourhoods. Moreover, mastectomy rates significantly elevated with 
increases in travel time to the nearest cancer centre having a radiation facility. More 
specific data regarding these factors can be found in the report. Even when incorporating 
these factors, the discrepancies in provincial mastectomy rates were only marginally 
reduced in the adjusted rate, for a 26-percentage point absolute difference remaining 
between the highest and lowest mastectomy rates (35% to 61%). Saskatchewan remained 
the second highest, with an adjusted mastectomy rate of 60% and the Canadian 
mastectomy rate changed from 39% to 44%.(12) Table 2.5 shows the crude and adjusted 
mastectomy rates by province. 
Table 2.5: Crude and adjusted mastectomy rates among women with unilateral 
invasive breast cancer, by province, 2007-2008 to 2009-2010 
 Crude Rate Adjusted Rate Canada 
B.C. 46% 45% 44% 
Alta. 56% 56% 44% 
Sask. 65% 60% 44% 
Man. 36% 35% 44% 
Ont. 38% 39% 44% 
N.B. 47% 41% 44% 
N.S. 56% 52% 44% 
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P.E.I. 59% 56% 44% 
N.L. 69% 61% 44% 
Notes 
Data relates to patients who received their index procedure between 2007-2008 and 2009-2010. 
Excludes data for residents of the three territories and Quebec. 
Adjusted rates control for age group, neighbourhood income quintile and travel time to closest cancer centre. 
Crude rates in this table differ from those presented in Figure 1 due to calculations of denominators for each province included in the analysis 
Canadian Institute for Health Information. Breast Cancer Surgery in Canada 2007-2008 to 2009-2010 [Internet]. Canadian Institute for 
Health Information; 2012 Oct. Available from: https://secure.cihi.ca/estore/productFamily.htm?locale=en&amp;pf=PFC1936 
 
Reports presenting data collection and analysis at a national level are subject to 
many limitations and cautions when interpreting results. Chief among these is 
unavailability or omission of data on stage of disease, which is a crucial determinant of 
treatment. Although most invasive breast cancers do present with early stage,(11) use of 
mastectomy rates adjusted for stage of disease or stratification of the data by stage could 
significantly affect provincial variations in mastectomy rates. Additionally, procedural 
codes could not be used to distinguish between BCS and open excisional biopsy. If open 
excisional biopsy was the final procedure that women received to remove all their invasive 
breast cancer, they likely would have had no opportunity to decide between BCS and 
mastectomy, having not been diagnosed prior to that procedure. Although use of open 
excisional biopsy is low compared to needle biopsy, the inclusion such cases could result in 
underestimation of index and final mastectomy rates. 
The variation-related findings highlighted in this report raise questions about how 
Canadian women are exercising their treatment options and about the related quality of 
surgical care. Breast Cancer Surgery in Canada reports that “[e]xamination of clinical 
practices by province/territory will be needed to better understand these variations.”(12) 
Further investigation using more rigorous study designs is needed to improve 
understandings of variations in treatment and their relation to quality of care. As the 
limitations in this report could be significant, future studies should adjust for them when 
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seeking to confirm this reports findings. From there, opportunities for research and quality 
improvement broaden. As suggested by CIHI and CPAC, areas in need of research include: 
examination of local practice patterns, examination of patient factors affecting decision-
making, internal audits of practices, and education in quality improvement. 
2.2.2 Distribution by Stage of Disease 
Data on distribution by stage of disease were not provided in the Breast Cancer 
Surgery in Canada but were presented in a separate CPAC report, ‘Breast Cancer Control in 
Canada’.(11) This report presented a stage-based distribution of diagnosis in Canada, by 
province, for 2010. Although data presented covered just one year, they indicated general 
distribution by stage of disease. In Canada, more than 80% of invasive breast cancer cases 
were diagnosed with early stage disease (stage 1 or 2). Figure 2.3 shows interprovincial 
variations in breast cancer stage distribution, including most notably with Newfoundland’s 
higher percentage of advanced disease diagnosis.(11)  
Figure 2.3: Distribution by stage at diagnosis of women diagnosed with 




Canadian Partnership Against Cancer. Breast Cancer Control in Canada: A System Performance Special Focus Report [Internet]. Canadian 
Partnership Against Cancer; 2012. Available from: 
http://www.cancerview.ca/idc/groups/public/documents/webcontent/breast_cancer_control_rep.pdf 
2.2.3 The 2015 Cancer System Performance Report 
 In 2015, the CPAC published updated data on cancer system performance indicators 
including a Canadian breast cancer update.(27) This report covered women who had 
unilateral invasive breast cancer who underwent surgery between April 2008 and March 
2013. Data were obtained from hospital abstract databases maintained by CIHI. Data 
reporting was similar to the previous ‘Breast Surgery Cancer in Canada’ report.(12) 
Because data were not linked to provincial cancer registries, they might include some 
women who had recurrent disease, although selection criteria were employed to minimize 
inclusion. Because open excisional biopsies and BCS still did not have differentiating 
procedural codes, provinces utilizing more open biopsies could have higher rates of BCS 
first followed by mastectomy. Results were presented by index procedure rates(the 
patients’ first procedure) and final procedure rates, with the mastectomy rate including 
women who initially had BCS but subsequently underwent mastectomy within a year.(27) 
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 Figure 2.4 presents mastectomy rates by province. Index mastectomy rates ranged 
from 20.9% in Quebec to 56.4% in Saskatchewan. Final mastectomy rates ranged from 
25.3% in Quebec to 68.3% in Newfoundland and Labrador.(27) Canada as a whole had an 
index mastectomy rate of 32.8% and a final rate of 38.1%.(28) Figure 2.1, which compares 
updated final mastectomy rates of provinces with previously reported crude mastectomy 
rates (crude and final mastectomy rates are synonymous), shows little notable difference 
for the majority of provinces. For Saskatchewan, the final mastectomy rate for invasive 
cancer changed from 65% to 63.4% between reports.(12,27) 
Figure 2.4: Percentage of breast cancer resections that are mastectomies, by 
province/territory – from 2008/2009 to 2012/2013 fiscal years combined 
 
Canadian Partnership Against Cancer. The 2015 Cancer System Performance Report [Internet]. Canadian Partnership Against Cance r; 
2015. Available from: systemperformance.ca 
2.3 Surgical Variation 
 Regional variations in surgery are not unique to treatment of ESBC but are in fact a 
well-documented phenomenon throughout medical practice for many surgical procedures. 
James Glover published a seminal article in 1938 that described a twenty-fold difference in 
tonsillectomy rates between the highest- and lowest-rated school districts, which were 
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separated by just seven miles.(29) Variation in that particular procedure was due to the 
referring medical officer. A recent Lancet publication reviewed surgical variation and 
concluded that the relative variation in population-based rates of many common 
procedures has remained largely stable over the past twenty years despite major advances 
in clinical sciences in the past few decades – highlighting the need for continued work in 
this field.(30) 
 Variation in surgical provision often raise questions about whether proper care is 
being provided. Are surgical procedures being overused in the relatively high-utilization 
areas, or are they being underused in the relatively low-utilization areas – or some 
combination of both? Are the surgical practices in line with the best clinical practice 
guidelines, or do other reasons underlie inconsistencies? Are surgeons’ or surgical groups’ 
attitudes and beliefs regarding certain procedures that are influencing surgical rates? Are 
patient preferences based on societal and cultural differences that are influencing these 
differences? Are variations the result of more upstream factors such as diagnostic patterns 
or referral patterns? High rates of surgical procedures are often attributed to inappropriate 
use but findings from a recent systematic review concluded there was little evidence to 
support or refute this conclusion, as there were only five studies identified in that past 
thirty years that have examined this relationship.(31)  
 Surgical variations between procedures cannot all be viewed the same. Wenneberg 
et al grouped practice variations into three categories: effective care, preference sensitive 
care, and supply sensitive care.(32) Effective care includes treatments for which good 
evidence supports one intervention, with no good alternative options available. Examples 
included colectomy for colon cancer or repair of a hip fracture. Variations in this category 
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generally suggest inappropriate underutilization in lower-use areas. Preference sensitive 
care includes interventions for problems that have more than one acceptable treatment 
option. Examples include radical prostatectomy, radiotherapy, or active surveillance for 
prostate cancers and BCT or mastectomy for ESBC. Ideally, differences reflect patient 
preferences and values, but they could vary for other reasons as well. Supply sensitive care 
includes services limited by the availability of resources. Examples are availability of 
physician visits, hospital beds or specialist consultations. Most surgical interventions do not 
fall under this category. Preference sensitive care represents the largest of the categories 
for surgery, which includes decision-making between mastectomy and BCT in cases of 
ESBC. 
 In 2014, Reames and colleagues published their results of a systematic review 
focusing on strategies for reducing regional variation in the use of surgery.(33) The review 
focused on two major strategies to improve consistency and the appropriateness of health 
care: dissemination of clinical practice guidelines or consensus statements, and shared 
decision-making tools and decision aids. Results for clinical guideline dissemination 
demonstrated varied results with some studies showing decreased procedure rates, but 
others showing no effect or increased rates. Recommendations for procedure choice 
generally showed a measurable increase in the use of the recommended procedure. With 
respect to BCT rates, some studies demonstrated a narrowed range of regional variation 
rates, while others demonstrated a wider range of procedural rates.(34) Decision aids have 
also shown mixed results, with three of five studies not showing a statistically significant 
change in rate of procedure after administration, while the other two studies have 
demonstrated discrepant effects – one study showing increased rates of BCT while the 
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other showed decreased rates. Although the overall findings show that both clinical 
guidelines and shared decision-making tools have the potential to substantially reduce the 
extent of variation in surgical care, these seem dependent on the clinical situation. These 
findings were confirmed by a recent Cochrane systematic review that have also shown 
decision aids were inconsistent in their ability to change outcomes in terms of surgical 
variation.(34) 
To broadly examine influences on treatment decision-making, Birkmeyer and 
colleagues presented a conceptual model to examine regional variations in the use of 
surgery (Figure 2.5).(30) This model depicts the steps in the pathway from health and 
patient patient evaluation to the final surgical procedure, with potential influences on 
surgical variation. Many factors that may affect surgical rates that are independent of the 
surgeon, including disease incidence, access to health care, patient proclivity to seek care, 
diagnostic testing, and referral patterns of primary physicians. Physicians are well 
documented as having different opinions on optimal treatment or procedures and may be 
biased towards certain risks and benefits, which may account for regional variation. 
Furthermore, in preference-sensitive therapies differences in the degree to which 
physicians incorporated patients’ values, beliefs, and preferences into the treatment 
decision may account for regional variations. The model also highlights other broad 
environmental factors that may affect regional variation in the use of surgery. The 
substantial increase in rates of cholecystectomy after the introduction of laparoscopic 
surgery exemplifies the concept of technology diffusion. Because physicians’ practice tends 
to resemble the way they were trained, training can have significantly influence a region’s 
‘surgical signature’.(35) Other factors such as financial incentives and regulatory 
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environment can also affect surgical variation; rates of procedures such as cataract surgery 
or arthroscopy done in privately owned outpatient ambulatory surgical centres are twice 
those of the same procedures done in the community hospital setting. The scope and focus 
of this model are intended to allow evaluation at the level of the surgical procedure, 
permitting comparisons and explanations of rates of a specific procedure amongst regions 
or comparison of different rates for different procedures. In following a patient’s pathway 
to surgery, this model is well structured to capture the key factors that may influence and 
distinguish effective care, preference sensitive care, and supply-sensitive care.  





2.4 Theory of Planned Behavior 
The Theory of Planned Behavior (TPB) is a conceptual framework that links beliefs 
and behavior. Since its development, it has become one of the theories most commonly 
used theories to predict human functioning and behavior. The number of citations for the 
TPB totaled 4,550 in 2010 alone, and it has served as the model for more than 1,200 
empirical studies of behavioral prediction and change.(36) The theory states that the most 
proximal determinant of a given behavior is intention, which represents the person’s 
motivation or decision to act. Intention, in turn, is a function of three sets of belief-based 
perceptions of behavior: attitude toward the behavior, subjective norms, and perceived 
behavioral control (PBC). Attitude towards a behavior reflects a person’s overall positive or 
negative feeling about performing the behavior. Subjective norm reflects the person’s 
perception of the social pressure to perform a given behavior. PBC reflects a person’s 
overall judgment about whether he or she has the ability and resources needed to engage in 
the target behavior. Figure 2.6 below depicts Ajzen’s Theory of Planned Behavior.  





This theory proposed by Icek Ajzen in 1985, was popularized by his 1991 article 
‘The Theory of Planned Behavior’.(38) This theory is an extension of an earlier model 
developed by Ajzen and Martin Fishbein, the Theory of Reasoned Action (TRA), to which 
the TPB added measures of control belief and perceived behavioral control as additional 
determinants of intentions and behavior. PBC was included to account for potential 
constraints on action as perceived by the actor, as well as to explain why intentions do not 
always predict behavior. In the TRA, it is assumed that people have volitional control over 
the behavior of interest and that they realize that they are capable of performing the 
behavior if they so desire. Under these conditions, perceived behavioral control becomes 
irrelevant, so that the theory of planned behavior reduces to the theory of reasoned 
action.(38) 
Generally explained, the TRA states that if people evaluate a suggested behavior as 
positive (attitude towards behavior), and if they think that their significant others want 
them to perform the behavior (subjective norm), then they reach a higher level of intention 
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(motivation) and are thus more likely to perform the given behavior.  When an individual’s 
control over the behavior is incomplete, perceived behavioral control provides information 
about potential constraints on action, as perceived by the actor, and helps explain why 
behavioral intentions do not always predict actual behavior.  The TPB comprises six 
constructs, as defined in by Icek Ajzen that collectively represent a person’s actual control 
over the behavior(37,38):  
Behavioral Beliefs → Behavioral beliefs link the behavior of interest to expected 
outcomes. A behavioral belief is the subjective probability that the behavior will 
produce a given outcome. Although a person may hold many behavioral beliefs with 
respect to any behavior, only a relatively small number are readily accessible at a 
given moment. It is assumed that these accessible beliefs – in combination with the 
subjective values of the expected outcomes – determine the prevailing attitude toward 
the behavior. Specifically, the evaluation of each outcome contributes to the attitude in 
proportion to the person’s subjective probability that the behavior produces the 
outcome in question. 
Attitude Toward the Behavior → Attitude toward behavior is the degree to which 
performance of the behavior is positively or negatively valued. According to the 
expectancy-value model, attitude toward a behavior is determined by the total set of 
accessible behavioral beliefs linking the behavior to various outcomes and other 
attributes. The strength of each behavioral belief is weighted by the evaluation of the 
outcome or attribute, and the products are aggregated, to produce a sum attitude.  
Normative Beliefs → Normative beliefs refer to the perceived behavioral expectations of 
such important referent individuals or groups as the person’s spouse, family, friends, 
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and – depending on the population and behavior studied – teacher, doctor, supervisor, 
and coworkers. It is assumed that these normative beliefs – in combination with the 
person’s motivation to comply with the different referents – determine the prevailing 
subjective norm. Specifically, the motivation to comply with each referent contributes 
to the subjective norm in direct proportion to the person’s subjective probability that 
the referent thinks the person should perform the behavior in question. 
Subjective Norm → Subjective norm is perceived social pressure to engage or not to 
engage in a certain behavior. Drawing an analogy to expectancy-value model of 
attitude, it is assumed that subjective norm is determined by the total set of normative 
beliefs about the expectations of important referents. The strength of each normative 
belief is weighted by motivation to comply with the referent in question, and the 
products are aggregated, to produce a sum subjective norm. 
Control Beliefs → Control beliefs have to do with the perceived pressure of factors that 
may facilitate or impede performance of a behavior. It is assumed that these control 
beliefs – in combination with the perceived power of each control factor – determine 
the prevailing perceived behavioral control. Specifically, the perceived power of each 
control factor to impede or facilitate performance of the behavior contributes to 
perceived behavioral control in direct proportion to the person’s subjective 
probability of the control factor’s being present. 
Perceived Behavioral Control → Perceived behavioral control refers to people’s 
perception of their ability to perform a given behavior. Drawing an analogy to the 
expectancy-value model of attitude, it is assumed that perceived behavioral control is 
determined by the total set of accessible control beliefs, i.e., beliefs about the presence 
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of factors that may facilitate or impede performance of the behavior.  Specifically, the 
strength of each control belief is weighted by the perceived power of the control 
factor, and the products are aggregated, to produce a sum perceived behavioral 
control. To the extent that it is an accurate reflection of actual behavioral control, 
perceived behavioral control can, together with intention, be used to predict behavior. 
Intention → Intention indicates of a person’s readiness to perform a given behavior, and it 
is considered to be the immediate antecedent of behavior. The intention is based on 
attitude toward the behavior, subjective norm, and perceived behavioral control, with 
each predictor weighted for its importance in relation to the behavior and population 
of interest. 
 The TPB can be applied to decision-making for women whom have ESBC. The 
behavior of choosing mastectomy or BCT can be conceptualized as a planned decision. With 
respect to applying TPB to decision-making, Ajzen states that: ‘[t]he TPB emphasis is on the 
controlled aspects of human information processing and decision-making. Its concern is 
primarily with behaviors that are goal-directed and steered by conscious self-regulatory 
processes. From the TPB, expectations that performing a behavior will lead to experiencing 
pain, pleasure, regret, fear, elation, or other emotions are simply behavioral beliefs, i.e. 
beliefs about the likely consequences of the behavior, some positive and others 
negative’.(36) This theory has been utilized as a conceptual framework to study decision 
making in ESBC in past research.(39)  
TPB can be used to conceptualize the variety of factors that may potentially 
influence a woman’s choice of mastectomy or BCT. Using theoretical forestructure, 
hypothesized examples in relation to TPB are described hereafter. Sociodemographic 
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characteristics can have influences on all three of the belief constructs. Factors such as 
socioeconomic status or cultural background will directly relate to behavioral and 
normative beliefs. Personal life circumstances such as work obligations or distance from a 
treatment centre may heavily affect a person’s control beliefs. The influences of close family 
members and friends or a surgeon’s recommendations will be among the key referents 
involved in an individual’s subjective norms. Emotions such as fear of cancer recurrence 
and desire for peace of mind are often very important determinants of a woman’s choice of 
mastectomy. These behavioral beliefs can strongly affect her attitude towards the behavior 
as well as her subsequent behavioral intentions. Similarly, the value that individuals place 
on wanting to feel whole or on their feminine identity after treatment may strongly 
influence their behavioral beliefs. Figure 2.7 illustrates how the TPB can be used as a 
framework for considering the factors that influence a woman’s choice between 
mastectomy and BCT in cases of ESBC. 
Some potential limitations could hinder the use of TPB as a framework for 
examining factors that influence women’s choice between mastectomy and BCT in the 
setting of ESBC. Application of the TPB assumes that the patient is explicitly aware that he 
or she has a choice of therapy, which is not always the case. Additionally, translating 
influencing factors that are analyzed as subjective norms or PBC for clinical understanding 
may pose a further challenge. 
Figure 2.7: TPB applied to factors influencing decision -making between 









































































































































































2.5 Shared Decision-Making Framework 
 In 1999 Charles et al presented a conceptual framework for examining treatment 
decision-making that still informs decision-making concepts even in the absence of an 
agreed upon definition (Figure 2.8).(40) The framework includes three models of treatment 
decision-making included, which are the paternalistic model, shared model, and the 
informed model. Each models has three distinct steps, or analytic stages: information 
exchange, deliberation, and deciding on the treatment to implement. The framework 
describes the general path that each of the models follows as well as, more specifically, the 
behavioral expectations of both physicians and patients for implementation of each model. 
The separate analytic stages of each model make it easy to conceptually distinguish one 
model of treatment decision-making from another. The framework also recognizes the 
dynamic nature of decision-making and does not limit a single treatment interaction to one 
model, as the encounter may change as the interaction evolves. 





 Within this framework, decision-making is related to situations in which several 
treatment options are available that offer different benefits to risks ratios, and different 
patient outcomes. Charles identified four necessary characteristics:(41)  
1. At minimum, both physicians and patients are involved in the treatment decision-
making process. 
2. Both physician and patients share information with each other. 
3. Both physician and the patient take steps to participate in the decision-making 
process by expressing treatment preferences. 
4. A treatment decision is made in which both the physician and patient agree on the 
treatment to implement. 
In these appropriate situations, the three models can be divided into three analytically 
distinct situations to help distinguish their characteristics. Information exchange refers to 
the type and amount of information exchanged as well as the flow of information between 
physician and patient. Deliberation involves discussion of treatment options, and 
expression of treatment preferences. The final stage is the actual decision and choice of 
treatment to implement.(41) 
 The paternalistic model has traditionally been the predominant approach to 
treatment decision-making, in which it is generally assumed that the physician will make a 
better treatment decision than the patient would. In this model, information exchange is 
largely one-way in this model from physician to patient. The patient is generally a passive 
recipient, and information exchange from patient to physician is not seen as important to 
completing this interaction. During the deliberation stage, the physician considers the 
benefits and risks of each option alone or in consultation with other physicians, but the 
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patient is passive. The physician makes the final treatment decision alone. This model 
resembles a parent-child relationship, with an authority figure (the physician) making what 
is deemed to be the appropriate decision for the patient.(41) 
 The shared decision-making (SDM) model evolved with clinical medicine as 
treatment options increased for diseases; accompanied by greater emphasis on discussion 
of trade-offs between risks and benefits. In this model, information exchange goes both 
ways. The physician should provide all of the relevant decision-making information to the 
patient, and the patient should provide information about issues related to the treatment 
options including values, preferences, social circumstances, and their knowledge about the 
illness. As a result, deliberation can occur within the boundaries and context of the patient’s 
specific situation. Deliberation should be interactional in nature, with both members having 
input and being invested in the treatment decision. Expression of treatment preferences is 
important to this model. The decision on treatment should be agreed upon between both 
the physician and the patient. 
 The informed decision-making model differs from the SDM model in that the 
physician limits his or her primary role to providing information. Information exchange is 
thus largely one-way, so that the physician is the primary source of information for the 
patient, who weighs all of the treatment options and the benefits and risks of each option. 
Beyond information transfer, the physician does not participate further in the decision-
making process, leaving the patient to deliberate and make the final choice on the treatment 
on his or her own. An important fundamental difference from the shared model is that the 
physician should not be invested in the decision-making process or in the decision made. 
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This is to avoid influencing the patient towards the physician’s preferred treatment, which 
might not align with the interests of the patient.(41) 
 Recently, SDM scholars have urged the creation of a model that would extend 
beyond the physician-patient dyad to promotes an interprofessional approach to SDM. 
France Légaré, Dawn Stacey, et al. proposed a new model for interprofessional share 
decision-making (IP-SDM) with which to guide patient care.(42,43) The model has three 
levels: the individual (micro) level, the healthcare team/organization (meso) level, and the 
healthcare system (macro) level. (Figure 2.9) When used in an IP-SDM approach, this model 
assumes that multiple healthcare professionals are colloborating, concurrently or 
sequentially, to achieve SDM with the patient. The model also assumes that the clinical 
encounters cannot occur free of the influence of factors from the levels of the healthcare 
system. This model has the potential to unify the process of SDM in different healthcare 
settings and among different health professionals.(41) 
Figure 2.9: IP-SDM model – healthcare system (meso and macro) levels 





The individual level of care described by France Légaré et al. bears similarities to the 
Charles model,(41) but incorporates of multiple health care professionals, a decision coach, 
and family member involvement made explicit through the information, deliberation, and 
treatment decision stages. The meso level of the IP-SDM model is represented by the IP 
team members and includes the ways in which this team or organization functions. The 
macro level represents global healthcare environmental factors: resources, government 
policies, cultural values, professional organizations, and rules. Being a newly proposed 
model that has had limited development or application in real-world clinical scenarios, IP-
SDM requires further work to clarify the meso and macro levels.(43,44) In Saskatchewan’s 
ESBC setting, treatment decisions are made primarily with the involvement of a single 
healthcare professional, the surgeon. However, the expanding role and involvement of 
radiation oncology, which influences the length of radiation treatments; the increasing role 
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of adjuvant chemotherapy; and the involvement of nurse navigators may all have a roles in 
the IP-SDM model in the future. 
2.6 Background Literature Summary 
 In cases of ESBC, multiple prospective randomized control trials with good long-
term follow-up have established that BCT and mastectomy offer equivalent survival 
rates.(2–9) Current breast cancer management guidelines thus offer the option of BCT or 
mastectomy as an initial treatment for patients who have ESBC.(19,20) However, in 1990, 
the first NIH consensus conference on the treatment of ESBC recommended BCT as the 
‘preferable’ primary therapy: ‘Breast conservation treatment is an appropriate method of 
primary therapy for the majority of women who have stage one or two breast cancer and is 
preferable because it provides survival rates equivalent to those of total mastectomy and 
axillary dissection while preserving the breast’.(10) The belief that BCT is preferable has 
been perpetuated throughout the breast cancer literature, including in the Canadian CPAC 
reports: ‘BCT is therefore generally recommended for most women with Stage I or II breast 
cancer.’(11).  
Recently, two major national reports have used BCT and mastectomy rates as quality 
of care indicators.(12,27) The first, a report by CIHI and CPAC released in 2012, that looked 
at Canadian mastectomy rates from 2007 to 2010. The second, a CPAC update released in 
2015, covered surgery from 2008 to 2013. Both reports final figures for national 
mastectomy rate and interprovincial differences were very similar. In the 2015 CPAC 
report, the Canadian final mastectomy rate was 38.1%, ranging from 25.3% in Quebec to 
68.3% in Newfoundland and Labrador. As already noted, in Saskatchewan, the final 
mastectomy rate for invasive cancer was 63.4%. In the 2012 report, the group ran a 
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regression model that included age, neighbourhood income quintile, and travel time to the 
closest cancer centre so as to adjust for potential factors influencing mastectomy rates. 
However, the discrepancies in provincial mastectomy rates were only marginally reduced 
even when adjusting for other factors, for a 26-percentage point absolute difference 
between the highest and lowest mastectomy provinces (35% to 61%). Saskatchewan 
remained the second highest, with an adjusted mastectomy rate of 60%. This report’s 
conclusions included a recognition of the limitations of its analysis and suggested 
examination of local practice patterns to better understand patient factors affecting 
decision-making. 
Regional variation in surgery is not unique to treatment of ESBC, being a well-
documented phenomenon throughout medical practice for many surgical procedures. 
Practice variations between procedures can be grouped into three categories; effective care, 
preference-sensitive care, and supply sensitive care.(32) Effective care includes treatments 
for which good evidence supports a single intervention, with no good alternative options 
available. Examples included colectomy for colon cancer or repair of a hip fracture. 
Variations in this category generally suggest inappropriate underutilization in lower use 
areas. Preference-sensitive care includes interventions for problems having more than one 
acceptable treatment option, such as radical prostatectomy, radiotherapy, or active 
surveillance for prostate cancers and BCT or mastectomy for ESBC. Ideally, differences vary 
with patient preferences and values, but they could potentially vary for other reasons as 
well. Supply-sensitive care includes services that are limited by the resource availability, 
such as of physician visits, hospital beds or specialist consultations. Most surgical 
interventions do not fall under this category. Preference-sensitive care represents the 
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largest of the catoegy for surgery, including decision-making between mastectomy and BCT 
in cases of ESBC. 
The choice of mastectomy versus BCT is complicated, as there are many factors that 
influence therapy choice. Birkmeyer and colleagues presented a broad pathway model to 
evaluate the steps a patient takes from being a healthy individual to reaching the final 
surgical procedure, highlighting potential influencing factors along the pathway, such as 
variations in access, diagnostic testing, local training frameworks, physicians beliefs about 
procedures, and patient preferences.(30) On an individual patient level, the theory of 
planned behavior is a more appropriate framework for conceptualizing and theoretically 
explaining the ways in which a variety of factors may potentially influence a woman’s 
choice of therapy.(36,38) Interactions between the patient and physician are also complex; 
Charles et al. presented models of treatment decision-making between the dyad that offer 
insights into understanding its components by breaking down the steps of the 
interaction.(40,41) These frameworks and models were important in guiding our research, 
and subsequent chapters elaborate on their use.  
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 CHAPTER 3, MANUSCRIPT #1: REVIEW OF FACTORS INFLUENCING 
WOMEN’S CHOICE OF MASTECTOMY VERSUS BREAST CONSERVING 






3.1 Article Citation:  
 
Gu J, Groot G, Boden C, Busch A, Holtslander L, Lim H. Review of Factors Influencing 
Women’s Choice of Mastectomy Versus Breast Conserving Therapy in Early Stage Breast 
Cancer: A Systematic Review. Clin Breast Cancer. 2018 Aug;18(4):e539–54. 
 
Content included in this article does not significantly differ from the published manuscript. 
However, grammatical modifications have been made, and the document has been 





Background: No previous systematic review on this topic exists. 
Methods: We have performed a narrative synthesis. A literature search was conducted 
between January 2000 to June 2014 in seven databases. Initial search identified 2717 
articles, 319 underwent abstract screening, 67 underwent full-text screening, and 25 final 
articles were included. This review looked at ESBC in women only, excluding DCIS and 
advanced breast cancer. A conceptual framework was created to organize the central 
constructs underlying women’s choices: clinicopathological factors, physician factors, and 
individual factors with subgroups sociodemographic, geographical, and personal beliefs and 
preferences. This framework guided our review’s synthesis and analysis. 
Results: Larger tumor size and increasing stage was associated with increased rates of 
mastectomy. Results for age varied but suggested that old and young extremes of diagnostic 
age were associated with an increased likelihood of mastectomy. Higher socioeconomic 
status was associated with higher BCT rates. Resident rural location and increasing distance 
from radiation treatment facilities were associated with lower rates of BCT. Individual 
belief factors influencing women’s choice of mastectomy (mastectomy being reassuring, 
avoiding radiation, an expedient treatment) differed from factors influencing choice of BCT 
(body image and femininity, physician recommendation, survival equivalence, less surgery.) 
Surgeon factors including female sex, higher case number, and individual surgeon practice 
were associated with increased BCT rates. 
Conclusions: The decision-making process for women with ESBC is complicated and 
affected by multiple factors. Organizing these factors into central constructs of 
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clinicopathological, individual, and physician factors may aid health-care professionals to 
better understand this process. 
3.3 Key Words 




Breast cancer is the most commonly diagnosed cancer and the second most common cause 
of cancer death in women in North America.(11) Landmark trials have established breast 
conservation therapy (BCT) and mastectomy offer equivalent survival and can be viewed as 
equivalent treatments in early stage breast cancer (ESBC).(2–4,6) With equivalence of 
treatments, surgery for ESBC is often viewed and described as a preference-sensitive 
care.(32) Decision-making and variations in procedure rates should be ideally due to 
underlying patient preferences and values. However, since the seminal National Institute of 
Health Consensus Conference in 1999 recommended BCT as ‘preferable’,(10) there have 
been ongoing questions and research regarding quality of care as it relates to regional 
variation in BCT rates for treatment of ESBC.(45) Viewing procedural variation as a result 
of patient preferences compared to evaluating low BCT rates as a failure of meeting 
recommendations are dichotomous views. In Canada, there has been significant variation 
across the country with mastectomy rates ranging from 26% to 69% between 
provinces.(12) There has been similarly drastic variation in the United States and the 
United Kingdom that is not well explained.(46,47)  
The choice of mastectomy versus BCT is a complicated decision-making process; 
administrators should look beyond just mastectomy rates and aim to understand the 
reason behind these variations. The literature trying to identify factors that influence a 
woman’s choice between mastectomy and BCT for treatment of ESBC is heterogeneous in 
study design with limited experimental or prospective evidence. No systematic reviews 
evaluating this topic currently exist in the literature. Mac Bride et al have recently 
published a non-systematic review paper highlighting factors associated with therapy 
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choice.(13) They identified some key factors in the literature including patient 
sociodemographic factors, geographical factors, role of the surgeon, role of reconstruction, 
and influence of MRI use. However, this review included studies looking at Ductal 
Carcinoma in Situ (DCIS), which is a different disease process.(13) Furthermore, the review 
did not integrate literature covering other key components in decision-making including 
individual patient preference factors and clinicopathological factors such as tumor size. The 
aim of this systematic review is to provide a rigorous synthesis of the factors influencing 
women’s choice between mastectomy versus BCT with ESBC. 
3.5 Methods 
Because this review question is complex and underlying factors influencing decision-
making are numerous, the systematic review team has chosen to perform a narrative 
synthesis as described by Popay.(48) This synthesis method is ideal when there is 
considerable heterogeneity amongst the included studies in terms of methods, participants 
and a wide array of reported outcomes as is the case for factors influencing women’s choice 
of mastectomy versus BCT. A systematic review methodology was adopted that allowed 
inclusion of both quantitative and qualitative papers. Methods adhered to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA).(49)  
3.5.1 Conceptual Framework 
In surveying the literature, most research done in this area was conducted in a 
shotgun approach without a guiding framework. Each study generally only captured small 
portions of influencing factors without appropriate consideration of the phenomenon as a 
whole. As a first step to synthesizing the impact of these factors, we created a conceptual 
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framework that illustrates the central constructs underlying women’s choices (Figure 3.1). 
This framework provided a comprehensive basis to guide our review from conduct to the 
synthesis and analysis. Women’s choice of mastectomy versus BCT can be organized into 
three broad influencing constructs: clinicopathological factors, physician factors, and 
individual factors with subgroups of sociodemographic, geographic, and individual belief 
factors. This framework was developed through integrating previous frameworks, theories, 
models, literature, and clinical research.  
Figure 3.1: Conceptual framework illustrating the central constructs 
influencing women’s choice between mastectomy versus BCT  
 
3.5.2 Search Strategy and Information Sources 
In collaboration with the team’s librarian, a Population, Intervention, Comparison, 
Outcome (PICO) strategy was adopted to clearly define our research question for a 













mastectomy, breast conservation therapy, and decision-making.  Controlled vocabulary and 
natural language terms were identified for each of the four concepts. The terms for the 
‘breast cancer, ‘mastectomy’, and ‘breast conservation therapy’ concepts were derived in 
part from a Cochrane Breast Cancer Group search strategy.(50) An Epoch search strategy 
was adopted and amended for the term ‘decision making’.(51) Our search strategy was 
peer-reviewed by another librarian (V.D.), who is experienced in systematic reviews, using 
Peer Review of Electronic Search Strategies (PRESS).(52) Limits were set for the English 
language and a date of 2000 – current. This date limit was chosen because BCT was 
universally accepted as an equivalent treatment to mastectomy by 2000. English language 
was chosen for comparable cultures. No other search limits were applied. An initial 
literature search was conducted on August 21st, 2013. An example of the final Medline 
search strategy can be seen in Appendix B. The original databases chosen for our search 
were Medline, Embase, CINAHL, and PubMed. It was subsequently decided by the research 
team to expand the database search to include Scopus, Web of Science, and PsycINFO. 
Expansion of our search was to ensure our review was in line with an inclusive search 
strategy and with previous reviews done on this topic.  The final search was conducted on 
June 5th, 2014. Database searches from the original literature search were updated to 
include articles up to June 5th, and the additional databases were searched from 2000 to 
June 5th, 2014. Below lists the final 7 databases included in the review: 
Ovid Medline (R) – (1946-), searched 2000 to June 5th, 2014 
Ovid Embase – (1947-), searched 2000 to June 5th, 2014 
EBSCO CINAHL – (1937-), searched 2000 to June 5th, 2014 
PubMed – searched 2013 to June 5th, 2014 
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Scopus – (1823-), searched 2000 to June 5th, 2014 
Web of Science – (1899-), searched 2000 to June 5th, 2014 
PsycINFO – (1806-) searched 2000 to June 5th, 2014 
Duplicate records were removed from the search results and the records were 
stored in Refworks bibliographic management tool. Additionally, reference sections of key 
articles included were reviewed to identify potentially missed articles. 
3.5.3 Study Selection 
Two primary reviewers independently screened all articles in title screening, 
abstract screening, and full-text screening stages. Standardized forms were created for the 
review process and an online application, DistillerSR, was used to facilitate the screening 
process.(53) As part of an inclusive strategy, both reviewers were required to agree on 
exclusion for the article to be excluded during title screening. When screening abstracts and 
full-text articles, all conflicts were flagged for a third expert reviewer to resolve. Articles 
were included only if they met the following pre-specified inclusion criteria: a primary 
study or review, a full-length article, English text, published from 2000 onwards, a 
geographical location with culture comparable to North America, looking at simple stage 1 
and 2 breast cancer only (DCIS, stage 3 and 4 cancer, BRCA+, male breast cancer, and 
inflammatory breast cancer were excluded), radiation being a standard part of BCT 
treatment, and the focus of the study was on factors influencing the decision-making of the 
patient (not decision aids, etc). Specific inclusion and exclusion criteria for each stage of 
screening were decided and reviewed, in whole, by the systematic review team. The 
screening questions and forms are attached in Appendix C.  
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3.5.4 Data Collection 
Included studies were grouped into either qualitative or quantitative articles. The 
two researchers performing data extraction (J.G. and K.S.) both have MDs and were PhD 
students in epidemiology. This optimized both content knowledge on breast cancer and 
epidemiology. Data was independently extracted and in duplicate. An online application, 
Google Drive, was used to facilitate data extraction. A data extraction form was piloted from 
key references and was modified as further studies were examined. Separate forms were 
created for univariate data and multivariate data.  
3.5.5 Assessment of Bias 
Study designs were separated into quantitative studies, qualitative, or mixed-
methods studies. For quantitative studies, the Newcastle-Ottawa Scale (NOS) was the 
primary tool used for assessment of bias.(54) The use of the NOS has been popular in 
systematic reviews of non-randomized studies, and has been regarded as effective and easy 
to use.(55) Furthermore, this scale considers three fundamental domains: appropriate 
selection of participants, appropriate measurement of variables, and appropriate control of 
confounding.(56) In an attempt to mitigate some of the weakness of a single assessment 
tool, we have chosen to add a summary score of overall quality of study. Two researchers 
(J.G. and K.S.) independently evaluated all included quantitative studies in duplicate, and 
disagreements were resolved through discussion (Table 3.1).  
Qualitative studies were evaluated using a modified version of the Critical Appraisal 
Skills Programme (CASP) scale, which has been used in qualitative reviews in the 
past.(57,58) Two researchers, the lead author (J.G.) and a qualitative expert (L.H.) 
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independently evaluated all qualitative articles in duplicate. Disputes were resolved 
through discussion (Table 3.2).  
Table 3.1: NOS assessment of bias for quantitative articles  
Refid Author / 
Reference 
NOS-J NOS-K Overall-J Overall-K J-S J-C J-O/E K-S K-C K-O/E 
105 Lee et al., 
2012 
7 8 Strong Strong 4 2 2 4 2 3 
112 Dhage et al., 
2011 
4 6 Weak Strong 2 0 2 4 0 2 
176 Hershman 
et al., 2009 
7 9 Medium Strong 3 2 3 4 2 3 
208 Reitsamer 
et al., 2008 
8 8 Strong Strong 3 2 3 3 2 3 
223 Sauerzapf et 
al., 2007 
8 9 Strong Strong 3 2 3 4 2 3 
246 Temple et 
al., 2006 
8 7 Strong Strong 3 2 3 4 3 1 
258 Celaya et al., 
2005 
8 9 Strong Strong 3 2 3 4 2 3 
259 Osborn et 
al., 2005 
9 7 Strong Strong 4 2 3 4 2 3 
263 Chagpar et 
al., 2005 
8 9 Medium Strong 3 2 3 4 2 3 
292 Locker et 
al., 2004 
7 9 Medium Strong 3 1 3 4 2 3 
294 Molenaar et 
al., 2004 
8 8 Strong Strong 4 2 2 4 2 2 
318 Schou et al., 
2002 
5 5 Medium Medium 4 0 1 4 0 1 
329 Mastaglia et 
al., 2001 
6 5 Medium Medium 4 0 2 4 2 0 
330 Keating et 
al., 2001 
8 8 Strong Strong 4 2 2 4 2 2 
340 Cyran et al., 
2001 
8 6 Medium Medium 4 2 2 4 0 2 
341 Benedict et 
al., 2001 
6 5 Medium Medium 4 0 2 4 0 2 
343 Nold et al., 
2000 
5 4 Poor Medium 4 0 1 4 0 0 
386 Boscoe et 
al., 2011 
7 7 Strong Strong 3 2 2 4 2 1 
771 Roder et al., 
2014 
9 9 Strong Strong 4 2 3 4 2 3 
1096 Kelemen et 
al., 2001 
8 8 Strong Strong 4 2 2 4 2 2 
1160 Maskarinec 
et al., 2002 
8 8 Strong Strong 4 2 2 4 2 2 
1206 Olaya et al., 
2009 
8 8 Strong Strong 4 2 2 4 2 2 
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NOS denotes Newcastle-Ottawa Scale; J denotes researcher J.G.; K denotes researcher K.S.; S = selection subscale; C = comparability 
subscale; O/E denotes outcome or assessment of exposure subscale 
 
Table 3.2: CASP scores for qualitative articles  
Refid  Author / 
Reference 
Aims Methodology Overall-J Overall-L Average Score 
(24) 
110 Caldon et al., 
2011 
Yes Yes 19 21 20 
337 Mcvea et al., 
2001 
Yes Yes 17 16 16.5 
503 Kiloran et al., 
2006 
Yes Yes 19 19 19 
J denotes researcher J.G.; L denotes researcher L.H. 
3.5.6 Synthesis and Analysis  
Narrative synthesis was done following methods described by Popay (2006), (48) 
and general review principles described by Booth (2012)(59) were followed. The four main 
elements of synthesis described are (1): developing a theoretical model of how the 
interventions work, why, and for whom, (2) developing a preliminary synthesis, (3) 
exploring relationships in the data, and (4) assessing the robustness of the synthesis 
product. Developing a theoretical model and performing a preliminary synthesis was an 
iterative process. As previously described, the factors influencing decision-making between 
mastectomy and BCT are multifactorial and the literature is heterogeneous. We developed a 
conceptual framework to guide organization of results for more systematic synthesis and 
analysis. The five constructs in our conceptual model guiding our review are 
clinicopathological factors, demographic factors, geographical factors, individual belief 
factors, and surgeon-related factors. This is illustrated in Figure 3.1. 
All included studies were examined for reported results in any of the key constructs 
from our framework. Articles were then categorized based on the constructs reported. An 
article could be placed into multiple categories if they addressed multiple constructs. This 
resulted in 11 articles reporting clinicopathological factors, 15 articles reporting the 
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demographic factor age, 7 articles reporting geographical factors, 11 articles reporting 
individual belief factors, and 10 articles reporting physician-related factors. All articles 
within each grouping were then individually examined for the reported outcome variables 
within the construct category. Detailed information regarding each study including method 
of analysis, predicting variables, outcome, and variable reporting were recorded. This 
process was carried out through all five constructs and initial results were summarized. A 
meta-analysis was originally planned, but due to the heterogeneity of the reported 
outcomes, we determined no meaningful meta-analysis could be conducted for any group. 
Instead, we identified key factors within each construct and performed a narrative 
synthesis.  
There were three qualitative studies included in our review. These were reviewed 
(J.G. and L.H.) and we decided that there was not enough data to perform a meta-synthesis 
or thematic synthesis. These articles fell under the individual belief factors construct and 
were integrated into the individual belief constructs synthesis and analysis. 
3.5.7 Risk of Bias Across Studies 
Due to the level of heterogeneity between studies, assessing risk of bias across 
studies was not feasible in this review for quantitative and qualitative articles. All given 
results from included articles were incorporated into our analysis to minimize selective 




3.6.1 Study Selection 
Figure 3.2 illustrates our flow diagram. After de-duplication, the initial database 
search identified 1125 articles that underwent title screening. 319 articles moved on to 
abstract screening, and 67 articles underwent full-text screening, resulting in 25 articles 
meeting our final inclusion criteria. 22 articles were quantitative, 3 were qualitative, and 1 
was mixed-methods, which was grouped with the quantitative articles.  




3.6.2 Study Characteristics 
Study characteristics including study design, country of study, sample size, mastectomy 
rate, BCT rate, and study duration are shown in Table 3.3. A total of 274,416 patients were 
included in the studies. There were 15 studies from the USA, 3 from the UK, 2 from 
Australia, and 1 from Norway, Austria, and the Netherlands. 
Table 3.3: Summary of study characteristics  
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-

















































































110 Caldon et al., 2011 Qualitative UK 64 16 (25.0%) 48 
(75.0%) 
 
112 Dhage et al., 2011 Cross-Sectional USA 243 69 (28.3%) 174 
(71.6%) 
2004 – 2008 




208 Reitsamer et al., 2008 Cross-Sectional Austria 495 120 (24.2%) 375 
(75.8%) 
2002 – 2004 




246 Temple et al., 2006 Cohort Canada 157 45 (28.7%) 112 
(71.3%) 
1992 – 1995 
258 Celaya et al., 2005 Cross-Sectional USA 2,861 978 (65.8%) 1,883 
(34.2%) 
1998 – 2001 












294 Molenaar et al., 2004 Cross-Sectional 
/ Quasi-
Experimental 
Netherlands 172 49 (28.5%) 123 
(71.5%) 
1996 – 1999 












337 Mcvea et al., 2001 Qualitative USA N/A, N/A N/A  




341 Benedict et al., 2001 Cross-Sectional USA 192 157 (81.8%) 35 
(18.2%) 
1995 – 1998 
343 Nold et al., 2000 Cross-Sectional USA 96 43 (44.7%) 53 
(55.2%) 
1994 – 1999 
386 Boscoe et al., 2011 Cross-Sectional USA 104,730 34,980 (33.4%) 69,750 
(66.6%) 
2004 – 2006 
503 Kiloran et al., 2006 Qualitative USA N/A, N/A N/A  
771 Roder et al., 2014 Cross-Sectional Australia 30,299 11,729 (38.7%) 18,570 
(61.3%) 
1998 – 2010 




1160 Maskarinec et al., 
2002 
Cross-Sectional USA 722 341 (47.2%) 381 
(52.8%) 
1995 – 1998 
1206 Olaya et al., 2009 Cross-Sectional USA 47,837 13,023 (27.2%) 34,814 
(72.8%) 
1996 – 2005 
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Synthesis of Results 
3.6.3 Clinicopathological Factors 
Table 3.4: Tumor size and stage results  
Author / 
Reference 
N Country Predicting Variables Analysis* Larger T-Size / 
Stage Predicting 
Lee et al., 2012 383 USA Mast Just stage  Uni and Multi Mastectomy 
Dhage et al., 
2011 





Hersman et al., 
2009 
56,768 USA BCS Stage, hormone 
receptor, grade 
Uni and Multi Mastectomy 
Reitsamer et 
al., 2008 
495 Austria Mast T-size, hormone 
receptor, histology, 
grade, L.N. Status, 
localization, 
Uni and Multi Mastectomy 
Celaya et al., 
2005 
2,861 USA BCT T-size  Multi Mastectomy 
Osborn et al., 
2005 
202 UK Group Comparison Just T-size, Group 
Comparison 
Mastectomy 
Chagpar et al., 
2005 







Locker et al., 
2004 
9,365 USA Mast T-size, hormone 
receptor, grade, L.N. 
status 
Uni and Multi Mastectomy 







Uni and Multi Mastectomy 
Kelemen et al., 
2001 
7,815 USA BCT T-size Uni and Multi Mastectomy 
Maskarinec et 
al., 2002 
722 USA BCT Stage, T-size, Grade Uni and Multi Mastectomy 
* Uni denotes univariate analysis; multi denotes multivariate analysis; L.N. denotes lymph node 
Table 3.5: Other clinicopathological factors reported  
Author / 
Reference 
N Country Predicting Variables Analysis* 








USA BCS Hormone receptor, grade, 
differentiation 
Uni and Multi 





Austria Mast Hormone receptor, histology, 
grade, L.N. Status, localization,  
Uni and Multi 
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USA Mast Hormone receptor, grade, L.N. 
status 
Uni and Multi 






Australia Mast Hormone receptor, histology, 
grade, L.N. status, 
lymphovascular invasion, 
multifocality 
Uni and Multi 





USA BCT Grade Uni and Multi 
* Uni denotes univariate analysis; multi denotes multivariate analysis; L.N. denotes lymph node 
Eleven studies looked at clinicopathological factors. Various factors were examined 
across studies including, stage, tumor size, nodal status, hormone receptor status, grade, 
histology, and presence of lymphovascular invasion. Many of these items were addressed in 
only a few studies and did show a significant impact on undergoing mastectomy or BCT. 
The factors most commonly examined in the articles were tumor size and stage (Table 3.4), 
which are closely related in ESBC. These were also the most commonly significant factors. 
Other clinicopathological factors examined in multiple studies were grade, hormone 
receptor status, and tumor histology (Table 3.5). Category stratification amongst these 
factors varied too greatly to perform a meta-analysis on any of these categories.  
 Studies looking at stage reported decreasing BCT rates with higher stage of 
cancer.(60) A large database review by Hersmen et al. showed women were significantly 
less likely to undergo BCT with Stage II compared to Stage I disease [OR, 0.33, 95% CI, 0.36–
0.39].(61) Celeya et al. reported similar findings of decreasing likelihood of BCT with 
increasing cancer stage, IIA [OR, 0.57, 95% CI, 0.45–0.72] and IIB [OR, 0.28, 95% CI, 0.20–
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0.39] compared with stage I.(62) In a survey study by Lee et al., there was a trend for 
women with stage II, compared with stage I disease, to be more likely to undergo 
mastectomy [OR, 1.81, 95% CI, 0.89–3.68].(45) 
All studies looking at tumor size showed increased rates of mastectomy with a larger 
tumor size. Roder et al. reported tumors larger than 4cm were significantly less likely to 
undergo BCT compared to those less than 3cm [OR, 1.09, 95% CI, 1.02–1.17].(14) Locker et 
al. found tumor size >2cm was associated with increased likelihood of undergoing 
mastectomy [OR, 3.03, 95% CI, 2.74–3.35](63) while Kelemen et al. found BCT more likely 
with tumor size <2cm [OR, 2.46, 95% CI, 2.20–2.76].(46) Reitsamer et al. reported similar 
findings of decreasing likelihood of undergoing mastectomy with smaller tumor size, T1c 
[OR, 0.43, 95% CI, 0.24–0.77] and T1b [OR, 0.32, 95% CI, 0.13–0.81] compared with T2 
tumors.(64) A different study compared mean tumor diameter found the BCT treatment 
group had significantly smaller tumors compared to the mastectomy group, 15mm 
compared to 17mm [p=0.14].(65) Two other studies, Mascarenic et al and Chagpar et al. 
also supported the association between higher mastectomy rates with larger tumor 
sizes.(66,67) 
3.6.4 Individual Sociodemographic Factors 
Table 3.6: Age as a factor results 





105 383 Mast Age at 
diagnosis, % 
older than 50 
yo 
Uni BCT Mast BCT = 66.2% 
Mast = 52.3% 
112 243 Group 
Comparison 
Mean age at 
diagnosis 
Grp Comp BCT Mast BCT = 60 yo 
Mast = 54yo 





Mast BCT All older age groups 

















(Trend: Old + 
younger = mast, 
middle = BCT) 
223 5,830 BCT, Group 
Comparison 
Age at dx: <50, 
50-59, 60-69, 
70-79, 80+ 
Uni Mast BCT All older age groups 
more likely to 
undergo mast 






Mast BCT Increasing age = 
more likely to 
undergo mast 
259 202 Descriptive Mean age at 
diagnosis 
Grp Comp Mast BCT Mast = 61 yo 
BCT = 55 yo 




Mast BCT Younger than 55 yo 
= BCT 




Mast BCT All older age groups 
more likely to 
undergo mast 
340 176 BCT, Group 
Comparison 




BCT Mast Age  75 more likely 
to undergo BCT 
341 192 Grp 
Comparison 
Mean age at 
diagnosis 









(Mast = 57.4 yo 
BCT = 54.2 yo) 
386 104,730 Mast Age: 65+, 50-
64, <50 
Multi Mast Mast Old + younger = 
mast, middle = BCT 




Mast BCT Younger than 55 yo 
= mast 














(Trend: Old + 
younger = mast, 
middle = BCT) 







Mast Mast Old + younger = 
mast, middle = BCT 
* Uni denotes univariate analysis; multi denotes multivariate analysis 
Table 3.7: Individual sociodemographic factors results  
Refid  N Predicting Variables Analysis* Findings (not including age) 
105 383 Mast Age, Race, Education, 




None significant in multivariate 
modelling 
112 243 Group 
Comparison 
Age, Education, Annual 
Income, Race 
Grp Comp Differences in mean age, education, 
and race 




Race → black more likely to 
undergo BCT, Hispanic = no 
difference, other = more likely to 
undergo mastectomy 
SES → higher SES more likely to 
undergo BCT 
Married → more likely to undergo 
BCT 




223 5,830 BCT, Group 
Comparison 
Age, Deprivation Uni Deprivation → more deprived 
quartiles less likely to undergo BCT 




259 202 Descriptive Age, Partner Status Grp Comp Partner = more likely to undergo 
mastectomy 
263 4,086 BCT Age only Grp Comp 
and Multi 
N/A 
292 9,365 Mast Age, Body weight, BMI Uni + Multi Body weight > 70kg more likely to 
undergo BCT 






Education  high school = more 
likely to undergo BCT 
Race → not significant 
341 192 Grp 
Comparison 
Age, Education level, 
Marital status, Income, 
Employment, Insurance 
Grp Comp  Education = college associated with 
higher BCT 
Income = higher income associated 
with BCT 
386 104,730 Mast Age, Race, Ethnicity, 
Poverty rate 
Multi Race = Asian and unknown more 
likely to undergo mastectomy, 
Black and American Indian = no 
difference 
Ethnicity = Hispanic more likely to 
undergo mast 
1096 7,815 BCT Age only Grp Comp 
and Multi 
N/A 





1206 47,837 BCT, Group 
Comparison 
Age, SES, race/ethnicity Grp Comp 
and Multi 
SES → higher SES more likely to 
undergo BCT 
Race → Non-Hispanic black more 
likely to undergo BCT, 
Asian/Pacific Islander more likely 
to undergo mastectomy, Hispanic = 
no difference from White. 
* Uni denotes univariate analysis; multi denotes multivariate analysis 
Fifteen studies examined sociodemographic factors influence on choice of 
mastectomy versus BCT. All of these studies considered age as potential influencing factor 
(Table 3.6). Other sociodemographic factors reported in the literature include 
socioeconomic status (SES), race/ethnicity together or separate, education, marital status, 
annual income, area deprivation, poverty, body weight, BMI, employment, and insurance 
(Table 3.7). Even looking just at age, measures differed significantly throughout the studies 
with many considering averages such as means or medians, while others used various 
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cutoffs for group comparison from younger and older than 55 years old to 75 years old, or 
various stratified groupings. There were mixed results for the effect of age on treatment 
choice. Higher SES was linked to higher rates of BCT. Asian ethnicity was linked to higher 
rates of mastectomy, Black race was linked to higher rates of BCT, and other ethnic groups 
showed mixed results. 
For older women, most studies and the studies with better quality data supported 
increasing age favoring mastectomy. Nine of the studies concluded this with most studies 
having good sample sizes and six of the studies utilizing stratified age analysis. In contrast, 
only three studies favored older women choosing BCT, all of which had sample sizes under 
400 and used an average age comparison. Locker et al. conducted a review of data from the 
ATAC trial involving over 9000 patients and found older age groups were more likely to 
undergo mastectomy.(63) Compared to women diagnosed under the age of 60, those 
diagnosed from 60-69[OR, 1.28, 95%CI, 1.15–1.43], and 70[OR, 2.22, 95%CI, 1.95–2.52] 
were more likely to have mastectomy. In a SEER database review of 56,000 patients over 64 
years old, Hershman et al. also found increasing age was associated with decreasing 
likelihood of undergoing BCT.(61) Specifically, compared to a reference age of 65-69, all age 
groups including 70-74[OR, 0.91, 95%CI, 0.87–0.96], 75-79[OR, 0.83, 95%CI, 0.78–0.87], 
and 80+[OR, 0.77, 95%CI, 0.73–0.82] were less likely to undergo BCT.  
Two other large studies not only found older women were more likely to undergo 
mastectomy, but also younger women, with the middle age groups being relatively more 
likely to choose BCT. Olaya et al. conducted a database review of the California Caner 
Registry of more than 47,000 patients and found compared to women diagnosed at age 40-
64, those aged less than 40[OR, 0.73, 95%CI, 0.66–0.81] and those older than 64[OR, 0.85 
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95%CI, 0.81–0.89] were less likely to have BCT.(68) In another review of a large SEER 
database of over 100,000 patients, Boscoe et al. reported compared to women aged 65 and 
older, those 50-64 were less likely to have mastectomy [OR, 0.93, 95%CI, 0.90–0.96], and 
those younger than 50 were more likely to have mastectomy [OR, 1.31, 95%CI, 1.26–
1.36].(69) 
Other studies have shown younger women were more likely to undergo BCT. Two 
studies found that women aged younger than 55 were more likely to undergo BCT 
compared to those older than 55, Chagpar et al.(66) [OR, 1.46, 95%CI, 1.247–1.699] and 
Kelemen et al.(46) [OR, 1.22, 95%CI, 1.10–1.35]. Sauerzapf et al. conducted a chart review 
over 6000 patients the UK and found compared to women aged <50, other older age groups 
were significantly less likely to undergo BCT: 60-69[OR, 0.74, 95%CI, 0.61–0.89], 70-79[OR, 
0.37, 95%CI, 0.30–0.45], and over 80[OR, 0.32, 95%CI, 0.23–0.44].(70) 
Multiple studies found higher SES, or other indicators of SES including education and 
income associated with increased likelihood of BCT. Two large SEER database studies based 
in the USA found incremental increases in BCT rates with improving SES group.(61,68) SES 
was calculated based on participant’s zip code and census data from 2000 in both studies. 
Olaya et al. found that compared to SES quintile 1 (lowest SES), patients from quintiles 3 to 
5 were significantly more likely to undergo BCT 3[OR, 1.34, 95%CI, 1.09–1.29], 4[OR, 1.53, 
95%CI, 1.42–1.67], and 5[OR, 1.86, 95%CI, 1.72–2.01].(68) A UK-based study by Sauzerpauf 
et al. found similar results using the Index of Multiple Deprivation, a measure of 
poverty.(70) This study found that compared to the least deprived quartile, patients in the 
most deprived quartile were significantly less likely to undergo BCT[OR, 0.62, 95%CI, 0.54–
0.72].(70) A smaller survey conducted by Benedict et al. found the average income and 
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education level were significantly higher with individuals choosing BCT compared to 
mastectomy.(71) 
Studies measuring race and ethnicity varied in how they captured and grouped their 
information, but there were trends that Asian/Pacific Islander women were more likely to 
undergo mastectomy, while Non-Hispanic Black women were more likely to undergo BCT. 
Two studies reported that compared to White race, black or Non-Hispanic Black race was 
associated with increased rates of BCT, Hershman et al.(61) [OR, 1.19, 95%CI, 1.08–1.29] 
and Olaya et al.(68) [OR, 1.25, 95%CI, 1.13–1.39]. Conversely, two studies found 
Asian/Pacific Islander race associated with decreased likelihood of undergoing BCT, Olaya 
et al.(68) [OR, 0.61, 95%CI, 0.57–0.65] and Boscoe et al.(69) reported their results as 
increased likelihood of undergoing mastectomy[OR, 1.70, 95%CI, 1.60–1.80]. There were 
mixed or non-significant results for other race/ethnicities. 
3.6.5 Geographical Factors 
Table 3.8: Geographical factors results 
Author / 
Reference 
N Predicting Variables Analysis* Findings 
Hershman et al., 
2009 




Uni and Multi Non-metropolitan 
= lower BCT rate 
Sauerzapf et al., 
2007 
5,830 BCT, Group 
Comparison 
Travel time to RT 
facility, Lives 
within 800m of 





Travel time to RT 
= no difference. 
No bus service = 
higher 
mastectomy rate 
Celaya et al., 
2005 
2,861 BCT Distance to RT 
facility (straight 
line) (mi) 
Uni and Multi Increased 
distance to RT 
facility = lower 
BCT rate 





(urban vs rural) 
Group 
Comparison 
Rural = lower 
BCT rate 











Boscoe et al., 
2011 
104,730 Mast Distance to RT 
facility (by roads 
in km), Distance 
to surgery (by 
roads in km) 
Multi Increased 
distance to RT 




surgery centre = 
lower BCT rate 
Roder et al., 
2014 
30,299 Mast Resident location 
(major city, inner 
regional, more 
remote) 
Uni and Multi More remote 
location = higher 
mastectomy rate 
* Uni denotes univariate analysis; multi denotes multivariate analysis; RT denotes ration treatment 
Seven studies looked at geographical factors influencing mastectomy versus BCT. 
The variables reported include resident location, travel time or distance to a radiation 
treatment facility, living distance to bus service, wards with community transport, and 
distance to surgery centre (Table 3.8). The two most commonly examined factors were 
resident location and travel distance or time to a radiation treatment facility. Although 
some studies found no difference, most studies showed rural location and increased 
distance to a radiation facility were associated with lower rates of BCT. All studies were 
based in the USA, Australia, or the UK. Because the categories and definitions of variable 
were so mixed, no meta-analysis was possible for geographical factors.  
Four studies focused on resident location. In a large USA SEER database study 
looking at over 56,000 patients, Hersman et al. found individuals residing in non-
metropolitan areas were significantly less likely to undergo BCT on both univariate and 
multivariate analysis [OR, 0.43, 95% CI, 0.40–0.45].(61) Similarly, a large Australian 
database study conducted by Roder et al. found resident remoteness associated with 
increased rates of mastectomy [RR, 1.38, 95% CI, 1.23–1.54].(14) In their multivariate 
models, compared with major city residence, inner regional [RR, 1.05, 95% CI, 0.99–1.11] 
and more remote areas [RR, 1.09, 95% CI, 1.00–1.17] were still slightly more likely to 
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undergo mastectomy. In a smaller study, Mastaglia et al. also found women living in rural 
locations were more likely to choose mastectomy rather than BCT [χ2, 12.75, p=0.00].(72) 
Cyran et al. was the only study looking at resident location that did not find a significant 
difference between women living in rural or urban areas when it came to rates of 
mastectomy versus BCT[p=0.20].(16) 
 The three studies looking at living distance to a radiation facility were all travel 
focused studies examining related factors that may predict treatment choice. Both Celaya et 
al.(62) and Boscoe et al.(69) were US based studies that found individuals living farther 
from radiation treatment centres were less likely to undergo BCT. Celeya et al. found 
women living <20 miles from radiation treatment facility were at a decreased likelihood of 
undergoing BCT compared to women living at 20-40 miles [OR, 0.65, 95% CI, 0.53–0.79] 
and >60 miles [OR, 0.31, 95% CI, 0.15–0.65].(62) Boscoe et al. reported likelihood of 
mastectomy increased monotonically with increasing distances to both the nearest surgical 
and radiation treatment centres. For distance to a radiation treatment centre, the highest 
increase was found at 75– 100km [OR, 1.43, 95% CI, 1.23–1.65].(69) The UK study 
conducted by Sauzerpf et al. found differing results. They found that both distance to a 
radiation facility and estimated travel time were not predictors of treatment choice. The 
only exception found was women living further than 800m from a public transport service 
were less likely to undergo BCT.(70) 
3.6.6 Individual Belief Factors 
Table 3.9:  Individual belief factors results 
Author / 
Reference 
Study Design N Predicting Analysis* Findings 
Lee et al., 
2012 
Cross-Sectional  383 Mastectomy and BCT 
underlying reasons 
Questionnaire – Uni 
and multivariate 
Mastectomy – to gain peace of 
mind, avoiding radiation 
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BCT – keeping your breast 
Caldon et al., 
2011 




Mastectomy – fear of recurrence,  
BCT – body image concerns 




Cohort 157 Mastectomy and BCT 
underlying reasons 
Questionnaire – Uni 
and multivariate 
Mastectomy – concerns about 
recurrence 




Mixed-Methods 202 Mastectomy and BCT 
underlying reasons 
Structured interviews 
– analysis not 
specified 
Mastectomy - fear of cancer 
recurrence, potential side 
effects of radiotherapy, 
wanting a rapid solution 
BCT – local excision less 
disfiguring, less surgery 
involved, long-term outcome 






172 Mastectomy and BCT 
underlying reasons 
Questionnaire – Uni 
and multivariate, grp 
comparison 
Mastectomy – concern local 
recurrence 
BCT = concern loss of breast 
Schou et al., 
2002 
Cross-Sectional 194 Mastectomy and BCT 
underlying reasons 
Questionnaire – grp 
comparison, 
correlational 
Mastectomy – fear of recurrence 




Cross-Sectional 165 Mastectomy and BCT 
underlying reasons 
Questionnaire – grp 
comparison 
Mastectomy – no significant 
findings 
BCT – surgeon’s preference, no 
difference in survival 
Mcvea et al., 
2001 
Qualitative 43 Mastectomy and BCT 
underlying reasons 
Qualitative – template 
Style 
Mastectomy – more expedient, 
lower risk of LR 
BCT – comfortable with potential 
risks of LR, more aggressive local 




Cross-Sectional 192 Mastectomy and BCT 
underlying reasons 
Questionnaire – 
analysis not specified 
Mastectomy – cure rate better, 
quickly getting rid of cancer cells, 
avoiding radiation 
BCT – cure rate as good, 
appearance better 
Nold et al., 
2000 
Cross-Sectional 96 Mastectomy and BCT 
underlying reasons 
Questionnaire – grp 
comparison, 
Mastectomy – fear of breast 
cancer and recurrence, concern 
about radiation 
BCT – surgeon influence 
Kiloran et 
al., 2006 
Qualitative 62 Mastectomy and BCT 
underlying (Chinese-
US patients) 
Qualitative – general 
qualitative 
Mastectomy –based in vanity and 
therefore not safe, aesthetics not 
important, MRM safer 
BCT – physician recommendation 
* Uni denotes univariate analysis; multi denotes multivariate analysis 
Eleven studies looked at individual belief factors (Table 3.9). The majority of studies 
were survey-based and three of the studies were qualitative. Methodologically, they varied 
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greatly; specifically, data gathering and analysis. For questionnaires, there were differences 
in the number of individual factors provided, the wording of these factors, and whether 
they were rated on Likert scales or ranking lists. The analysis and reporting methods were 
also diverse from group comparisons to multivariate modeling. The qualitative studies also 
had varying methods. Specific methods and primary findings of each study are shown in 
Table 3.9. Overall, the main themes influencing women’s choice of mastectomy were 
mastectomy being the most reassuring option, avoiding radiation, and a more expedient 
treatment. The main themes influencing women’s choice of BCT were body image concerns 
and femininity, physician recommendation, long-term survival being equivalent, and less 
surgery being involved. 
The most common individual belief factors influencing choice of mastectomy can be 
grouped around the theme of mastectomy being the most reassuring option. This term was 
reported as fear of recurrence in six studies, gaining peace of mind in one study, and 
mastectomy being safer than BCT in 1 study. Schou et al. found individuals rating ‘fear of 
cancer recurrence’ highly correlated with choice of mastectomy [rs= 0.43, p=0.000].(73) 
Both Temple et al.[p=0.001](39) and Molenaar et al.[p<0.001](17) found women who 
underwent mastectomy rated fear of cancer recurrence significantly higher compared to 
women who underwent BCT. Lee et al. found those rating ‘removing your entire breast to 
gain peace of mind’ were significantly more likely to undergo mastectomy as well [OR, 1.88, 
95%CI, 1.60–2.20].(45) In a qualitative study, Caldon et al. reported ‘most reassuring 
treatment’ as the primary reason women chose mastectomy, further stating ‘many choosing 
mastectomy said this option reduced their anxiety about the completeness of cancer 
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excision…”.(47) In another qualitative study, Killoran et al. described ‘choosing BCT was 
inherently a decision based in vanity and was therefore not safe.’(74) 
The other individual belief factors found to influence mastectomy are avoiding 
radiation and being a more expedient treatment. Four studies reported ‘avoiding radiation’ 
or ‘potential side effects of radiotherapy’ as a significant factor influencing choice of 
mastectomy. Lee et al. found those rating ‘avoiding having radiation’ were significantly 
more likely to undergo mastectomy [OR, 1.23, 95%CI, 1.11–1.36].(45) Two studies reported 
patients choosing mastectomy because it provided a rapid solution for domestic or 
employment reasons.(65,75) McVea et al. conducted a qualitative study that reported “their 
decisions were based primarily on their preference for the option that was more 
expedient.”(75) 
The most common individual belief factor influencing the choice of BCT was related 
to body image concerns and femininity. Although potentially distinct, these two ideas were 
often not separated in the literature and often reported together or as connected. The exact 
terminology used in studies varied greatly including: ‘less disfiguring’, ‘physical 
appearance’, ‘appearance better’, ‘keeping your breast’, ‘local excision less disfiguring’, and 
‘importance of breast to sexuality’. Temple et al. found women who rated the factor 
‘importance of breast to sexuality’ highly was predictive of choice of BCT [95%CI difference 
in proportions %, 4.5–32.3, p=0.007].(39) This factor was related to ‘importance of breasts 
to feelings of being feminine’ in the study. Schou et al. found both ‘femininity’[rs= 0.26, 
p=0.000] and ‘physical appearance’[rs= 0.21, p=0.004] correlated with choice of BCT.(73) 
This was similarly found in a qualitative study by Caldon et al. who reported ‘body image 
concerns predominated among those choosing BCT”.(47) Lee et al. also found women rating 
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‘keeping your breast’ significantly less likely to undergo mastectomy compared with BCT 
[OR, 0.79, 95%CI, 0.70–0.88].(45) 
The other individual belief factors that were important for choice of BCT were 
physician recommendation, long-term survival being equivalent, and less surgery being 
involved. In a survey by Mastaglia et al., patients rated a list of factors that influenced their 
treatment decision. ‘Knowing my surgeon’s preference for the type of surgery’ was rated 
significantly higher for women choosing BCT compared to mastectomy [t=-2.30, 
p=0.023].(72) Nold et al. found similar results; the surgeon was significantly more 
influential in affecting choice of procedure for BCT rather than mastectomy[p<0.05].(76) A 
study by Benedict et al. found the most important factor for women’s choice of BCT was 
‘cure rate being equivalent between treatments’.(71) Mastaglia et al. found patients 
choosing BCT rated ‘no difference in survival’ significantly more important than those who 
chose mastectomy [t=-3.33, p=0.001].(72) This was similarly reported in a qualitative study 
by McVea et al.: ‘these women chose BCT reportedly because they felt comfortable with the 
potential risks of local recurrence, felt more aggressive local therapy was 
unnecessary…’.(75) 
3.6.7 Physician-Related Factors 
Table 3.10: Physician-related factors results  
Author / 
Reference 
N Predicting Variables Analysis* Findings 
Hershman et 
al., 2009 
56,768 BCT Surgeon demographics – 
Degree, Country of training, 
year of graduation, type of 
practice, No. of procedures 
(over cohort period), Gender 
Uni and Multi US-trained, >10 operations, 
graduation after 1975, and 




495 Mast Surgeon Comparison Uni and Multi Individual surgeon → 
predictor of mastectomy 
Temple et al., 
2006 
157 BCT Surgeon Comparison Uni and Multi Individual surgeon → 
predictive of mastectomy 
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Chagpar et al., 
2005 
4,086 BCT Surgeon demographics – No. 
of cases / year, % of practice 
breast-related, academic 
affiliation 
Uni and Multi Academic affiliation → 
increased BCT rates 
Keating et al., 
2001 




Consultation with a medical 
oncologist → increased BCT 
rates 





Primary physician in 
treatment planning (surgeon 
vs non), sex 
Grp Comp 
and Multi 
Female sex → increased 
BCT rates 






Grp Comp No difference between 
groups 
Roder et al., 
2014 
30,299 Mast No. of cases / year (mean 
per year) 
Uni and Multi Case load ≤ 10 → increased 
mast rates 
* Uni denotes univariate analysis; multi denotes multivariate analysis 
Nine studies examined how physician-related factors influenced patient’s choice of 
mastectomy versus BCT. The variables reported included comparing individual surgeon’s 
rates of BCT, medical oncology consultation, physician treatment recommendation, and 
specific surgeon demographics such as medical degree, country of training, gender, or 
number of procedures. Research design and factors investigated varied throughout the 
studies (Table 3.10). Overall, studies suggested female gender, higher case number, 
training, and individual surgeon practice in at a breast unit were associated with increased 
BCT rates. 
Hershmen et al. conducted a large SEER database review with over 56,000 patients; 
this study looked at the most influential surgeon-related characteristics. They found 
increased BCT rates associated with multiple characteristics including being US-trained 
[OR, 1.12, 95% CI, 1.03–1.22], performing >10 BCT procedures [OR, 1.29, 95% CI, 1.21–
1.38], year of graduation after 1975 [OR, 1.16, 95% CI, 1.08–1.25], and the most influential 
being female gender [OR, 1.40, 95% CI, 1.25–1.55].(61) A much smaller survey of Colorado 
women by Cyran et al. also found female physician gender associated with increased BCT 
rates [OR, 3.8, 95% CI, 1.21–14.4].(16) 
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There were a few studies to suggest that individual surgeons have varying practices 
and procedure rates. Reitsamer et al. conducted a single centre review of 3 specialized high 
volume breast surgeons, each with over 50 cases per year. After controlling for patient and 
tumor factors, compared to surgeon C, both surgeon A [OR, 2.88, 95% CI, 1.48–5.60] and 
surgeon B [OR, 2.63, 95% CI, 1.34–5.16] were significantly more likely to have patients 
undergo mastectomy.(64) Temple et al. similarly found that an individual surgeon was a 
predictor of being less likely to undergo BCT [95%CI difference in proportions %, 8.3–55.5, 
p=0.08].(39) 
Roder et al. conducted a large database review in Australia with over 30,000 
patients. They found surgeons with a mean annual breast surgery case load ≤ 10 associated 
with an increased likelihood of undergoing mastectomy [OR, 1.15, 95% CI, 1.05–1.25].(14) 
Chagpar et al. reviewed a Louisville breast sentinel lymph node study of more than 3,000 
patients. They found academic affiliation associated with increased BCT rates. [OR, 1.193, 
95% CI, 1.021–1.393].(66) 
3.7 Discussion 
The analysis and interpretation of this systematic review utilizes our conceptual 
framework of why women choose mastectomy versus BCT (Figure 3.1). Each construct was 
grouped and analyzed separately – clinicopathological factors, physician-related factors, 
and individual factors with subgroups of sociodemographic factors, geographical factors, 
and personal belief and preferences factors. The strength of conclusions that can be drawn 
from each of these constructs differs based on the results. 
Amongst the clinicopathological factors, larger tumor size, and therefore stage, is the 
clearest factor that is consistently associated with increased mastectomy rates. This is likely 
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multifactorial in reason. A larger tumor implies a potentially more technically challenging 
operation, and has been associated with an increased likelihood of requiring a re-
excision.(77,78) Furthermore, increasing tumor size has been associated with increased 
local recurrence rates.(22,23,79) Larger tumor size may also mean a poorer cosmetic 
outcome. These may all potentially bias the physician towards mastectomy and 
recommendation against BCT to the patient. Additionally, a larger tumor may influence the 
patient’s perception of the severity of disease, as well as their belief and faith in the 
effectiveness of BCT.  
For physician-related factors, we found data supporting female gender, higher case 
number, training, and individual surgeon practice variation were associated with increased 
BCT rates. Variations due to individual surgeon or surgeon gender certainly raise questions 
about how surgeons are influencing patient decision-making. If variations are due to better 
facilitation of patients’ treatment preferences, then some variation in procedure rates are 
acceptable. However, if these variations are due to individual physician bias, poor 
communication styles, or other innate characteristics like empathy and personality, this 
may reflect a poor standard of cancer care.  
The decision-making process between the physician-patient dyad is complicated and 
the details of the interaction are difficult to capture. There has recently been increasing 
research in this area; one popular model being adopted to capture this interaction is the 
shared decision-making (SDM) model.(41,43) This model breaks down the different steps 
in the treatment decision-making process and the individual roles through each step 
between physician and patient. In future research, we suggest it is not enough to capture 
only surgeon demographic characteristics, but also investigate the physician-patient 
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interaction to deepen the understanding of appropriateness and quality of this interaction. 
Researchers may wish to utilize a model like the SDM to ground their inquiries. 
For sociodemographic factors, age was the most prevalent that was reported. As 
detailed in the results, differing studies drew different conclusions as to how age affected 
treatment choice. The most consistent results from the literature, with good stratified 
analysis, seem to suggest that the extremes of diagnostic age are associated with increased 
likelihood of mastectomy. There have been various explanations hypothesized over how 
age leads to varying treatment choice. Some have hypothesized that women diagnosed at a 
young age are choosing mastectomy due to fear of recurrence; the increasing rates of 
contralateral prophylactic mastectomy in the young age group seems to support this.(80–
82) Alternatively, women of older age may choose mastectomy for a more expedient 
treatment, avoiding six weeks of radiation, and place less value on the cosmetic outcome as 
age increases. Another mechanism to explain the influence of age on treatment choice may 
be to view it as a moderator in the decision-making process for breast cancer instead of it 
being the main influence underlying treatment choice. For example, a woman may choose 
mastectomy because of fear of cancer recurrence, and diagnosis at a young age amplifies or 
increases this patient’s fear.  
Higher SES was repeatedly found to be associated with higher BCT rates.(61,68) The 
exact mechanisms causing this disparity are not clear. Is it related to income and/or 
education? Is it life-circumstances that limit individuals’ abilities to comply with six weeks 
of adjuvant radiation? There have been studies associating lower SES with later 
presentation of disease, which may influence both the patient and physician towards 
choosing mastectomy.(83,84) These finding raise many questions related to accessibility 
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and quality of care. If patients of low SES groups do not feel supported in their ability to 
undergo BCT, these hurdles need to be identified so strategies can be put in place to address 
their needs. Perhaps more time needs to be spent with patients from lower SES groups to 
explain treatment options and explore availability of local support programs, such as 
lodging and other social services aid. 
For geographical factors, most studies suggest that both resident rural location as 
well as increasing distance from radiation treatment facilities are associated with lower 
rates of BCT. The obvious conclusion is that because radiation treatment requires daily 
appointments for 4 to 6 weeks, both travel and/or accommodation may be significant in 
limiting patients’ choice. Furthermore, the potential financial, family, and overall life-impact 
may be more for those living far from rural locations. Other possible explanations for 
varying rates would include culture or community influences from rural areas on 
effectiveness of treatments, or wishing to avoid aspects of treatments such as radiation.  
Although individual belief factors may be one of the most important set of factors 
influencing women’s decision-making, it is the most difficult and often least well studied. To 
practically capture this information, researchers are required at the minimum to utilize 
questionnaires or interviews, which is unfortunately impractical and too resource intensive 
for large-scale studies. Studies examining individual preferences frequently found women 
chose mastectomy because it was the most reassuring option, and this was often the most 
important reason behind their treatment choice.(16,17,39,73,85) More recent studies have 
found this belief is complicated and that worry about cancer recurrence was always due to 
a secondary underlying reasons – observing failed BCT treatments, avoiding follow-up 
imaging, or family history of breast cancer.(86) The other individual belief factors found to 
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influence choice of mastectomy were avoiding radiation and being a more expedient 
treatment. As outlined in the results, many of these studies were survey or interview based 
with relatively small sample sizes. It would be interesting to see in larger scale studies how 
incorporation of individual belief factors such as avoiding radiation interacted with 
geographical factors such as rural location would affect the impact of each factor on BCT 
rates. The main themes influencing women’s choice of BCT were body image concerns and 
femininity, physician recommendation, long-term survival being equivalent, and less 
surgery being involved.  
If variations in procedure rates are assumed to be due underlying patient values and 
preferences, why have there been ongoing questions and research(45,69) regarding quality 
of care as it relates to regional variation for treatment of ESBC? This stems from the seminal 
National Institute of Health (NIH) Consensus Conference in 1999, which recommended BCT 
as ‘preferable’ because it was thought to be less invasive and cosmetically superior.(10) 
Subsequently, mastectomy rates have been used by health care researchers and policy 
makers as an indicator of quality of breast cancer care.(87) Researches have frequently 
cited ‘underuse’ of BCT(16) and even gone as far as calling BCT the ‘standard of care’ in 
some studies.(64) However, viewing procedural variation as a result of patient preferences 
compared to evaluating low BCT rates as a failure of meeting recommendations are 
dichotomous views.  
There has been a recent shift in thinking away from looking at just mastectomy rates 
and placing more focus on patient-centered care and SDM.(40) With newer research, there 
is increasing evidence that many patients choose mastectomy for many of their own 
reasons. As well, some studies have even demonstrated that if physicians recommended a 
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procedure to patients, BCT was usually suggested. Some authors have even suggested that 
the use of mastectomy rates as a quality indicator may actually bias the physician treatment 
against patients’ wishes.(88) One study found decreased patient satisfaction and physician 
trust if surgeons attempt to push BCT as the treatment modality to patients who truly 
preferred mastectomy.(74) With this shift, there is beginning to be more acceptance of 
higher mastectomy rates if they vary for underlying patient preferences and not other 
reasons.(89) Within Canada, this is reflected in the latest 2015 Canadian Partnership 
Against Cancer(27) report that stated ‘the interprovincial differences do not necessarily 
reflect differences in the appropriateness of treatment or the quality of care’(p.82). They 
further go on to state that there are no formal Canadian performance targets for actual 
treatment rates.  
3.8 Conclusions 
This review provides a good summary of the factors influencing why patients choose 
mastectomy versus BCT. By utilizing a conceptual framework, we have organized the 
numerous factors under broader constructs, which will provide clinicians a logical 
framework for consideration while counseling patients. We strongly suggest any future 
work done in this area to utilize a framework, such as the one we have proposed, to achieve 
a comprehensive understanding of this complicated topic. 
We can conclude from this review that the choice of mastectomy versus BCT is a 
complicated decision-making process and influenced by many factors. When reviewing 
ESBC procedure rates, administrators should consider the complexity behind treatment 
choice. Instead of focusing on mastectomy rates as a quality of care indicator, there should 
be a shift in attention to whether patient-centered care and SDM are being achieved. Care 
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teams should ensure patients are making treatment decisions based on informed personal 
preferences and values. Additionally, future research can be aimed to identify barriers to 
appropriate care, such as long travel times and lack of lodging for radiation treatments.  
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CHAPTER 4: METHODS  
4.1 Exploratory Sequential Mixed Methods Design 
Many definitions of mixed methods are available in the literature; one such 
definition is ‘research in which investigator collects and analyzes data, integrates the 
findings, and draws inferences using both qualitative and quantitative approaches or 
methods in a single study or program of inquiry’.(90) (p.4) In 2011, the National Institutes 
of Health (NIH) commissioned a report on ‘Best Practices for Mixed Methods Research in 
Health Sciences’ to assist investigators in using mixed methods and aiding reviewers in 
evaluating it.(91,92) They describe what are commonly accepted as the four major mixed 
method specific designs: convergent (parallel or concurrent) design, sequential designs 
(explanatory sequential or exploratory sequential), embedded (nested) designs, and 
multiphase design.(92) This program of research followed the classical description of an 
exploratory sequential mixed methods design. This research was conducted in two phases 
beginning with an initial exploratory qualitative phase followed by a second phase of 
quantitative data collection and analysis that builds on the results of the first qualitative 
phase.(93) 
4.1.1 Rationale Behind Mixed Methods Design 
This program of research has employed mixed methods research for multiple 
reasons. The most important reason was choosing a research design that best fit the 
research aims. Decision-making around ESBC therapy is complicated and we sought to 
create a study design that best investigated the full extent of factors influencing therapy 
choice while still capturing a maximal proportion of the study population. We felt using a 
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combination of qualitative and quantitative approaches enabled us to better understand 
our research query rather than utilizing any single approach alone.(94) By utilizing 
qualitative methods initially, we were able to investigate in depth connections underlying 
patients therapy choice. By using quantitative methods subsequently, we were able to 
directly apply what was learned in the initial qualitative phase of research, as well as from 
other literature, to more broadly study the Saskatchewan population and obtain results that 
are more generalizable.  
A primary goal of employing an exploratory sequential design is to use the initial 
qualitative results to help inform and improve the quantitative study.(94) This is often to 
help develop an instrument based on the results.(93) These goals are directly in-line with 
our own research goals. As little was known about Saskatchewan’s local practice patterns 
and patient preference factors in ESBC, an initial qualitative study greatly improved our 
ability to design a pertinent survey. The qualitative study was aimed at identifying the 
factors that influenced patients’ choice within our population of interest, Saskatchewan 
women with ESBC. These findings directly guided creation of the portion of our 
questionnaire aimed at capturing individual preferences and values. As the questions were 
grounded in Saskatchewan patients’ perspectives, specific questions, terminology, wording, 
and follow-up questions were based on our initial qualitative study. For example, if a 
participant rated worry about cancer recurrence as an important factor influencing her 
choice of therapy, she was asked a follow-up question to identify the secondary reason that 
impacted this worry about recurrence. This depth in questionnaire design and the specific 
response options were created based on findings from our initial qualitative study. 
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We are able to compare and contrast the results of the exploratory qualitative 
thematic findings with those from the quantitative survey. If findings from both studies and 
data sources are congruent, the conclusions drawn will be stronger and more 
contextualized. If some results are contrasting, this may point to areas needing further 
investigation in future research. Reporting and drawing results from two intersecting 
studies will also more readily bridge the gap of understanding between research and 
practice. 
Another reason to choose an exploratory sequential design is if there are no guiding 
frameworks in place.(93,94) There were previously no guiding framework on 
understanding the factors that influence a woman’s choice between mastectomy versus 
BCT in ESBC. Most of the past research on this topic has been clinically based and not 
theoretically driven. As this topic is complicated and multifaceted, an initial qualitative 
exploration enabled the research team to use their results, in combination with other 
resources, to create a conceptual framework (see chapter 7).(95) This framework was 
important in guiding design and creation of the survey in the following quantitative phase 
of research. 
4.2 Initial Qualitative Phase 
4.2.1 Interpretive Description 
The methodological approach for the qualitative study is interpretive description 
(ID). ID is a qualitative framework originating from the nursing field, first introduced by 
Sally Thorne and colleagues in 1997.(96) ID arose from a need for an applied qualitative 
research approach that better aligned to complex clinical phenomena within applied health 
disciplines.(97) As described by Thorne (2008), ‘Interpretive description is a qualitative 
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research approach that requires an integrity of purpose deriving from two sources: (1) an 
actual practice goal, and (2) an understanding of what we do and don’t know on the basis of 
available empirical evidence (from all sources)’.(97) It is not a prescribed set of steps to 
perform in a study, but rather a design logic model whereby qualitative studies that are 
generally performed in applied disciplines can be designed and enacted with meaningful 
results.  ID can serve as a framework for which various data collection and analytic 
strategies can be used, depending on the study query, as long as there is consistency and 
logic between methods and intent of study. 
The epistemological foundation of ID aligns closely with naturalistic inquiry, 
acknowledging the constructed and contextual nature of human experience that at the same 
time allows for shared realities.(98) Thorne elaborates on the philosophical underpinnings 
and assumptions about knowledge in her book(97): 
- Are conducted in as naturalistic a context as possible in a manner that is respectful 
of the comfort and ethical rights of all participants 
- Explicitly attend to the value of subjective and experiential knowledge as one of the 
fundamental sources of clinical insight 
- Capitalize on human commonalities as well as individual expressions of variance 
within a shared focus of interest 
- Reflect issues that are not bounded by time and context, but attend carefully to the 
time and context within which the current expressions are enacted 
- Acknowledge a socially ‘constructed’ element to human experience that cannot be 
meaningfully separated from its essential nature 
- Recognize that, in the world of human experience, ‘reality’ involves multiple 
constructed realities that may well be contradictory, and 
- Acknowledge an inseparable relationship between the knower and the known, such 
that the inquirer and the ‘object’ of that inquiry interact to influence one another 
- A priori theory cannot encompass multiple realities that are encountered; rather, 
they recognize that theory must emerge from or be grounded in that phenomenon 
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In this way, these philosophical underpinnings provide a foundation of coherence for ID 
studies and separate them from other blended approaches or generic qualitative 
description. 
ID stresses the value of building inquiries within existing knowledge so findings can 
be constructed on the work of others, calling it ‘theoretical scaffolding’(97) similar to what 
is described as an ‘analytic framework’ in the literature.(96) Establishing a foundational 
forestructure has two critical elements to create an appropriate platform on which to build 
a qualitative design. The first element is the review of the literature; this is to ground the 
study within existing knowledge and draw conclusions about what is known in relation to 
the clinical problem that concerns the investigator.  This is an opportunity to critically 
reflect on what exists and does not and offer commentary on the overall body of knowledge.  
The second element is theoretical forestructure, which refers to recognizing the researchers 
own orientation and theoretical ideas that they bring from their discipline.  Expert clinical 
knowledge is seen as solid grounding for research design, especially in areas where 
empirical data about a phenomenon are limited.  Expert clinical knowledge can provide 
relevant structure and orientation for initiating an inquiry. As this is explicitly done as a 
foundation of the inquiry, it will typically be challenged as the inductive analysis proceeds.  
This also provides a basis upon which the design logic and the inductive reasoning in 
interpreting meanings with the data can be judged.(96) 
 ID promotes the use of purposeful sampling and theoretical sampling, reflecting 
awareness of expected and emerging variations within the phenomenon of study.(98) 
Multiple data sources and triangulation are also encouraged. A collateral data source that is 
also discussed by Thorne is the ‘thoughtful clinician’, whose perspectives will have been 
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formulated based on seeing large numbers of cases, each with their own potential 
variations and diversities. The ‘thoughtful clinician test’ may be built into the study design 
to help avoid analytic errors as well. This triangulation technique with other participant 
data can improve the power of study findings.(97) Data analysis is not restricted to one 
method, but instead promotes interpretation of data while exploring meanings and 
explanations that may yield clinical implications.  General techniques such as concurrent 
data collection and analysis, constant comparative analysis, and iterative analysis are 
suggested.(98) There are several limitations to the use of ID as a methodological 
framework. One of the primary challenges is the relative novelty of this method. Although 
texts describing the method are thorough, its implementation in study designs throughout 
the literature is limited. Therefore, there are few resources that can be referred to for 
further guidance and examples. 
The choice of ID as a framework to examine why Saskatchewan women choose 
mastectomy versus BCT was a natural fit. Not only does the philosophical basis align with 
the perspective of the researcher, the framework provides excellent congruency between 
intended research design, methodology, objectives and methods in the project. As the study 
objectives and applications are clinically grounded, ID provides a methodology that best 
orients the research process towards the clinical context and the generation of practice-
relevant findings. This fits well with the overall sequential mixed methodology study as 
well. Furthermore, the clinical expertise of the researchers involved in this study provide an 
excellent basis for theoretical forestructure, as well as a clinical basis for interpretation. 
Despite being a relatively new qualitative approach, expert qualitative researchers such as 
Margaret Sandelowski strongly support this method: ‘Indeed Thorne is to be commended 
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for acknowledging and celebrating accommodations of method to research imperatives and 
disciplinary agendas of the scholars using them’.(97)  
4.2.2 Thematic Analysis 
The method of analysis chosen for this study is thematic analysis, as described by 
Braun and Clark (2006).(99) This method has a clearly outlined process, application, 
guideline to use, and evaluation. This method is specifically outlined into six steps: (1) 
familiarizing yourself with your data, (2) generating initial codes, (3) searching for themes, 
(4) reviewing themes (5) defining and naming themes (6) producing the report.(99) These 
steps are each described in greater detail below. General qualitative research strategies like 
constant note writing, recursive processing, and simply taking time to examine and think 
about the data, are emphasized throughout all steps. It is important to note that although 
the analysis is outlined in a linear phase-by-phase process, thematic analysis is more 
realistically conducted as a fluid and recursive process.(99,100) 
The initial familiarization phase should have the researcher become familiar with all 
aspects of the data. This can be achieved through many means: participating in data 
collection, active reading and re-reading for meanings and patterns, orthographic 
transcription of data, and taking notes. Reading the data should be done in an ‘active way – 
searching for meanings, patterns and so on’.(99) Immersion into the data should be to the 
extent that the researcher is familiar with the depth and breadth of the content. It is 
recommended to start making notes and formulate some overall ideas for coding in the 
subsequent phase.  
The second phase is generalizing an initial set of codes from the data. The process of 
coding is considered part of the analysis, as the data are organized into meaningful groups. 
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Coding can be performed in a data-driven/inductive way or theoretical/deductive way. 
Inductive or bottom up analysis creates codes close to the data, without trying to fit them 
into pre-existing coding frames or the researchers’ analytic preconceptions. Deductive or 
top down analysis is generally more explicitly theoretically or analyst driven, and often 
driven more specifically by the research question. The entire data set should be analyzed 
systematically, paying full and equal attention to each data item to identify interesting 
aspects in the data set.  These codes will form the basis of repeated patterns (themes) 
across the data set. A comprehensive and inclusive approach should be taken for the initial 
coding phase.  
The next phase is searching for themes. This involves sorting the different codes into 
potential themes and collating the relevant data extracts from within the identified themes. 
Organization of themes may be done with a variety of methods including: tables, mind-
maps, theme-piles, and/or thematic maps. This phase involves further analysis of codes, as 
the researcher is considering how different codes may combine to form themes. A 
candidate or initial thematic map is encouraged as this promotes thinking about the 
relationship between codes, between themes, and between different levels of themes.  
The fourth phase is reviewing the themes. This process of refining and reviewing 
themes is a two-stage process. The first is reviewing themes at the level of individual coded 
data extracts to see if they fit into the candidate themes. All collated codes need to be re-
read for each theme to consider fit and whether they appear in a coherent pattern. Codes 
may need to be redirected to different themes, or candidate themes themselves may need to 
be collapsed, expanded, combined, or discarded. The second phase is reviewing the validity 
of individual themes relative to how they fit to the entire data set. The researchers’ 
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theoretical approach may influence how this review step is conducted. The candidate or re-
worked thematic map is reviewed for how accurately it reflects the meanings of the data set 
as a whole. Coding additional data within the reworked themes is also encouraged, and 
often done as an ongoing process. This phase can also be conceptualized as examining for 
‘internal homogeneity’ and ‘external heterogeneity’. This phase may be an iterative process 
until the researcher is satisfied with the fit of the themes and thematic map with the overall 
data set. 
The fifth phase is defining and naming themes. Defining a theme is meant to identify 
the ‘essence’ of what each theme is about. This explanation should include what scope and 
aspect of the data set each theme captures and what it does not. Final data extracts for each 
theme can be collated, organized, and be given a consistent account with narrative. It is 
important to go beyond summarizing or paraphrasing in order to identify the interesting 
features of theme, with supporting evidence. This detailed analysis should also consider 
how the theme fits into the broader overall story relative to the research questions or 
objectives. Identified subthemes can be similarly defined and explained at this stage. By the 
end of the stage, final names for each theme should be given for final analysis. 
The sixth and final phase is producing the actual report. This may be for the purpose 
of publication, an assignment, or dissertation. Whatever the end goal, the report should 
convince the reader of the merit and validity of the analysis. Braun and Clarke emphasize 
the importance that the analysis ‘provides a concise, coherent, logical, non-repetitive and 
interesting account of the story the data tell – within and across themes’.(99) Data extracts 
should be used to exemplify the essence of the themes. Interpretive claims may be related 
 
 81 
to existing literature. The overall analytic narrative should go beyond description to make 
an argument in relation to the research question. 
Initial familiarization with the data included reviewing all transcripts of the 
interviews to become submerged in the data. Subsequently three members of the research 
team, two of the interviewers and one qualitative expert (J.G., Y.H., A.L.), individually 
created an initial set of codes using sample interviews transcripts. The team met on 
multiple occasions to discuss the initial candidate codes. When appropriate, in vivo codes 
were created by using participants’ language as labels. These codes were then sorted to 
create, modify, and complete an initial thematic index. Throughout this process, there was 
emphasis on being comprehensive and inclusive of coded data.  
Subsequent analysis was completed by JG. In-depth, line by line coding utilizing the 
initial thematic index was conducted for all interviews. Coding and modification of the 
thematic index was an iterative process (Appendix D). Once completed, an initial candidate 
thematic map was created using the TPB as a guiding framework (Appendices E and F). 
Separate maps were created for the mastectomy and BCT data sets.  
All codes and themes were reviewed in the next stage of analysis. All coded data 
extracts for a theme were individually reviewed and refined to ensure they formed a 
coherent pattern. Any co-existing codes within a data extract had codes and originating 
themes compared for associations. This process was conducted through all candidate 
themes. Individual themes were subsequently reviewed in relation to other themes, the 
concept map, as well as the data set as a whole. Re-working the codes, themes, and concepts 
maps was an iterative process. Constant-comparison techniques were utilized to confirm 
and challenge ideas throughout themes.(98) This was done in both the mastectomy and 
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BCT analysis, producing final thematic maps and results (Figure 5.1 + 5.2). To increase the 
validity of findings, the ‘thoughtful clinician’ test as described by Thorne was employed.(98) 
Expert clinicians with surgical oncology or breast fellowships, familiar with the decision-
making process, were consulted to review study results to see the extent to which they 
match or enlarge their clinical hunches. The findings were shared with clinicians, 
encouraging them to challenge or confirm the evolving interpretations. Member checking 
with patients was not performed due to time constraints. 
Thematic analysis was chosen because this method allows for the theoretical 
flexibility to be tailored to both interpretive description and applied research. In contrast to 
many other analytic methods, thematic analysis is not wed to any pre-existing theoretical 
framework and is not a full research methodology on its own. ‘What is important is that the 
theoretical framework and methods match what the researcher wants to know’.(99) 
Combining this flexibility with interpretive description as a qualitative approach provides 
an opportunity for congruency throughout the analytic process. Thematic analysis allows 
for the use of theoretical forestructure, both from the literature and clinical expertise, to be 
incorporated into the analysis. The applied research goals of interpretive description and 
thematic analysis are both appreciated. Despite the flexibility of thematic analysis, rigorous 
research can be achieved through clear and explicit explanation of analysis. Reicher and 
Taylor (2005) state that ‘rigour lies in devising a systematic method whose assumptions are 
congruent with the way one conceptualizes the subject matter’.(99) Furthermore, this is a 
relatively easy method to learn, making it ideal for a novice qualitative researcher. 
 There are several potential limitations of thematic analysis. Although flexibility of 
the method is an advantage, this does leave opportunity for a range of potential problems 
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throughout the analysis. As there is potential variability on how data are analyzed, specific 
guidelines for higher-level analysis is limited. Furthermore, if thematic analysis is not linked 
to an existing theoretical framework, its analytic and interpretive power is limited beyond 
description. Because novice qualitative researchers often use thematic analysis, its methods 
can be misused by not following proper methods and qualitative research principles. This 
has led to thematic analysis sometimes appearing as a generic qualitative analysis.  
4.2.3 Remaining Qualitative Study Details 
An interview guide can be seen in Appendix G. Remaining qualitative study details 
including: recruitment/instrumentation, analysis, mastectomy participant result, BCT 
participant results, discussions, limitations, and conclusions are detailed in the published 
journal article in Chapter 5. 
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CHAPTER 5, MANUSCRIPT #2: UNDERSTANDING WOMEN’S CHOICE OF 
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Content included in this article does not significantly differ from the published manuscript. 
However, grammatical modifications have been made, and the document has been 





Objective: To identify factors that influence Saskatchewan women’s choice between breast 
conservation therapy (BCT) or mastectomy in early stage breast cancer (ESBC) and to 
compare and contrast underlying reasons behind choice of BCT versus mastectomy. 
Methods: Interpretive description methods guided this practice-based, qualitative study. 
Data were analyzed using thematic analysis and presented in thematic maps. 
Results: Women chose mastectomy consistent with one of three main themes: worry about 
cancer recurrence, perceived consequences of BCT treatment, or breast-tumor size 
perception. In contrast, women chose BCT consistent with one of three different themes: 
mastectomy being too radical, surgeon influence, and feminine identity.  
Conclusions: Although individual reasons for choosing mastectomy versus BCT have been 
discussed in the literature, the different rationales underlying each choice have not been 
previously described. These results are novel in identifying interdependent subthemes and 
secondary reasons for each choice. This is important for gaining increased understanding of 









In North America, breast cancer is the most commonly diagnosed cancer and the second 
most common cause of cancer death for women.(11) For early stage breast cancer (ESBC), it 
is well established that breast conservation therapy (BCT) and mastectomy offer equivalent 
survival.(2–4,101) Treatment for ESBC can therefore be viewed as preference sensitive 
care, so that decision-making between treatment options should vary according to patient 
preferences and values, although it could also vary for other reasons.(32)  
Quantitative studies have examinied the factors that influence therapy choice, but 
this literature is limited to mostly chart or database reviews, is largely retrospective, and 
has been conducted mostly outside of Canada.(13–15) Common demographic factors 
examined in such studies include age, education, and ethnicity. Age has shown discrepant 
results, with the most consistent finding being an increased likelihood of undergoing 
mastectomy in those younger than 40 or 50.(13) The middle age groups generally do not 
show significant findings. Age groups older than 70 or 80 have shown mixed results, with 
some studies noting increased mastectomy rates but others showing decreased 
rates.(16,26) Furthermore, some studies have not found any association of age with 
mastectomy rates.(47,102) With respect to ethnicity, African American, Hispanic, and Asian 
/ Pacific Islander women have independently been associated with increased rates of 
mastectomy.(13,74)  
Travel-related factors such as distance to a radiation treatment centre have shown 
varying effects on rates of BCT versus mastectomy. Although several studies have 
demonstrated a decreasing rate of BCT as distance to radiation centre increases(62,69,70), 
others have found no difference.(75,103)  
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Individual values and preferences may be the most important subset of factors 
influencing choice of mastectomy versus BCT, yet are the least well studied. The complex 
nature of decision-making in ESBC makes fully understanding the spectrum and 
significance of these factors difficult. The majority of this research has been through simple 
stand-alone questionnaires, or descriptive qualitative studies. Important personal beliefs 
and preferences previously noted in the literature include equivalent survival between BCT 
and mastectomy, fear of cancer recurrence, cosmetic appearance, and feminine 
identity.(16,71,73,76)  
Mastectomy rates across Canada have varied greatly over the past decade with the 
latest reports from 2008 to 2013 showing interprovincial rates ranging from 25.3% to 
68.3%.(27) This geographical variation raises many unanswered questions: Are differences 
related to quality or appropriateness of care? Are attitudes and beliefs of clinicians 
influencing procedure rates? Are treatment choices related to local patient factors such as 
belief patterns or geography? This study takes place in the province of Saskatchewan, which 
had the second highest mastectomy rate of 63.4%, compared with a national average of 
39%.(27) To better understand the nature of this variation as well as the factors that 
informs women’s treatment options, further research is needed, beginning with patient 
decision-making at the regional level . The objective of this study was to identify factors that 
influence Saskatchewan women’s choice between BCT and mastectomy in cases of ESBC, 





The Interpretive Description qualitative methodology was used to guide this 
research.(26) This methodology is often used in complex clinical phenomena for applied 
qualitative research within health disciplines such as nursing, psychiatry, and 
medicine.(96–98,104) The philosophical basis aligns well with the researchers’ 
perspectives, and the framework provides congruency between the methodology, 
objectives, and methods in this project.(26) The choice between mastectomy and BCT can 
be viewed as a planned behavior. The Theory of Planned Behavior is a conceptual 
framework that links beliefs and behavior.(38) This framework, which has been used to 
study ESBC decision-making in the past(39), and helped guide this study’s framework and 
analysis. 
5.5.2 Sampling and Recruitment 
REB approval was obtained from the University of Saskatchewan. The Saskatchewan 
Cancer Agency (SCA) provided recruitment support. Women who had ESBC and who had 
been treated in the calendar year preceding July 2013, were identified. The SCA recruited 
participants by mailing letters of invitation to potential participants. A purposeful sampling 
plan was aimed at capturing diversity and variation in the phenomenon under study – 
specific characteristics identified included different age groups, minority groups, and urban 
versus rural location of residence. No incentive was offered for participation. Potential 
research participants contacted the researchers and face-to-face interviews were arranged 
at the convenience of the participant, including in rural locations.  
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Data collection was conducted by the lead author, who is a surgical resident and 
doctoral student (J.G.), and by two research assistants who were medical students. 
Supervision was provided by a clinical expert (G.G) and a qualitative expert (A.L.). 
Interviews for thirteen women who chose mastectomy and twelve women who chose BCT 
were included for analysis. Two mastectomy and three BCT interviews were excluded 
because the patients felt that they had not been offered treatment options, and thus had not 
engaged in a decision-making process. Semi-structured interviews allowed for in-depth 
open-ended discussions based on questions formed from factors previously known in 
literature(13,14,66) as well as from other clinically-based hypothesized factors. All 
interviews were audio-recorded and transcribed verbatim.  
5.5.3 Analysis 
The ATLAS.t.i. software was used for data management and analysis. Thematic 
analysis followed Braun and Clark was conducted.(99) Three members of the research team 
– two interviewers and one qualitative expert (J.G., Y.H., A.L.) – created a set of codes using 
sample interviews from the primary data. When appropriate, in vivo codes were created by 
using participant’s language as labels. These codes were then sorted to create, modify, and 
complete an initial thematic index. 
Subsequent analysis was completed by JG. In-depth, line-by-line coding using the 
initial thematic index was done for all interviews. Coding and modification of the thematic 
index was an iterative process. After completion, an initial candidate thematic map was 
created using the Theory of Planned Behavior as a conceptual framework. Separate maps 
were created for the mastectomy and BCT data sets. Next, all coded data extracts for a 
theme were individually reviewed and refined to ensure that they formed a coherent 
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pattern. Individual themes were subsequently reviewed in relation to other themes, the 
concept map, and the data set as a whole. Re-working the codes, themes, and concepts maps 
was an iterative process. Constant-comparison techniques were used to confirm and 
challenge ideas throughout themes.(98) This was done in both the mastectomy and the BCT 
analysis, producing final results illustrated in thematic maps (Figures 5.1 and 5.2). To 
increase the validity of findings, the ‘thoughtful clinician’ test described by Thorne was 
employed.(98) Expert clinicians with surgical oncology or breast fellowships were asked to 
review the study results and challenge or confirm them. 
Audio recordings, participant transcripts, thematic indexes, concept maps, and early 





 Thirteen patients who underwent mastectomy and twelve patients who underwent 
BCT were interviewed. Averages ages and rural versus urban distribution of participants 
were comparable. Demographic data appear in Table 5.1. 
Table 5.1: Demographics          
Characteristic Mastectomy (N)* BCT (N)* 
Median age in years at the time of diagnosis 
(range) 
64 (33-89) 60 (46-80) 
Participant’s home in a rural location 4 (30.8) 5 (41.7) 
Participant’s home in an urban location 9 (69.2) 7 (58.3) 
Participant’s home located in a tertiary centre 
with a radiation centre 
7 (53.8) 6 (58.3) 
Participants of a visible minority 1 (7.7) 1 (8.3) 
* Number in parentheses refers to percentages unless otherwise specified 
 
5.6.2 Mastectomy 
Women who chose mastectomy primarily based their decision on one of three main 
themes: worry about cancer recurrence, worry about the consequences of BCT treatment, 
or perception of the breast-to-tumor size ratio. The final thematic map indicating women’s 
reason for choosing mastectomy is shown in Figure 5.1. 




Worry about cancer recurrence. This theme was the main reason most women chose 
mastectomy. Participants were concerned about cancer recurrence and wished to do 
everything they could to minimize this risk. This concept formed by combining two earlier 
themes, minimizing cancer recurrence and obtaining peace of mind. The choice of 
mastectomy relieved these participants’ concerns about breast cancer and was described as 
‘eliminating risk’, ‘getting rid of it all’, and obtaining ‘peace of mind’. This is well exemplified 
through the following participant response: ‘And just eliminating the risk, and I am a 
worrier, and I would probably always be feeling my breast and think “oh no”’ (Mastectomy 
participant 2). The source of worry about cancer recurrence was always related to another 
underlying reason, or subtheme: observed failed BCT, avoiding follow-up imaging, and 
family history.  
Observed failed BCT. A common reason for worry about cancer recurrence was 
having had a close family member or friend fail BCT. Failures were described as requiring 
re-excisions, having subsequent mastectomy, cancer recurrence, or death from cancer. 
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These negative experiences in the lives of close individuals caused significant apprehension 
and deterred participants from believing, trusting, or pursuing BCT. 
I had known always, and I've said this for years, but if I ever had breast cancer I 
would have a mastectomy. I don't believe in lumpectomy, and I don't believe in 
radiation treatments. I've had many friends who have had lumpectomy in the past 
and they've all had cancer recurrence. And then had to have more surgery again. So I 
don't believe in lumpectomy (Mastectomy participant 7). 
Avoid follow-up imaging. Some participants did not want the continual follow-up 
imaging required with BCT. The process of repeated imaging tests checking for recurrence 
caused fear. Participants felt more comfortable having all of the breast tissue removed, 
knowing that they would not have to deal with this source of worry. ‘I always thought I 
would always get it all taken care at once. The risk of recurrence, and the fear finding a 
lump again, and the fear of always checking, I would always be looking for a lump and I 
didn't want that’ (Mastectomy participant 3). 
Family history. A strong family history influenced two participants’ decisions to 
choose mastectomy. This increased worry about recurrence was evident when a 68-year-
old participant said: ‘Even if it was a lumpectomy today, what is the chances I might not get 
it again… .The guiding factor was my strong family history of breast cancer’ (Mastectomy 
participant 13). 
Consequences of BCT Treatment. Some participants held firm opinions that choosing BCT 
would result in consequences that they did not wish to experience. These were either side 
effects of radiation therapy or the potential of requiring more surgery. Avoidance of 
radiation was based on individuals’ having observed adverse side effects afflicting someone 
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they knew, or from workplace experiences: ‘I didn’t like the idea of radiation, I work in the 
OR and I’ve seen surgeons complain of radiated fields so I did not want to have radiation. So 
that’s the reason I chose mastectomy’ (Mastectomy participant 13). Some participants 
wanted to undergo surgery only once, without risking re-operation. Although wanting to 
avoid radiation and re-operation risk were often related, only one was central in the 
decision to have mastectomy. 
Breast–Tumor Size. The size in this theme refers to what was perceived by the participant 
throughout her treatment interactions. The perceptions of having a large tumor, small 
breast, or large tumor-breast ratio were important influences in the choice of mastectomy. 
‘I remember in my mind lumpectomy was never an option. I never was considering it. 
Because of the size of the tumor I just wanted the whole breast gone. And with lumpectomy 
I wouldn’t have been left with very much breast tissue anyways’ (Mastectomy participant 
8). 
5.6.3 Breast Conservation Therapy 
The central themes that influenced women to choose BCT were: mastectomy being too 
radical, surgeon influence, and feminine identity. The final thematic map illustrating why 
women chose BCT is shown in Figure 5.2. 




Mastectomy Too Radical. Having the entire breast removed with a mastectomy was 
viewed as being too radical or extreme for the stage of disease patients’ felt they had. 
Mastectomy being too radical was related to some main subthemes: perceived recovery 
time, perceived tumor size, and confidence in BCT. 
 Perceived recovery time. The subjective difference in the impact of operation 
between mastectomy versus BCT surgery influenced women’s decision making. 
Participants choosing BCT wanted surgery that put less stress on the body, had a shorter 
recovery time, and had less overall effect on their life. This was sometimes due to 
participant’s older age or the presence of comorbid disease.  
I wanted the one that took less time, had less impact on my life. I think the 
mastectomy would have taken more time to recover. A friend of mine has gone 
through it, she is still off of work and it has been almost three years. She has gone 
through a lot of struggles and physiotherapy and I felt lucky that we caught it early 
and I didn’t have to deal with that part (BCT participant 12). 
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Perceived tumor size. A central reason behind many women’s decision for BCT was 
that mastectomy was viewed as too radical considering to the size of the tumor. Several 
participants felt that they didn’t need a drastic surgery to control a small tumor. ‘Because it 
had been so small, if it was massive I would say, “Look, let’s do something major”. It was so 
small – why should I lose a whole breast?’ (BCT participant 06). 
 Confidence in BCT. Several women explicitly expressed confidence in BCT treatment 
and were comfortable with the potential consequences of this approach. Furthermore, they 
acknowledged the possibility of a further surgery, preferring a ‘staged approach’:  
I think because there is less complications if I go that way. Also I have a second 
chance to go that way if I have to. I have a firm belief that science has come so far 
over the years. Those things were encouraging for me (BCT participant 11). 
Surgeon Influence. Surgeon influence was a common reason for women’s choice of BCT. 
The surgeon was held as an important referent whose opinion was highly valued. In fact, 
several women completely defaulted their treatment decision to their surgeon’s 
recommendation. These women expressed strong trust and faith in their surgeon.  
And of course he influenced it – he knows more about the area than I do. And when 
he said if it was his mother he would recommend the lumpectomy … even though 
you are a retired health care provider its different when you are on the other side of 
the fence. You don’t think logically. It was mostly his recommendation to have the 
lumpectomy (BCT participant 5).  
Often the recommendation for BCT was due to the perceived small size of the tumor from 
the surgeon’s perspective. This idea was repeatedly cited by participants: ‘Whatever the 
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surgeon recommended I was willing to do…. after she explained to me how small the tumor 
was and the treatment available I didn’t even have to think about it’ (BCT participant 12). 
Feminine Identity. Feminine identity encompassed the ideas of self-esteem related to 
body image, retaining one’s own breast, and feeling whole as a woman. Participants felt that 
breasts were an important part of their body image, which impacted their individual and 
feminine identity. Furthermore, women explained that breasts are an important part of 
their feminine identity, and keeping them was central to feeling whole as a person. ‘It is 
really important for me to maintain that female body form. So the image for me was huge, 




The aim of this study was to explore the decision-making of women in Saskatchewan 
who had early stage breast cancer, identifying key themes underlying the choice of 
mastectomy or BCT. The main themes identified by the two treatment groups were 
different, suggesting that women chose to undertake mastectomy or BCT for different 
reasons. Although the individual reasons identified in this study have been seen in previous 
literature(17,39,85), choice of mastectomy or BCT has not previously been described as 
having completely different reasons underlying each choice of therapy. Furthermore, the 
subthemes or secondary reasons for each choice are also novel observations in this study. 
The thematic maps created are useful tools for providing visual depictions of decision-
making factors for patients and health care workers. 
Fear and worry about cancer recurrence has been found in the literature to be an 
important reason behind women’s choosing mastectomy(17,85) and often also the most 
influential factor for treatment decision-making.(16,39,73) This study confirmed the 
significance of worry, as well as that these feelings’ relation to an additional underlying 
reason: having observed failed BCT, wishing to avoid follow-up imaging, or family history. A 
secondary level of connection has never before been identified in the breast cancer 
literature and would be an important area of further exploration. The most common 
subtheme was related to the negative BCT or positive mastectomy experience of a close 
family member or friend who had ESBC, which influenced choice. This has been known to 
affect decision-making and cancer risk assessment for patients in the past; other studies 
have suggested that patients make choices based on experiential interpretation instead of 
on statistical probabilities.(75,85) Despite clinicians’ explanations of equivalent survival, 
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the subjectively perceived risk of each treatment option often supersedes the objective 
information given.(105) A plausible explanation for this theme’s prominence in this study is 
that Saskatchewan has many smaller communities, both urban and rural, which may 
contribute to greater communication between residents about cancer experiences. This is 
an area that requires further research.  
 Smaller breast and larger tumor size are well-known factors that increase the 
likelihood of undergoing mastectomy.(62,66) This study confirms these findings 
qualitatively and increases the depth of understanding of previously observed data. Two 
participants felt that BCT was never an option owing to their perceived breast or tumor 
size, and were thus excluded from the study. This is likely explained because a large tumor 
to breast ratio is a relative contra-indication to BCT.(19) 
A proportion of women chose mastectomy to avoid consequences of BCT treatment: 
length of treatment required for radiation, side effects specific to radiation, and risk of re-
excision as a result of positive margin. Other studies have identified similar trends.(71,75) 
These may be due to poor communication or understanding of side effects specific to breast 
radiation. Further investigations into these specific factors are required.  
Mastectomy being considered too radical was an important reason women chose 
BCT in this study; choice was related to recovery time from surgery, perceived tumor size, 
and confidence in the BCT approach. Choosing BCT as a way of avoiding extensive surgery 
has been previously discussed in the literature, especially for older age groups.(16,106) 
Prior studies using surveys have commonly reported equivalent survival between BCT and 
mastectomy as a main reason for choosing BCT, listing ‘equivalent survival’ as a selection 
item.(16,71) In contrast, our study used open-ended questions, which resulted in 
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mastectomy being too radical as the emerging central theme. These results suggest that not 
only the knowledge that survival between treatments is equal but also the early stage of 
disease causes mastectomy to be viewed as an extreme treatment option. A perception that 
the tumor was small also influenced patient’s views that mastectomy was radical. Although 
quantitative data have consistently associated smaller tumor size with higher BCT 
rates(13–15), this study provides an explanation behind this finding.  
The literature varies on whether distance to radiation centre affects rates of BCT. 
Although several studies show a decreasing rate of BCT as distance to radiation centre 
increases,(69) numerous studies that show no difference.(70,75,103) Despite 
Saskatchewan’s large rural population, this study did not find that travel distance to a 
radiation treatment centre deterred participants from choosing BCT. Regional investigation 
on a larger scale may be important to confirm this finding.  
 Surgeon influence was a primary reason underlying many women’s choice of BCT. 
Those who had difficulty choosing between therapies would often default to the surgeon’s 
recommendation. Literature has previously shown surgeon influence and 
recommendations to be an important factor in treatment decision-making.(16,39,107) A 
unique finding in this study, differing from previous literature, was that surgeon influence 
was an important theme underlying women’s choice of BCT but not choice of mastectomy. 
This is an important distinction that should be considered for future research.  
The theme of feminine identity was an important reason many women chose BCT. In 
our study, this theme encompassed the ideas of body image, feeling whole as a female, and 
keeping one’s own breast tissue. The influences of these ideas have previously been 




This study was retrospective, which presents potential limitations that include recall 
bias and post-treatment experiences. It is possible that patients reported their decisions 
based on post-hoc justification instead of citing the reasons that were important at the time 
of decision-making. Patients were recruited based on chart review clinical criteria for ESBC. 
However, whether explicit choice of therapy was offered or memory lapsed during the 
encounter was unclear in some circumstances, which may have led to unnecessary 
exclusion from this study. Other studies have identified that patient recall of events 
surrounding cancer diagnosis may be problematic.(108,109) Morever, the type, amount, 
and style of information presented from physicians may have varied. Our sampling plan 
included diversity in minority groups, but unfortunately this was not achieved due to lack 
of recruitment response. A targeted recruitment strategy may be required in future studies 
to capture these groups. 
5.9 Implications for Practice and Research 
This paper has added to understandings of reasons behind choice of therapy for 
women who have ESBC. These insights, along with the thematic maps, can help guide 
clinicians and allied health care workers counsel and care for patients who are going 
through this complicated decision-making process. Some of the novel findings including 
separate reasons for choosing mastectomy versus BCT, should be further explored in future 
research. The generalizability of these results should be established in larger-scale survey 
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Frameworks have been incorporated in research among many fields, such as 
population health, public health, and education. However, clinical medicine has lagged in 
understanding utilizing frameworks and using them to guide research. As a result, research 
has at times been incomplete, redundant, and less effective in drawing conclusions. 
Furthermore, in the current research environment, establishing methods to increase 
understanding between disciplines is critical. This article will highlight the importance of 
using a conceptual framework to guide clinical research, describing how doing so can 
improve the research process and giving an example of creating a new framework to 
examine why women choose mastectomy versus breast conserving therapy (BCT). 
6.4.2 What Is a Conceptual Framework? 
Carpiano and Daley define a conceptual framework as a set of variables and the 
relations among them that are presumed to account for a set of phenomena.(110) This can 
range in scope from a modest set of variables to the capturing of complicated phenomenon 
such as the WHO conceptual framework for action on determinants of health.(111) 
Although frameworks set the stage for a scientific inquiry, they do not provide direct 
explanations for exact outcomes. Understanding a framework’s role in research is often 
done alongside theory and a model, each of which declines in scope but increases in 
specificity. Briefly, theory can be broadly thought of as the ‘draft’ explanation for why a 
phenomenon is observed, such as for why some women choose BCT but others do not. A 
model is a tool used to make specific assumptions about a limited set of parameters and 
variables that can be tested.(110) 
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 A framework has multiple purposes, the most important of which is to help 
understand the phenomenon of interest in a more complete fashion.(110) It should identify 
all the important constructs of a problem and organize them sensibly in a way that can be 
readily explained. More than one conceptual framework may be relevant to a situation, but 
often a framework is designed to capture a specific lens or view of an inquiry.(112) It is 
important to understand the lens and scope for which a framework was created, as well as 
how it might be optimally used, before adopting it for one’s own research purposes. The 
latter half of this article gives an example of this process.   
  Use of a well-constructed framework allows the rest of the research process to 
follow a coherent structure. A conceptual frame can start by defining the scope of the 
literature review and can aid in its organization. It will assist in variable selection within 
each construct to be measured, and it will guide analysis by allowing researchers to 
structure their inquiry and interpret their results based on theory and relationships 
between different constructs. Based on the results, researchers are better able to fit their 
conclusions and add knowledge within the larger context of the overarching framework. 
One of a framework’s most important purposes is that of highlighting and communicating 
the ways in which the researcher has chosen to define and structure the phenomenon 
under study. This can be especially important in aligning disciplines within the context of 
multi-disciplinary research. 
Why, then, has so much clinical research not been grounded in theory or based on a 
framework? To start, many clinicians are not familiar with conceptual frameworks unless 
they have completed graduate studies. Of those that have come across the term, many do 
not understand the full scope and purpose of a framework. Furthermore, clinical research 
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in medicine often follows a course that fails to identify and implement a guiding framework. 
A clinician may notice something in practice or read a report that inspires a clinical 
question, then conduct a literature search to identify major relativent works that have been 
published and a review of existing data on the research query. During this process, the 
researchers might come across a framework or theory that other researchers have used, 
but these are rare in clinical journals, as authors will use a traditional literature review to 
set the stage for their research without considering a framework. When there is no 
precedent for establishing a framework prior to commencing research, the cycle continues. 
In an attempt to capture a holistic snapshot of the existing literature, many 
researchers will look to a review of the literature, or a systematic review. However, even 
these are often not based on a framework and may be missing important aspects of a 
research query. For example, the only published literature review evaluating why women 
choose mastectomy compared with BCT was by Macbride et al. in 2013.(13)  They 
synthesized the literature and identified a number of potential factors, including patient 
sociodemographic factors, race and ethnicity, geographical factors, role of the surgeon, role 
of reconstruction, decision aids, and influence of BRCA mutation gene.(13)  However, 
despite this being a review article, they did not integrate literature covering key 
components of this decision-making process, including individual patient preference factors 
and clinicopathological factors such as tumor size. This review did not rely on a conceptual 
framework to guide their work or the synthesis of the literature, which may have played a 
role in the absence of important factors. 
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6.4.3 Breast Cancer in Canada 
In North America, breast cancer is the most commonly diagnosed cancer and the 
second most common cause of cancer related death for women.(1) Landmark trials have 
established that BCT and mastectomy offer equivalent survival rates and can be viewed as 
equivalent treatments in early stage breast cancer (ESBC).(2–4,101) Treatment for ESBC 
can therefore be viewed as preference-sensitive care, with decision-making between 
treatment options varying according to patient preferences and values, though possibly a.so 
for other reasons.(32) However, in 1999 the seminal National Institute of Health Consensus 
Conference recommended BCT as ‘preferable’(10), prompting ongoing questions about 
research into quality of care as it relates to regional variation in treatment of ESBC.(45,69) 
Significant variations in mastectomy rates among regions has resulted in a large 
body of literature exploring the various factors influencing women’s choice of mastectomy 
versus BCT.(46,47) For example, Canada has great interprovincial variation in mastectomy 
rates, ranging from 26% to 69%.(12) Unfortunately the cause of these variations is poorly 
understood and has gone largely unexplained, primarily owing to the absence of a 
framework that can appropriately guide the research question.(12,27) How do researchers 
integrate political, psychological, biological, and health care system factors into a research 
project? What about previous literature, individual belief factors, individual life 
circumstances, the physician-patient interactions, and psychological factors? Exploring 
these questions and seeking to understand Canada’s regional variation that has led us to 




6.5.1 Creating a New Framework – Why Women Choose Mastectomy Versus BCT 
The factors that influence a woman’s choice of mastectomy or BCT for ESBC are 
complicated and multifaceted. At present, no guiding framework is available for doing so. 
Most of the research on this topic has been clinically based, and not theory-driven. Although 
various frameworks and theories inform individual choice behaviors on a micro scale, as 
well as  shared decision-making between the patient and surgeon at the dyad level, no 
appropriate framework is available of sufficient scope to holistically underpin our research. 
The aim of this article is to present a framework of our own devising that can fill this gap in 
the research. The framework was constructed through integration of previous frameworks, 
theories, models, literature, and clinical research. In the remainder of this paper, we will 
introduce our framework and review the key work referenced in creating this framework, 
highlighting important elements taken into considered.  
6.6 Results 
We present a conceptual framework of our own devising to illustrate the central 
domains that influence women’s choice between mastectomy and BCT (Figure 6.1). These 
have been organized into three broad constructs: clinicopathological factors, physician 
factors, and individual factors with subgroups of sociodemographic, geographic, and 
individual belief factors. The purpose of this framework is to provide a comprehensive basis 
for describing, examining, and explaining the factors that influence women’s choice of 
mastectomy versus BCT at the individual level.  
Figure 6.1: Conceptual framework illustrating the central constructs 




Clinical Literature Supporting Each Construct 
6.6.1 Clinicopathological Factors 
Clinicopathological factors are placed in an independent domain because they 
include tumor biological factors over which neither the patient nor the clinician has any 
direct control, including tumor size, stage, hormone receptor status, and cancer type, and 
grade. Among these factors, larger tumor size, and thus stage, is most clearly and 
consistently associated with higher rates of mastectomy.(46,63,67,71) More differentiated 
tumor grades have also been associated with higher BCT rates.(67) These findings are likely 
multifactorial in reason, with effects on both the individual patient and the surgeon. A 
larger tumor potentially means a more technically challenging operation, and larger tumors 
have been associated with increased likelihood of requiring a re-excision.(77,78) 
Furthermore, larger tumor size has been associated with increased local recurrence 
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rates.(22,23,79) Larger tumor size may also mean a poorer cosmetic outcome. These 
reasons could bias the physician towards discouraging BCT and decrease the patient’s own 
belief in the success of BCT.  
6.6.3 Individual Factors 
Individual factors can be subdivided into sociodemographic, travel-related, and 
personal belief and preference factors.  
Common sociodemographic factors examined in studies include age, socioeconomic 
status (SES), and race/ethnicity. Age has been examined differently across the literature 
with discrepant results. The most consistent finding was an increased likelihood of 
mastectomy in younger age groups, under 40 or 50 years old.(13,68,69) The middle age 
groups have generally not shown significant findings. The older age groups have shown 
variable results, with some studies finding increased rates of mastectomy among those 
older than 70 or 80 but others showing decreased rates.(16,26,61,63) Furthermore, some 
studies have found no association between age and mastectomy rates were found.(47,102) 
Multiple studies have found higher SES or other indicators of SES, including education and 
income, to be associated with increased likelihood of BCT.(61,68,70,71) Ethnicities 
including African American women, Hispanic women, and Asian/Pacific Islander women 
have been shown to be independently associated with increased rates of 
mastectomy.(13,74)  
Travel-related factors, including distance to a radiation treatment centre, have 
shown varying effects on BCT versus mastectomy rates. Although several studies found no 
difference(70,75,103), numerous studies have shown a decreasing rate of BCT as distance 
to radiation centre increases.(14,62,69,70) In our own qualitative exploration, we 
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hypothesized that travel distance would significantly affect rates of BCT for Saskatchewan’s 
large rural population. However, our initial qualitative research did not support our 
hypothesis and further research in Canada would thus be useful for evaluation.(86) 
Individual values and preferences may be the most important subset of individual 
factors but are the least well studied and THE hardest to understand. The majority of 
research into this category has been conducted through simple stand-alone questionnaires, 
or descriptive qualitative studies. Important personal belief and preference factors 
influencing choice of mastectomy include fear of recurrence desire to avoid radiation, 
desire for expedient treatment, and desire to avoid the consequences of BCT 
treatment.(16,17,47,75) Personal belief factors influencing choice of BCT include a view of 
mastectomy as being too radical, surgeon influence, feminine identity, and belief in 
equivalent survival between BCT and mastectomy.(72,76,86)  
6.6.4 Physician Factors 
Physician-related factors have also been examined throughout the literature. 
Multiple studies have shown that surgeon influence and recommendations are an 
important factor in treatment decision-making.(17,39,76,109) Various associations have 
been identified, including physician gender, case number, individual surgeon practice, 
subspecialty training, and academic hospital affiliation.(13,14,66) Results have differed 
across studies, with female surgeons being more likely to provide BCT in some studies, but 
less likely in others.(13,16,61) A few studies have also suggested that individual surgeon 
practice can be a predictor of procedural variation among colleagues.(39,64)  
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6.6.5 Procedural Variation in Surgery 
 Surgical variations between all procedures cannot be viewed as a whole. Wenneberg 
et al. proposed the grouping of practice variations into three categories: effective care, 
preference-sensitive care, and supply-sensitive care.(32) Effective care includes treatments 
that have good evidence behind one intervention in the absence of good alternative options. 
Examples include colectomy for colon cancer or repair of a hip fracture. Variations in this 
category generally suggest underutilization in lower use areas. Preference-sensitive care 
includes interventions for problems that have more than one acceptable treatment option, 
such as radical prostatectomy, radiotherapy, or active surveillance for prostate cancers and 
BCT or mastectomy for ESBC. Ideally, differences vary with patient preferences and values 
but they could vary for other reasons as well. Supply-sensitive care includes services 
limited by the availability of resources, such as of physician visits, hospital beds, or 
specialist consultations. Most surgical interventions do not fall under this category. 
Preference-sensitive care represents the largest of the categories for surgery, which 
includes decision-making between mastectomy and BCT in ESBC. 
 In 2014, Reames and colleagues published their results of a systematic review 
focusing on strategies for reducing regional variation in the use of surgery.(33) The review 
focused on two major strategies for improving consistency and the appropriateness of 
health care: dissemination of clinical practice guidelines or consensus statements and use of 
shared decision-making tools and decision aids. Clinical guideline dissemination produced 
demonstrated varied results, with some studies showing decreased rates, but others 
showing no effect or increased rates. Recommendations for procedure choice generally 
showed a measurable increase in the use of the recommended procedure. For BCT rates, 
some studies demonstrated a narrowed range of regional variation rates, but others 
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demonstrated a wider range. Decision aids also showed mixed results, with three of five 
studies not showing a statistically significant change in rate of procedure after 
administration and the other two studies demonstrating discrepant effects – one showing 
increased rates of BCT but the other showing decreased rates. Although the overall findings 
show that both clinical guidelines and shared decision-making tools have the potential to 
reduce the extent of variation in surgical care, these seem dependent on the clinical 
situation. These findings were confirmed by a recent Cochrane systematic review showing 
that decision aids were inconsistent in their ability to change outcome in terms of surgical 
variation.(34)  
6.6.6 Theory of Planned Behavior 
The Theory of Planned Behavior (TPB) is a conceptual framework that links beliefs 
and behavior (Figure 6.2).(37,38) It has been frequently cited and has become one of the 
theories most commonly used to predict human functioning and behavior [60]. The theory 
states that the most proximal determinant of a given behavior is intention, which 
represents a person’s motivation or decision to act. Intention, in turn, is a function of three 
sets of belief-based perceptions of behavior: attitudes toward the behavior, subjective 
norms, and perceived behavioral control (PBC). Attitude towards a behavior reflects a 
person’s overall positive or negative feeling of performing the behavior. This is influenced 
by behavioral beliefs, which link the behavior of interest to a subjectively expected 
outcome. Subjective norms, which reflect the person’s perception of the social pressure to 
perform a given behavior, are influenced by normative beliefs, or the perceived behavioral 
expectations of important referents to the individual such as family members, friends, 
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teachers, or doctors. PBC reflects a person’s overall judgment about whether he or she has 
the ability and resources needed to engage in the target behavior. 
Figure 6.2: Theory of Planned Behavior Diagram 
 
 The TPB can be applied to decision-making for women who have ESBC. The behavior 
of choosing mastectomy or BCT can be conceptualized as a planned decision. Accordingly to 
Ajzen: ‘[t]he TPB emphasis is on the controlled aspects of human information processing 
and decision-making. Its concern is primarily with behaviors that are goal-directed and 
steered by conscious self-regulatory processes. From the TPB, expectations that performing 
a behavior will lead to experiencing pain, pleasure, regret, fear, elation, or other emotions 
are simply behavioral beliefs, i.e. beliefs about the likely consequences of the behavior, 
some positive and others negative’.(36) in prior research this theory has been used to study 
decision-making in cases of ESBC.(39) 
TPB can be used to conceptualize and theoretically explain how different factors 
may influence a woman’s choice of mastectomy or BCT. Sociodemographic characteristics 
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can influences on all three of the TPB belief constructs. Factors such as socioeconomic 
status or cultural background will directly relate to behavioral and normative beliefs. 
Personal life circumstances such as work obligations or distance from a treatment centre 
may affect a person’s control beliefs. The influences of close family members and friends or 
a surgeon’s recommendations will be among the key referents involved in an individual’s 
subjective norms. Emotions such as fear of cancer recurrence and or peace of mind are 
often very important determinants of a woman’s choice for mastectomy. These behavioral 
beliefs can strongly affect attitudes towards the behavior as well as subsequent behavioral 
intentions. Similarly, an individual’s value of feeling whole or feminine after treatment may 
have a strongly influence on behavioral beliefs. Figure 3 illustrates how the TPB can be used 
to examine factors influencing the choice between mastectomy and BCT in cases of ESBC. 





The TPB has been important in guiding our earlier research, specifically by serving 
as the theoretical foundation in an exploratory qualitative research project titled 
‘Understanding Women’s Choice of Mastectomy Versus Breast Conserving Therapy in Early-
Stage Breast Cancer’.(86) The TPB helped frame our qualitative research and organize our 
analysis, which included creation of thematic indices, coding, and creation of thematic 
maps. Although the TPB can potentially account for the full spectrum of factors influencing 
a patient’s choice of therapy, it is best positioned for identifying and examining the 
individual belief and preference factors. The TPB is not structured well to account for 
broader clinical or health system factors. Moreover, the theory was designed to account for 
all human behavior and is therefore structured at a high level of abstraction, making it 
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difficult for clinicians to relate to in specific clinical situation such as when making a 
decision about ESBC management. We deemed the TPB insufficientlyt specific enough for 
our research, and decided instead to develop a more targeted and applicable framework. 
Nevertheless, incorporating aspects of the TPB and our prior qualitative research played a 
critical role in our creation of a new conceptual framework for examining why women 
choose mastectomy in the setting of BCT. 
Figure 6.6.7 Patient-Physician Shared Decision-Making 
 In 1999, Charles et al. presented a framework for examining treatment decision-
making that still informs today’s decision-making concepts.(40) It included three models of 
treatment decision-making: paternalistic, shared, and the informed model. Each was 
distinguished into three separate steps, or analytic stages: information exchange, 
deliberation, and decision about what treatment to implement. The framework describes 
the general path that of the models follows as well as, more specifically, the behavioral 
expectations of both physicians and patients for implementing each model. The models’ 
separate analytic stages make them easy to conceptually distinguish from one another. The 
framework also recognizes the dynamic nature of decision-making and does not limit one 
treatment interaction to one model, recognizing that an encounter may change as the 
interaction evolves. 
 In this framework, decision-making is related to situations in which several 
treatment options are available that offer different benefit-to-risk ratios, and different 
patient outcomes. Charles identifies four necessary characteristics(41): 




2. Both physician and patients share information with each other. 
3. Both physician and the patient take steps to participate in the decision-making 
process by expressing their treatment preferences. 
4. A treatment decision is made, with both the physician and patient agree on the 
treatment to implement. 
In the appropriate situations, the three models can be divided into three analytically 
distinct situations to help distinguish their characteristics. Information exchange refers to 
the type and amount of information exchanged, and the flow of information between 
physician and patient. Deliberation includes discussion of treatment options, and 
expression of treatment preferences. The last stage is the actual decision and the choice of 
which treatment to implement. 
 The paternalistic model has traditionally been the most prevalent approach to 
treatment decision-making, generally assuming the physician knows best how to make the 
optimal treatment decision for the patient. Information exchange is one-way in this model 
from physician to patient. The patient is a passive recipient, and information exchange from 
patient to physician is not seen as being important to completing this interaction. During 
the deliberation stage, the physician will consider the benefits and risks of each option 
alone or in consultation with other physicians, but the patient is passive. The physician 
makes the final treatment decision alone. This model is called paternalistic because it 
resembles to a parent-child relationship, in which the authoritative figure (the physician) 
makes what is deemed to be the appropriate decision for the patient. 
 The shared decision-making (SDM) model evolved with clinical medicine as 
treatment options increased for diseases, coupled with greater emphasis on discussion 
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about tradeoffs between risks and benefits. Information exchange goes both ways in this 
model. The physician should provide the patient with all information needed to make a 
decision and the patient should provide information on issues related to the treatment 
options including values, preferences, social circumstances, and his or her knowledge about 
the illness. When this information is provided, deliberation can occur within the boundaries 
and context of the patient’s specific situation. Deliberation should be interactional in nature, 
ensuring that both members have input and are invested in the treatment decision. 
Expression of treatment preferences is important to this model. The treatment used should 
be agreed upon between both the physician and patient. 
 The informed decision-making model differs from the SDM model in that the 
physician limits his or her role to providing information. Information exchange thus is 
largely one-way, with the physician is the primary source of information for the patient, 
who weighs all the treatment options, including and benefits and risks of each. Beyond 
information transfer, the physician does not participate in the decision-making process, 
leaving the patient to deliberate and make the final choice of the treatment on his or her 
own. An important fundamental difference from a shared model is that the physician should 
be invested in the decision-making process or in the decision made. This is to avoid 
influencing the patient towards a direction that reflects the physician’s treatment bias, 
which might not align with the interests of the patient. 
SDM scholars have recently pushed for the creation of a model that extends beyond 
the physician-patient dyad while promoting an interprofessional approach to SDM. France 
Légaré, Dawn Stacey, et al. proposed a new interprofessional shared decision-making (IP-
SDM) model with which to guide patient care.(42,43) The model comprises of three levels: 
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the individual (micro), the health care team/organization (meso), and the health care 
system (macro) levels (Figure 6.4).[65] For an IP-SDM approach, this model assumes that 
multiple healthcare professionals from different professions collaborate, concurrently or 
sequentially, to achieve SDM with the patient. The model also assumes that clinical 
encounters cannot occur independent of the influence of factors from the health care 
system levels. This model has the potential to unify the process of SDM in different 
healthcare settings and with different health professionals. 




The individual level of care is similar to the Charles et al. (1999) model but 
incorporates multiple health care professionals, a decision coach, and family members who 
are explicitly involved through the information, deliberation, and treatment decision stages. 
The meso level of the IP-SDM model is represented by the IP team members and features 
how the team or organization functions. The macro level represents global healthcare 
environmental factors: resources, government policies, cultural values, professional 
organizations, and rules. IP-SDM being a newly proposed model that has had limited 
development or application in real-world clinical scenarios, requires further work to clarify 
the meso and macro levels.(43,44) Currently in many North American health care systems, 
treatment decisions related to breast cancer surgery are made primarily with the 
involvement of a single health care professional, the surgeon. However, the role and 
involvement of both medical and radiation oncology in the decision-making process are 
expanding, prompting discussions of the various lengths of radiation treatments and 
differing chemotherapy indications, which may increase the role of the IP-SDM model in the 
future. 
These models illustrate the complexities behind patient-physician treatment 
decision-making. For ESBC, definitive care is centred on surgery, so a decision between the 
patient, with his or her supports, and the surgeon determines treatment choice. The shared 
decision-making frameworks presented highlight the physician’s influence on the patient’s 
choice of therapy, specifically by brining to light some of the complexities behind the 
physician-patient interaction that are not generally captured in the clinical literature. 
Whether interactions between the physician and patient following the paternalistic model, 
the shared model, or the informed model will bring varying degrees of physician influence 
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on the patient, differentiated through the analytic steps. Depending on the style of 
interaction, patient values, beliefs, and preferences will be incorporated into the treatment 
decision to varying degrees. Apart from the decision-making process as described by the 
SDM models, the impact of surgeon trust needs to be considered; this can be explained 
through the normative beliefs construct in the TPB. The influence of trust is especially 
strong for women, who highly value the recommendations and expectations of their 
surgeon. Recognizing the importance of the patient-physician relationship has led to 
‘physician factors’ being a key construct in our conceptual framework. We understand that 
this interactive relationship is complex, and that it differs among individuals, but we have 
presented some of the leading thoughts on how to examine this relationship’s influence on 
decision-making. 
6.7 Discussion 
The framework we have presented in this article was designed to examine factors 
influencing women’s choice of mastectomy versus BCT in ESBC only (stage 1 and 2). It was 
not designed for patients who have ductal carcinoma in situ (DCIS), high risk patients such 
as those who have BRCA, or patients who have advanced disease such as stage 3 or 4 breast 
cancer. Although it may be considered for use in these clinical situations, we advise 
adaptation and critical thinking, for the treatment decisions and influencing factors will be 
different than for ESBC.  
We believe that the three constructs created – clinicopathological factors, individual 
factors, and surgeon factors – are appropriate domains for organizing and categorizing the 
potential influencing factors influencing women’s choice. These constructs were developed 
with a view to allow  clinicians to readily visualize and understand them as individual 
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domains of factors as well as within the broader context of the framework as a whole. The 
framework purposefully places the individual in the centre, for treatment is focused on the 
individual patient. The three constructs have been equally weighted, for the importance of 
each can vary depending on the individual. Clinicians should approach each clinical 
encounter without bias towards one construct. 
We recognize that conceptual frameworks are often dynamic entities and invite 
commentary and alteration as needed. 
6.8 Conclusion 
In this article, we have presented  a conceptual framework that is both unique and 
novel. It is important to remember that each framework is created to present a view of a 
phenomenon through a specific lens. These lenses can vary in scope andlevel of abstraction, 
and can highlight different constructs for the topic at hand. We have created a conceptual 
framework for examining why women choose mastectomy compared with BCT with the 
purpose to help health care workers and policy makers better understand the multitude of 
factors that influence a patient’s choice of therapy at an individual level. From a research 
stance, we hope that future scholars will use, challenge, and build upon this in their own 
work on decision-making in the setting of breast cancer. For clinician-researchers who have 
limited experience with frameworks, we hope that this paper has highlighted the 
importance of using a conceptual framework to guide future research and has provided a 
base from which to begin doing so. For more experienced academics, we invite feedback 
and express our hope for continued growth in this field.  
List of abbreviations 
 BCT – Breast conserving therapy 
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 DCIS – Ductal carcinoma in situ 
 ESBC – Early stage breast cancer 
IP-SDM - Interprofessional shared decision-making  
 PBC – Perceived behavioral control 
 SDM – Shared decision-making 
SES – Socioeconomic status 
 TPB – Theory of Planned Behavior 
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 CHAPTER 7: SURVEY DEVELOPMENT 
7.1 Survey Conceptual Development 
The construction of our survey was based on the conceptual framework of what 
influences women to choose mastectomy versus BCT (see Chapter 6 for full details). This 
framework, which illustrates the central constructs that underlying women’s choices, is 
presented again Figure 7.1. The creation of this framework was based on previous 
literature, which is further explained below, prior theory, prior models, and the initial 
exploratory qualitative research. We have organized women’s choice of mastectomy versus 
BCT into three broad influencing constructs: clinicopathological factors, physician factors, 
and individual factors. These constructs have often been measured individually, or in 
fragmented combinations in the past. With our survey, we planned to study these 
constructs holistically in a way that links them together. By examining how each factor and 
their interactions influence a patient’s choice, we hoped to gain greater overall 
understanding of this phenomenon.  
Figure 7.1: Conceptual framework illustrating the central constructs 




7.2 Survey Organization 
 The survey as a whole is aimed at capturing influences from the three main 
constructs: clinicopathological factors, individual factors, and physician factors. The survey 
is composed of a questionnaire and a dataset from the Saskatchewan Cancer Agency (SCA). 
The questionnaire is aimed at capturing individual values or preference factors, potential 
decisional conflict factors, travel-related factors, and individual demographic factors. A 
dataset from the SCA, which is linked to the questionnaire data, captures clinicopathological 
factors for the patients.  The survey as a whole can be seen in Appendix H. 
7.2.1 Clinicopathological Data from the Saskatchewan Cancer Agency 
 The researchers collaborated with the research group from the SCA to obtain 
clinicopathological data to link with the questionnaire participants. Data items collected 
were based on previous literature described in the conceptual development of the survey. 













1. C-code  
2. C-code English description 
3. Morphology 




8. Multiplicity Counter 
9. Tumor Size 
10. Regional Nodes Positive  
11. Regional Nodes Examined 
12. SSF 1 – ER Assay 
13. SSF 2 – PR Assay 
14. SSF 14- HER2: Result of Other or Unknown Test 
15. SSF 16 – Combination ER, PR & HER2 
16. Overall Stage, T, N and M stage values  
17. Surgery Date 
18. Radiation therapy 
19. Chemo therapy 
20. Hormone therapy 
A full legend describing the breast data set is in Appendix I. 
7.2.2 Individual Sociodemographic Factors 
Demographic factors such as age, SES, and race / ethnicity have also shown varying 
associations with treatment choices (specific details described in Chapter 4). This 
questionnaire included questions on age, ethnicity, income, education, occupation, and 
relationship status to capture this data. 
The Statistics Canada defines ethnic origin as ‘the ethnic or cultural origins of the 
person ancestors. An ‘ancestor is usually more distant than a grandparent’.(113) In the 
2016 census, they collected ethnic origin data on eight major categories, with over 100 
subcategories.(113) While we have used the term ‘Caucasian’ in our survey, we recognize 
this term is derived from an old classification, and there may be better terms such as 
Caucasoid, European, or White to use in the future.(114) 
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7.2.3 Geographical Factors 
Travel related factors or distance to a radiation treatment centre have shown 
varying results in the literature as to whether there is an effect on rates of BCT versus 
mastectomy (specific details described in Chapter 4). We hypothesized that in 
Saskatchewan, travel distance would significantly affect rates of BCT due to Saskatchewan’s 
large rural population. Interestingly, the initial qualitative research did not support this 
hypothesis. Nonetheless, it is important to evaluate potential geographic barriers to therapy 
choice. This questionnaire included questions on travel distance to surgical and radiation 
treatment centres, rural versus urban living location, and lodging for radiation treatments. 
7.2.4 Personal Beliefs and Preferences Factors 
The individual values and preference factor questions emerged from the results of 
our initial qualitative study, which was also based in Saskatchewan (see Chapter 6). The 
results of that study gave us a guiding list of factors that influenced patients’ choice at an 
individual level. The initial qualitative process further aided in organizing these factors into 
dominant themes and their accompanying subthemes or secondary factors. These are 
displayed in Table 7.1. This organization directly informed how we created our 
questionnaire and the use of branching logic.(115) Branching logic, or skip logic, is a feature 
that changes what question a respondent sees based on how they answer previous 
questions. This was done to ensure all questions were relevant to respondents. For 
example, if a participant responded to an initial question about ‘worry about cancer 
recurrence’ as an important factor, they would subsequently have a follow-up question 
inquiring about what the reason behind that worry was with response options also based 
on the initial study. However, if a participant did not rate that factor as important, they 
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were not asked specific follow-up questions. As well, there were some belief factors that are 
specific to either mastectomy or BCT groups only. These questions were asked of only the 
applicable group. 
Table 7.1: Individual Values and Preference Factors  
Mastectomy Participants 
A. Worry about cancer recurrence 
a. Causes of this worry: 
i. Observed failed BCT (family / friend) 
ii. Observed mastectomy success (family / friend) 
iii. Avoiding follow-up imaging 
iv. Family history of breast cancer 
v. Age 
b. Increasing chance of cure 
c. Obtain peace of mind 
d. Get rid of all of the tissue 
e. Wanting a prophylactic mastectomy 
B. Avoiding consequences of BCT treatment 
a. Avoiding potential for additional surgery 
b. Avoiding radiation therapy 
i. Travel distance for radiation treatments 
ii. S/E of radiation 
C. Breast-tumor size ratio 
a. Perceived small breasts 
b. Perceived large tumor 
 
BCT Participants 
A. Mastectomy is too radical 
a. Relative to perceived tumor size 
b. Confidence in BCT procedure 
c. Perceived recovery time too long 
i. Influenced by age 
ii. Influenced by comorbidities 
B. Surgeon influence 
a. Surgeon’s recommendations 
b. Reputation of the surgeon 
c. Reasons behind surgeon choices: 
i. Perceived breast size 
ii. Perceived tumor size 
C. Feminine identity 
a. Body image 
b. Sexuality / desirability / attractiveness 
c. Being whole / retaining one’s own breast tissue 
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7.2.5 Physician Factors 
Previous literature on physician factors have largely focused on physician 
demographics such as gender, age, type of training, and practice patterns (specific details 
described in Chapter 4). Evaluating these factors was impractical in our study as there are 
greater than twenty surgeons from eight different surgical centres in Saskatchewan. 
Additionally, due to ethical and logistical restrictions, we were unable to link patient 
treatment to individual physicians’ care. Instead, we focused on the patients’ perceptions of 
the physician’s influence. The questionnaire evaluated the physician interaction and their 
perceived influence of on therapy decision-making. 
To help evaluate an aspect of physician interaction, we utilized the Decisional 
Conflict Scale (DCS), which is a 16-item questionnaire that was designed and validated by 
O’Connor to examine decisional conflict and other aspects of the decision-making 
process.(116) The scale has five sub-scales: certainty, information, clarification of values, 
support or pressure from others, and the respondent’s perception of the quality of the 
decision process. The DCS has been used in the past to do the following: diagnose a patient’s 
decisional conflict, identify the patient’s decision support needs (knowledge, values 
clarification, support), determine the quality of the decision process, and evaluate the 
impact of decision support interventions.(117,118) Each item is measured on a 5-point 
Likert scale with total scores between 0-100, with 100 indicating extremely high decisional 
conflict. The DCS is designed to have the specific wording of questions adapted for each 
questionnaire on different topics. The DCS was adapted for use in our survey, which is also 
included in Appendix H. 
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7.3 Survey Questionnaire Design 
 This questionnaire was designed in accordance with best practice recommendations 
from Jon Krosnick and Stanley Presser.(115) Beyond obtaining the correct information 
from questions, we aimed to maximize optimal patient responses and minimize satisficing 
tendencies. Some general principles we followed were using simple familiar words, 
avoiding ambiguous meanings, making sure response options were exhaustive and 
mutually exclusive, avoiding leading or loaded questions, and only asking about one thing at 
a time. Following these principles meant that many of our answers included a combination 
of close-ended responses with an open ended ‘other’ response to ensure the participants 
could be exhaustive in their responses. A 5-point Likert scale with values from strongly 
disagree to strongly agree was chosen because using word labels has shown higher 
reliability in questionnaires and avoids acquiescence.(115) If respondents attempted to 
advance to the next question without responding to the question, they were prompted to 
answer the question, but not forced into an answer. 
 The order of questions was also crafted under best practice principles for this 
questionnaire.(115) Questions of similar topics and concepts were grouped together, which 
followed a funneling technique of proceeding from general to specific. Questions under the 
same domains of interest were randomized to prevent question order effect biases. Filter 
questions were included, where appropriate, to avoid asking respondents questions that 
may not apply to them. Questions were placed at the start of the survey that explicitly 
address the main topic of the survey and are the most cognitively challenging to optimize 
responses. Factual and demographic questions were placed at the end of the survey, as 
these topics are less susceptible to satisficing.(115)  
 
 132 
7.4 Questionnaire Pre-testing 
 This survey underwent multiple iterations of pretesting. The researcher, his 
supervisors, and collaborators created an initial version of the survey with the U of S Social 
Science Research Lab (SSRL) survey designer. The survey then underwent pre-testing with 
methodology experts in survey design, as well as the Saskatchewan’s Breast Advisory 
Group. Specific considerations that were asked to be reviewed during pre-testing included: 
specific wording choices, question ordering and grouping, content covered, and question 
appropriateness with the target population. Survey methodology experts within various 
departments at the U of S were consulted including in psychology, epidemiology, and the 
director of the SSRL. The Saskatchewan’s Breast Advisory Group is composed primarily of 
breast surgeons, but also has representation from oncology and the SCA. Changes made to 
the questionnaire were iterative.  
7.5 Questionnaire Piloting 
To pilot the study, we collaborated with the Saskatoon Breast Health Centre. This 
was an external participatory pilot survey, meaning the pilot participants were not included 
in the main survey, and we informed the respondents that we were in a pilot phase, and 
asked them for constructive feedback upon survey completion. The inclusion criteria for 
pilot participants were the same as for our main survey – Saskatchewan women who have 
been diagnosed and treated for ESBC (stage 1 or 2). Excluded from the study were women 
with DCIS, known BRCA, stage 3 or 4 breast cancer, male breast cancer, and inflammatory 
breast disease. Potential participants were those diagnosed after December 31, 2015 to 
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avoid overlap with participant recruitment for our main survey data. 40 participants 
partook in the pilot process, which was about 10% of our survey’s goal sample size. 
The Breast Health Centre nurses helped identify potential participants that met our 
pilot inclusion criteria. They then asked the patients if they would be interested in speaking 
with the researcher / interviewer, J.G., about the study when they were at the Saskatoon 
Breast Health Centre for an appointment. A study information pamphlet was available for 
the nurses to utilize as well (Appendix J). If the patient agreed, J.G. spoke to them about the 
study and obtained consent using the same consent form as for the main survey. 
Participants were encouraged to evaluate the survey design and record problems they may 
have come across with any portion of the survey; pen and paper were also provided. 
Participants were asked to complete the survey online in a self-administered fashion; a 
tablet device was provided to allow participants to complete the survey on-site. 
Alternatively, the participants could ask the researcher to administer the survey in person. 
If this was requested, the interviewer entered the responses into the QualtricsTM program 
to maintain centralized data. Upon completion of the survey, the pilot participants were 
asked to provide feedback on the survey. Specific feedback questions targeted question 
wording, appropriateness, relevance, terminology, response categories, repetitiveness, 
other comments or criticisms, and general feedback. Field notes were recorded. No 
identifying data were recorded beyond what was asked in the survey.  
7.6 Sample Size 
The sample size calculation was based on our framework and the central constructs 
that influence women’s choice between mastectomy versus BCT (Figure 7.1). The 
constructs include clinicopathological factors, physician-related factors, and individual 
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(patient-based) factors. For each of these factors we calculated sample sizes required to 
detect differences between mastectomy and BCT groups for one main difference of interest 
in each construct group. All chosen sample size values were from studies with multivariate 
analysis, and odds ratios were selected throughout. Based on CIHI data, there are 
approximately 478 Saskatchewan patients diagnosed with ESBC per year, of whom 53% 
initially undergo mastectomy and 47% BCT.(12) We assumed the two groups proportions 
to be equal, 50% each in our calculations. Sample sizes were calculated using PASS 
software.(119) Tests for two proportions detecting inequality using odds ratios were 
performed. 
For clinicopathological factors, Locker et al found tumor size greater than 2cm was 
associated with an odds ratio (OR) of 3.03 times higher likelihood of undergoing 
mastectomy.(63) We wanted to determine if this factor would likewise be significantly in 
our study population. If the ratio between the two groups, group A (BCT) and group B 
(mastectomy), resulted in anything other than the null value of 1, we would conclude that 
tumor size is an important variable. Sample size for this factor was calculated using data 
from Locker et al study, looking at the odds of outcome in group A, pA(1- pA), compared to 
with the odds of outcome in group B, pB(1- pB), where pA and pB are the probabilities of the 
outcome in the two groups.  
The null hypothesis: H0: OR = 1 
The alternate hypothesis: H0: OR  ≠ 1  
OR = pA(1- pB) 
          pB(1- pA) 
Using PASS, the sample size required to detect a difference between group A and B for 
tumor size was 102.  
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Similar sample size calculations were performed for constructs in other groups. For 
physician-related factors, Cyran et al found that female physician gender was associated 
with an OR of 3.80 times higher likelihood of undergoing BCT.(16) Using this information 
and PASS, the sample size required to detect this difference was 78. For individual factors, 
we chose to test both travel distance as well as personal beliefs and values factor. Celaya et 
al found that travelling a distance to radiation facility greater than 60 miles was associated 
with an OR of 0.31 times less likelihood of undergoing BCT.(62) Based on this study, the 
sample size required to detect this difference was 92. Lee et al found that women who 
strongly valued peace of mind were associated with an OR indicating 1.88 times higher 
likelihood of undergoing mastectomy.(45) As the proportions of women valuing peace of 
mind were not given, we tested a range of possible proportions from 35% to 45% for those 
not valuing peace of mind choosing mastectomy. This sensitivity testing revealed that 
changing the proportion did not significantly affect our sample size. Taking the above into 
account, the sample size required to detect this difference was 320 with a proportion 
valuing peace of mind choosing mastectomy being 60%. Outputs for all calculations are 
included in the appendix. (Appendix K) 
The individual factor of peace of mind required the highest sample size to detect a 
significant finding of interest and was used as a base sample size. To account for the 
multivariable nature of this study, potential confounders, and our hypothesis that all of 
these constructs may influence women’s choice, we increased the sample size to account for 
confounding from each construct. The adjustment was calculated by increasing the sample 
size by 15% per each additional construct. Our final goal sample size was 423 participants. 
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7.7 Target Population 
Our target population included all women diagnosed and treated with ESBC in 
Saskatchewan. ESBC is defined as women with stage one or two breast cancer as per the 
NCCN guidelines.(19) Participants had to be residents of Saskatchewan. Excluded from this 
study were women with DCIS, known BRCA, stage three or four breast cancer, male breast 
cancer, and inflammatory breast cancer.  
7.8 Ethics Approval 
Ethics approval was obtained from the University of Saskatchewan Behavioural Research 
Ethics Board (Beh-REB). The ethics file is Beh 15-355. 
7.9 Patient Recruitment 
Patient recruitment was done with the support from the Saskatchewan Cancer 
Agency. Through the SCA database, all patients who were treated for ESBC in Saskatchewan 
during an inclusive 2-year period from January 2014 to December 2015 were identified. 
Inclusion dates were based on the date of the procedure that led to their pathological 
diagnosis, i.e., biopsy date for invasive cancer. Patients were mailed an invitation letter to 
participate from the SCA (Appendix L). If there was no response to our initial survey 
request, a single reminder invitation to participate letter was sent out at an 8-week interval 
from the initial letter. The initial invitation to participate letter was mailed out on 
December 7th, 2017 and the reminder letter was mailed out February 2nd, 2018. Closure of 
the survey and data collection ended on April 4, 2018. No incentive-based recruitment 
strategies were employed with this survey. 
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 The SCA does track and remove deceased individuals from their database. However, 
if any of these patients were missed and a family member contacted and informed the 
researchers the individual was deceased, these numbers were tracked and removed from 
response rate denominator. As well, if a participant called to inform the researcher they did 
not meet our study inclusion criteria, we also removed these individuals from our study 
denominator. We tracked these with the individual survey’s unique linking variable to 
protect the participant’s confidentiality. 
 Based on 478 patients per year diagnosed with ESBC,(12) we estimated that a 
recruitment response of 45% would allow us to reach the goal sample size during the 2-
year period. 
7.10 Survey Implementation 
The proposed survey was hosted online by QualtricsTM, a program that the SSRL 
uses frequently. During the piloting phase of the study, servers were located in the USA and 
subject to US laws. The privacy of the information provided was subject to the laws of that 
other jurisdiction. However, at the time we conducted the primary survey, database servers 
were relocated to Canada and were subject to Canadian privacy laws; the data collection 
system at the SSRL was also changed to Voxco at this time. Participants were encouraged to 
complete the survey online in a self-administered fashion. Alternatively, the participants 
could contact the researchers and have the survey administered via a phone interview. 
There was a separate oral telephone script consent form that the researcher followed. 
(Appendix M) During the phone interview, the interviewer entered the participant 
responses into the Voxco program to maintain centralized data. 
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7.11 Data Collection and Management 
 All questionnaire data were collected via the Voxco system. These data can be 
exported to Excel. Survey clinicopathological data including tumor location, pathology, 
staging, and adjuvant treatment information was obtained from the SCA database. These 
datasets were linked using a linking variable, the individual participant code.  
 Each potential participant recruitment letter included a unique patient identifier. 
This identifier was composed of two sections: a 4-character number – character – number – 
character combination, and a four-digit number running from 0000 to 1000. These two 
components were combined to create an 8-character unique patient identifier for all 
patients in our target population. The first 4 characters would make incorrect entry of the 
unique identifier very unlikely. The last 4 digits would make it easier for the researchers, 
who did not have access to the master list, to link the two datasets together. With a sample 
size of over 400 participants and a total target recruitment population of close to 1000, this 
number would not be able to be used as an identifying feature. A master code sheet was 
kept to track the patients. The creation of a master code sheet linking identifying patient 
information to the data sets was created and kept within the SCA at all times. The 
researchers did not have access to the master code sheet at any time. 
 All original data files were stored in a passcode protected computer that was 
secured in a locked room at all times. 
7.12 Data Analysis  
Statistical analysis was performed using Stata 14.2.(120) Our primary outcome was 
odds of mastectomy versus BCT. Independent variables included clinicopathological factors, 
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individual patient factors, and physician factors. Baseline differences between groups were 
evaluated using chi-squared test for categorical data and independent sample t test for 
continuous data. Univariate logistic regression was applied to identify key predictors of 
choice of mastectomy versus BCT. Multivariable logistic regression analysis was used to 
create the main effects model. Variables with a p <0.10 in the univariate logistic regression 
were included in the multivariable model and backwards elimination of variables with p 
<0.05 was then performed. Clinically important effect modifiers were individually tested for 
potential inclusion in the model using an interaction term. Goodness of fit was assessed 
using the Akaike information criterion. For missing data, we used complete case analysis 
when there was less than 10% and indicator method when more than 10% of missing data 
points to reduce bias.  
 Geocoding and mapping was performed in conjunction with the Spatial Division of 
the U of S Social Sciences Research Laboratories. Geocoding was performed by joining 
spatial information (latitude and longitude) to patients’ home based on the first 3 letters of 
postal code provided. Visualizing routes and generating GIS files was done using a WebGIS 
solution developed by the local team to visualize patients’ home location, hospital locations, 
and travel routes. These routes were manually edited as arcs and routes were downloaded 
as GIS layers. GIS layers were imported to create PDF maps using ArcGIS. 
7.13 Additional Results from Survey Not Included in Manuscript 
 There are additional methods and results from this survey that were not included in 
the manuscript (Chapter 8) but deemed important for this dissertation. These are detailed 
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The general content included in this article does not significantly differ from the published 
manuscript. However, grammatical modifications, minor changes to tables and figures, and 
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Background and objectives: The choice of mastectomy versus breast conservation 
therapy (BCT) in early stage breast cancer (ESBC) is a complicated decision-making 
process. Canada’s interprovincial mastectomy rates vary from 25% to 68%, with 
Saskatchewan reporting the nation’s second highest mastectomy rate, at 63%. The aim of 
our research was to better understand why women with ESBC choose mastectomy 
compared with BCT in Saskatchewan. 
 
Materials and methods: We created a survey based upon a previously developed 
framework that organizes the influencing factors into three constructs: clinicopathological, 
physician, and individual belief factors. 
 
Results: Treatment choice was influenced by disease stage and multiple individual belief 
factors. Women who had stage two disease were significantly more likely to undergo 
mastectomy that those who had stage one disease (OR, 7.48). Patients rating ‘worry about 
cancer recurrence’ (OR, 3.4) and ‘total treatment time’ (OR, 1.8) as more influential on their 
choice were also more likely to undergo mastectomy. Conversely, women rating ‘wanting to 
keep own breast tissue’ (OR, 0.17), ‘tumor size’ (OR, 0.66), or ‘surgeon’s opinion’ (OR, 0.69) 
as influential to their choice were more likely to undergo BCT. 
 
Conclusions: Our study demonstrates that treatment choices for Saskatchewan women 
who had ESBC were primarily influenced by disease stage and individual belief factors. 
These findings would suggest that women are making their treatment choices 
predominantly based on individual values and preferences. The use of mastectomy and BCT 
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rates as an indicator of quality of care may be misleading. Instead, a shift in attention 
towards patient-centred care is more appropriate. 
8.2 Keywords  
Breast cancer; decision-making; mastectomy; breast conserving therapy; patient centred 
care. 
8.3 Abbreviations 
ESBC = early stage breast cancer 
BCT = breast conservation therapy 
SCA = Saskatchewan Cancer Agency 




8.4.1 Research Problem  
In North America, breast cancer is the most commonly diagnosed cancer and the 
second most common cause of cancer death in women.(1) For early stage breast cancer 
(ESBC), it is well established that breast conservation therapy (BCT) and mastectomy are 
equivalent treatments for survival.(2,4,6,9) Treatment for ESBC can thus be viewed as 
preference sensitive care, in which decision-making between treatment options varies with 
according to patient preferences.(40) In Canada, interprovincial mastectomy rates vary 
greatly from 25% to 68% between provinces, with a national average of 38%.(11) 
Saskatchewan has consistently reported the nation’s second highest mastectomy rate with 
the latest report showing 63%.(12,27) International research has investigated why women 
choose mastectomy compared with BCT,(13,39,45,68,72,121) but there are few data from 
Canada to explain these provincial variations.(12) 
The equivalent efficacy of mastectomy and BCT for treatment of ESBC suggests that 
treatment choice should be made based on underlying patient values and preferences; 
however, mastectomy rates have repeatedly been used as performance and quality 
indicators.(122–125) This stems from the National Institute of Health Consensus 
Conference in 1999, which recommended BCT as ‘preferable’ to mastectomy because it was 
thought as less invasive and cosmetically superior.(10) Researchers have frequently cited 
‘underuse’ of BCT(16) and even called BCT the ‘standard of care’ in some studies.(64) 
Viewing procedural variation through a patient-centered care lens, as opposed to a 
standard of care assessment allows researchers to explore existing variations with curiosity 
rather than judgement. Research conducted to understand what drives patients’ decision-
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making will not only help guide evaluation of quality of care in the setting of ESBC but also 
allow for identification of areas of focus for quality improvement. The aim of our research is 
to better understand why women choose mastectomy compared with BCT in Saskatchewan. 
8.5 Material and Methods 
Approval was obtained from the University of Saskatchewan Behavioural Research Ethics 
Board. 
8.5.1 Survey Conceptual Development and Design 
This survey is the second stage of a sequential mixed-methods study.(86) The 
construction of our survey was based on a previously developed conceptual framework, as 
shown in Figure 8.1.(95) This framework provided a logical guide to organize our inquiry 
while maintaining the individual patient decision as the central focus. 
Figure 8.1: Conceptual framework illustrating the central constructs 




This framework organizes the potential influencing factors affecting women’s choice between mastectomy 
versus BCT into three central factor constructs: clinicopathological, physician, and individual with subgroups 
of sociodemographic, geographical, and personal belief factors.  
 
The survey is composed of an online questionnaire linked with a clinicopathological 
dataset from the Saskatchewan Cancer Agency. The questionnaire was designed in 
accordance with best practice recommendations from Krosnick.(115) For individual 
factors, all participants were asked to rate fourteen personal belief questions on a 5-point 
Likert scale. Five additional factors were mastectomy-specific and two were BCT-specific. 
For physician factors, participants were asked to reflect on the physician’s involvement in 
the treatment decision-making process on a 5-point scale ranging from entirely the 
individual’s choice to entirely the physician’s choice, with a shared-decision in the middle. A 
detailed explanation of the survey design and the full survey can be viewed in Appendices A 
and B. 
8.5.2 Study Participants 
Our study population included all Saskatchewan women diagnosed and treated with 
ESBC in 2014-2015. ESBC was defined as women who had stage one or two cancer (AJCC 7th 
edition).(19) Patients who had DCIS, known BRCA, stage three or four breast cancer, male 
breast cancer, and inflammatory breast cancer were excluded. 
Participant recruitment was done in collaboration with the Saskatchewan Cancer 
Agency (SCA). Through the SCA database, all patients treated for ESBC in Saskatchewan 
during the inclusive two-year period from January 2014 to December 2015 were identified. 
Patients were mailed a letter from the SCA inviting them to participate in December 2017, 
with a single reminder invitation eight-weeks later (Appendix C). Data collection ended on 
April 30, 2018. No incentive-based recruitment strategies were employed. 
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The questionnaire was hosted online through Voxco.(126) Participants were 
encouraged to self-administered the survey online. Alternatively, the participants could call 
the researcher and have the questionnaire administered via a phone interview.  
8.5.3 Data Collection and Management 
 Clinicopathological data including tumor location, pathology, and staging were 
obtained from the SCA database and linked to the questionnaire data using a unique eight-
character alphanumerical identifier thatpatients also used to access the online survey. 
8.5.4 Data Analysis 
 Statistical analysis was performed using Stata 14.2.(120) Our primary outcome was 
odds of mastectomy versus BCT. Independent variables included clinicopathological factors, 
individual patient factors, and physician factors. Baseline differences between groups were 
evaluated using the chi-squared test for categorical data and independent sample t test for 
continuous data. Univariate logistic regression was applied to identify key predictors of 
choice of mastectomy versus BCT. Likert scale variables were treated as ordinal variables. 
Multivariable logistic regression analysis was used to create the main effects model. 
Variables for which p < 0.10 in the univariate logistic regression were included in the 
multivariable model, after which backwards elimination was performed of variables for 
which p < 0.05. Clinically important effect modifiers were individually tested for potential 
inclusion in the model using an interaction term. Goodness of fit was assessed using the 
Akaike information criterion. For missing data, we used complete case analysis when less 
than 10% of data points were missing and the indicator method when more than 10% were 
missing to reduce bias.  
 
 147 
 Geocoding and mapping were performed in conjunction with the Spatial Division of 
the University of Saskatchewan Social Sciences Research Laboratories. Geocoding was 
performed by joining spatial information (latitude and longitude) to patients’ home based 
on the first three letters of the postal code provided. Visualizing routes and generating GIS 
files was done using a WebGIS solution developed by the local team to visualize patients’ 
home location, hospital locations, and travel routes.  
8.6 Results 
A total of 276 out of 1056 (26.1%) participants completed the survey; 150 of whom 
underwent mastectomy (54.3%) and 126 of whom underwent BCT (45.7%). Twenty-five 
(9%) of the participants completed the questionnaire via telephone. 
8.6.1 Cohort Characteristics 
The only significant difference in sociodemographic and geographical characteristics 
between women undergoing BCT versus mastectomy was in annual household income 
(Table 8.1). For clinicopathological factors, the mastectomy group had more advanced 
overall stage, tumor stage, tumor size, nodal stage, and higher pre-operative MRI rates 
(Table 8.2).  
Table 8.1: Participant cohort characteristics  
 
Mastectomy (N= 
150) n (%) 
BCT  (N = 126) 
n (%) 
p-value 
Mean Age 58.9 59.6 0.64* 
Age   0.15 
<50 36 (24.0) 27 (13.5)  
50-65 62 (41.3) 64 (50.8)  
65-80 44 (29.3) 39 (31.0)  
>80 8 (5.3) 6 (4.8)  
Ethnicity   0.08 
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Caucasian 145 (96.7) 119 (94.4)  
First Nations, Metis, Inuit 0 (0.0) 4 (3.2)  
Other 5 (3.3) 3 (2.4)  
Annual Household Income   <0.01 
< $40,000 29 (27.4) 13 (14.6)  
$40,000 – $100,000 41 (38.8) 56 (62.9)  
 $100,000 36 (34.0) 20 (21.5)  
Employment Status   0.95 
Employed 65 (43.6) 55 (44.0)  
Not Employed 84 (56.4) 70 (56.0)  
Highest Level of education   0.26 
Less than high school 10 (6.7) 8 (6.4)  
Completed high school 31 (20.7 28 (22.2)  
Some technical or community 
college 
14 (9.3) 11 (8.7)  
Completed college 46 (30.7) 24 (19.1)  
Some university 14 (9.3) 20 (15.9)  
Bachelor’s degree 24 (16.0) 18 (14.3)  
Master’s degree 5 (3.3) 7 (5.6)  
Professional degree or doctorate 6 (4.0) 10 (7.9)  
Smoking Status   0.94 
Never 72 (48.0) 62 (49.2)  
Ex-smoker 66 (44.0) 53 (42.1)  
Current Smoker 12 (8.0) 11 (8.7)  
Relationship Status   0.69 
In a relationship 120 (80.5) 103 (82.4)  
Not in a relationship 29 (19.5) 22 (17.6)  
Children   0.90 
Yes 120 (86.0) 21 (14.0)  
No 109 (86.5) 17 (13.5)  
Menopausal Status   0.52 
Pre-menopause 47 (31.3) 103 (68.7)  
Post-menopause 35 (27.8) 91 (72.2)  
Breast size   0.12 
 A 15 (10.0) 3 (2.4)  
B 41 (27.3) 33 (26.2)  
C 38 (25.3) 35 (27.8)  
D 45 (30.0) 40 (31.2)  
E 5 (3.3) 4 (32.0)  
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F 6 (4.0) 11 (8.7)  
Urban vs Rural Residence   0.34 
Urban 85 (56.7) 78 (62.4)  
Rural 65 (43.4) 47 (37.6)  
City of Surgery   0.43 
Saskatoon 79 (52.7) 62 (49.2)  
Regina 60 (40.0) 49 (38.9)  
Other 11 (7.3) 15 (11.9)  
Distance from Surgical Centre 107.4 km 101.3 km 0.79* 
Note: denominators may vary depending on response rate. 
Comparison between mastectomy and BCT were made using Pearson’s chi-square test unless otherwise specified. 
*Two tailed t-test was used for this analysis. 
p-values listed used significance level of 0.05. 
 
Table 8.2: Clinicopathological characteristics  
 
Mastectomy (N= 
150) n (%) 
BCT  (N = 126) 
n (%) 
p-value 
AJCC Stage   <0.01 
I 69 (46.0) 85 (67.5)  
II 81 (54.0) 41 (32.5)  
Tumor Stage   <0.01 
T1mic 6 (4.0) 2 (1.6)  
T1A 6 (4.0) 3 (2.4)  
T1B 24 (16.0) 35 (27.8)  
T1C 46 (30.7) 55 (43.7)  
T2 65 (43.3) 30 (23.8)  
T3 3 (2.0) 0 (0)  
Mean Tumor Size 2.0cm 1.6cm <0.01* 
Nodal Stage   0.036 
N0 105 (70.0%) 102 (80.1%)  
N1 45 (45.0%) 24 (19.0%)  
Estrogen Receptor (ER) Assay   0.46 
ER + 134 (89.3) 114 (90.5)  
ER - 16 (10.7) 10 (7.9)  
Progesterone Receptor (PR) 
Assay 
  0.27 
PR + 122 (81.3) 107 (84.9)  
PR - 28 (18.7) 17 (13.5)  
HER2 Assay   0.32 
HER2 + 13 (25.0) 5 (12.8)  
HER2 - 37 (71.2) 33 (84.6)  
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Borderline 2 (3.8) 1 (2.6)  
Combination of ER, PR, HER2 
Assays 
  0.07 
Not favorable** 30 (20.8) 15 (12.4)  
Favorable 114 (79.2) 106 (87.6)  
Tumor Grade   0.07 
Grade 1 31 (22.0) 34 (27.8)  
Grade 2 62 (44.0) 62 (50.8)  
Grade 3 48 (34.0) 26 (21.3)  
Tumor Description   0.42 
Infiltrating Ductal 105 (70.0) 90 (71.4)  
Infiltrating Lobular 20 (13.3) 11 (8.7)  
Ductal & Lobular 6 (4.0) 3 (2.4)  
Mucinous Adenocarcinoma 6 (4.0) 4 (3.2)  
Other 13 (8.7) 18 (14.3)  
Tumor Multiplicity Counter   0.34 
01 110 (79.7) 110 (87.3)  
02 16 (11.6) 9 (7.1)  
03 6 (4.4) 3 (2.4)  
>04 6 (4.4) 3 (2.4)  
Tumor Side   0.24 
Left 81 (54.0) 59 (46.8)  
Right 69 (46.0) 67 (53.2)  
Tumor Location   0.02 
Breast other*** 112 (74.7) 77 (61.1)  
Upper-outer 38 (25.3) 48 (38.9)  
Pre-operative MRI   0.05 
Yes 90 (60.0) 61 (48.4)  
No 60 (40.0) 65 (51.6)  
Note: denominators may vary depending on response rate. 
Comparison between mastectomy and BCT were made using Pearson’s chi-square test unless otherwise specified. 
*Two tailed t-test was used for this analysis. 
**Not favorable combinations: ER-/PR-/ HER2-, ER-/PR-/HER2+, ER-/PR+/HER2+, ER+/PR-/HER2+, and ER+/PR+/HER2+. 
Favorable combinations: ER+/PR+/HER2-, ER-/PR+/HER2-, and ER+/PR+/HER2-. 
***Breast other: Breast not otherwise specified, central, lower-inner, lower-outer, overlap, and upper-inner. 
p-values listed used significance level of 0.05. 
8.6.2 Predictors of BCT Compared with Mastectomy 
Results of the univariate logistic regression are presented in Table 8.3. The final model from 
multivariate logistic regression resulted in six significant factors influencing therapy choice 
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(Table 8.4). Stage of disease was the only clinicopathological factor; the remainder were 
individual belief and preference factors.  




95% C.I. p-value 
Age    
<50 1.00 Referent  
50-65 0.46 0.23 – 0.90 0.02 
65-80 0.53 0.26 – 1.09 0.09 
>80 0.63 0.19 – 2.10 0.45 
Ethnicity    
Caucasian 1.00 Referent  
First Nations, Metis, Inuit N/A N/A N/A 
Other 1.22 0.34 – 4.44 0.31 
Annual Household Income    
< $40,000  Referent  
$40,000 – $100,000 0.33 0.15 – 0.71 <0.01 
 $100,000 0.81 0.34 – 1.89 0.09 
Employment Status    
Employed 1.00 Referent  
Not Employed 1.02 0.63 – 1.64 0.95 
Highest Level of education    
Less than high school 1.00 Referent  
Completed high school 0.89 0.31 – 2.56 0.82 
Some technical or community 
college 
1.02 0.30 – 3.45 0.98 
Completed college 1.53 0.54 – 4.39 0.43 
Some university 0.56 0.18 – 1.77 0.33 
Bachelor’s degree 1.07 0.35 – 3.24 0.91 
Master’s degree 0.57 0.13 – 2.50 0.46 
Professional degree or doctorate 0.48 0.12 – 1.90 0.30 
Smoking Status    
Never 1.00 Referent  
Ex-smoker 1.07 0.65 – 1.76 0.78 
Current Smoker 0.94 0.39 – 2.28 0.89 
Relationship Status    
In a relationship 1.00 Referent  
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Not in a relationship 1.13 0.61 – 2.09 0.69 
Children    
Yes 1.00 Referent  
No 1.04 0.52 – 2.08 0.90 
Menopausal Status    
Pre-menopause 1.00 Referent  
Post-menopause 0.84 0.50 – 1.42 0.52 
Breast size    
 A 1.00 Referent  
B 0.25 0.07 – 0.93 0.04 
C 0.22 0.06 – 0.81 0.02 
D 0.23 0.06 – 0.85 0.03 
E 0.25 0.03 – 1.52 0.13 
F 0.13 0.03 – 0.57 0.02 
Urban vs Rural Residence    
Urban 1.00 Referent  
Rural 1.27 0.78 – 2.06 0.34 
City of Surgery    
Other 1.00 Referent  
Saskatoon 1.74 0.75 – 4.05 0.20 
Regina 1.67 0.70 – 3.96 0.25 
Distance from Surgical Centre 1.00 1.00 – 1.00 0.80 
AJCC Stage    
I 1.00 Referent  
II 2.43 1.49 – 3.98 <0.01 
Tumor Stage    
T1mic 1.00 Referent  
T1A 0.66 0.08 – 5.54 0.71 
T1B 0.23 0.04 – 1.23 0.09 
T1C 0.28 0.05 – 1.45 0.13 
T2 0.72 0.14 – 3.79 0.70 
Mean Tumor Size 1.04 1.02 – 1.07 <0.01 
Nodal Stage    
N0 1.00 Referent  
N1 1.82 1.04 – 3.21 0.04 
Estrogen Receptor (ER) Assay    
ER + 1.00 Referent  
ER - 1.36 0.59 – 3.12 0.47 
Progesterone Receptor (PR) 
Assay 
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PR + 1.00 Referent  
PR - 1.44 0.75 – 2.78 0.27 
HER2 Assay    
HER2 + 1.00 Referent  
HER2 - 0.56 0.22 – 1.50 0.26 
Combination of ER, PR, HER2 
Assays 
   
Not favorable** 1.00 Referent  
Favorable 1.78 1.22 – 2.60 <0.01 
Tumor Grade    
Grade 1 1.00 Referent  
Grade 2 1.10 0.60 – 2.00 0.76 
Grade 3 2.02 1.02 – 4.00 0.04 
Tumor Description    
Ductal & Lobular 1.00 Referent  
Infiltrating Lobular 0.75 0.11 – 4.90 0.76 
Infiltrating Ductal 0.91 0.19 – 4.37 0.91 
Mucinous Adenoca 0.58 0.14 – 2.40 0.46 
Other 0.26 0.07 – 1.72 0.20 
Tumor Multiplicity Counter    
01 1.00 Referent  
02 1.78 0.75 – 4.19 0.19 
03 2.00 0.48 – 8.20 0.96 
>04 2.00 0.48 – 8.20 0.96 
Tumor Side    
Left 1.00 Referent  
Right 0.75 0.47 – 1.21 0.24 
Tumor Location    
Breast other*** 1.00 Referent  
Upper-outer 0.53 0.32 – 0.89 0.02 
Pre-op MRI    
Yes 1.00 Referent  
No 0.3 0.39 – 1.01 0.06 
Worry About Cancer Recurrence 2.75 2.12 – 3.33 <0.01 
Age 1.20 0.99 – 1.46 0.06 
Other Individual Medical History 1.14 0.94 – 1.37 0.19 
Family History of Breast Cancer 1.34 1.10 – 1.64 <0.01 
Previous Breast Disease 1.16 0.94 – 1.44 0.17 
Breast Size 1.00 0.81 – 1.24 0.99 
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Tumor Size 0.61 0.50 – 0.75 <0.01 
Travel Distance 1.08 0.85 – 1.38 0.51 
Surgeon’s Opinion 0.66 0.54 – 079 <0.01 
Feminine Identity 0.63 0.51 – 0.79 <0.01 
Sexuality 0.64 0.50 – 0.81 <0.01 
Wanting to Keep Breast Tissue 0.31 0.23 – 0.42 <0.01 
Incorporating Reconstruction 1.11 0.91 – 1.38 0.29 
Total Treatment Time 1.24 1.00 – 1.54 0.05 
Note: denominators may vary depending on response rate for each questionnaire item.  
Univariate logistic regression was used to evaluate likelihood of mastectomy versus BCT unless otherwise specified. Higher odds favours 
mastectomy. 
*two tailed-t-test was used for this analysis. 
**Not favorable combinations: ER-/PR-/ HER2-, ER-/PR-/HER2+, ER-/PR+/HER2+, ER+/PR-/HER2+, and ER+/PR+/HER2+. 
Favorable combinations: ER+/PR+/HER2-, ER-/PR+/HER2-, and ER+/PR+/HER2-. 
***Breast other: Breast not otherwise specified, central, lower-inner, lower-outer, overlap, and upper-inner. 
p-values listed used significance level of 0.05. 
 




95% C.I. p-value 
AJCC Stage    
I 1.00 Referent  
II 7.48 2.98 – 18.82 <0.01 
Worry About Cancer Recurrence 3.44 2.32 – 5.11 <0.01 
Tumor Size 0.66 0.47 – 0.94 <0.01 
Surgeon’s Opinion 0.69 0.50 – 0.96 0.03 
Wanting to Keep Breast Tissue 0.17 0.10 – 0.30 <0.01 
Total Treatment Time 1.81 1.19 – 2.75 <0.01 
8.6.3 Clinicopathological Factors 
In multivariate analysis only overall stage remained a significant factor; women who 
had stage two disease had 7.5 times the odds of undergoing mastectomy compared to those 
who had stage one disease. Among participants who rated ‘tumor size’ as an important 
influencing factor, the actual tumor size between groups was amplified (Table 8.5). In this 
subgroup, the mean tumor sizes for mastectomy and BCT participants were 2.5cm 
compared with 1.5cm, respectively.  
Table 8.5: Participants rating ‘tumor size’ as an important factor influencing 






BCT  (N = 96) n 
(%) 
p-value 
Mean Tumor Size 2.52cm 1.54cm <0.01* 
Tumor Stage   <0.01 
T1mic 2 (2.9) 0 (0.0)  
T1A 1 (1.45) 3 (3.1)  
T1B 7 (10.3) 31 (32.3)  
T1C 13 (19.2) 39 (40.6)  
T2 42 (61.8) 23 (24.0)  
T3 3 (4.4) 0 (0.0)  
Note: denominators may vary depending on response rate or testing by the cancer centre.  
Comparison between mastectomy and BCT were made using Pearson’s chi-square test unless otherwise specified. 
*two tailed-t-test was used for this analysis. 
p-values listed used significance level of 0.05. 
8.6.4 Individual Factors 
8.6.4.1 Personal Belief and Preference Factors 
In our final model, factors that were rated as significantly more important for mastectomy 
patients were worry about cancer recurrence and total treatment time (Figure 8.2). Factors 
that were significantly more important for BCT patients were ‘wanting to keep own breast 
tissue’, ‘tumor size’, and ‘surgeon’s opinion’. Individual belief factors for mastectomy 
(Figure 8.3) and BCT (Figure 8.4) participants are displayed in order of cumulative 
importance.   













Figure 8.4: Personal belief and preference factors for BCT participants only  
 
 
8.6.4.2 Sociodemographic Factors 
No sociodemographic factors remained significant in our final main effects model. 
8.6.4.3 Geographical Factors 
The cohort as a whole did not demonstrate any significant geographical factors 
affecting treatment choice. Figure 8.5 depicts travel from patients’ home residence to 
surgical centre. Figure 8.6 depicts BCT patients travel to one of two radiation centres in the 
province. In the mastectomy cohort, participants rating travel distance as important had a 
significantly higher mean distance to radiation centre – 195km versus 105km (p<0.01). 
Figure 8.7 depicts mastectomy participants rating ‘travel distance’ as important and their 















Figure 8.7: GIS map of mastectomy patients rating ‘travel distance’ as 




8.6.5 Physician Factors 
Women who made the treatment decision completely on their own were more likely to 
undergo mastectomy (Table 8.6). Conversely, when the decision was shared or mostly the 
physician’s choice, participants were significantly more likely to undergo BCT. 
Table 8.6: Involvement in treatment decision-making process  
 
Mastectomy 
(N= 150) n (%) 
BCT  (N = 
126) n (%) 
Odds 
Ratio 
95% C.I. p-value 
Involvement in Decision Making      
Completely your choice, no 
physician input 
30 (20.0) 8 (6.5) 1.00 Referent  
Mostly your choice, minimal 
physician input 
51 (34.0) 32 (25.8) 0.43 0.17 – 1.04 0.06 
Shared decision 47 (31.3) 57 (45.9) 0.22 0.09 – 0.52 <0.01 
Mostly your physician’s choice 13 (8.7) 20 (16.1) 0.17 0.06 – 0.49 <0.01 
Completely physician’s choice, no 
individual input 
9 (6.0) 7 (5.7) 0.34 0.10 – 1.21 0.10 
Univariate logistic regression was used to evaluate likelihood of mastectomy versus BCT. Higher odds favours mastectomy. 
p-values listed used significance level of 0.05. 
 
8.6.6 Moderating Effects of Disease Stage with Surgeon’s Opinion and Disease Stage 
with Subjective Tumor Size 
There were two significant interaction terms in our model: stage of disease with 
surgeon’s opinion and stage of disease with subjective tumor size (Table 8.7). Participants’ 
stage of disease, whether stage one or two, moderated the effect of tumor size as an 
important influence on treatment choice (Figure 8.8). Of participants who rated ‘tumor size’ 
as important to their treatment choice, those who had stage one disease were significantly 
more impacted by their subjective tumor size compared with those who had stage two 
disease. Women who had stage one disease and who also placed more importance on tumor 
size were twice as likely to undergo BCT (OR, 0.48; 95% CI, 0.29 – 0.82). 
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A similar relationship was observed between earlier stage of disease and surgeon’s 
opinion (Figure 8.9). For participants who valued ‘surgeon’s opinion’ on their therapy 
choice, those who had stage one disease had significantly more impact on their treatment 
choice as compared with those who had stage two disease. Women who had stage one 
disease and who placed more value on ‘surgeon’s opinion’ were also more than twice as 
likely to undergo BCT (OR, 0.44; 95% CI, 0.26 – 0.75). 
Table 8.7: Moderating effects of disease stage on ‘surgeon’s opinion’ and 
disease stage on subjective ‘tumor size’ for mastectomy versus BCT 




95% C.I. p-value 
Stage 2 
OR 
95% C.I. p-value 
Tumor Size 0.48 0.29 – 0.82 <0.01 0.87 0.54 – 1.39 0.56 
Surgeon’s Opinion 0.44 0.26 – 0.75 <0.01 1.14 0.73 – 1.77 0.57 
Univariate and Multivariate logistic regression was used to evaluate likelihood of mastectomy versus BCT. Higher odds favours  
mastectomy. 
p-values listed used significance level of 0.05. 
 
Figure 8.8: Moderating effects of disease stage with ‘tumor size’ for 
mastectomy versus BCT 
 
 
Figure 8.9: Moderating effects of disease stage on ‘surgeon’s opinion’  for 









8.7 Discussion  
The choice of mastectomy versus BCT is a complicated decision-making process that 
is influenced by a wide array of factors. Our study demonstrates that treatment choices for 
Saskatchewan women who had ESBC were primarily influenced by tumor stage and 
individual belief factors. These findings suggest that women are making their treatment 
choices predominantly based on individual values and preferences. 
Later stage of disease, as determined by tumor size in cases of ESBC, was a 
significant factor influencing women to undergo mastectomy. This association has 
consistently been demonstrated in the literature.(121) Although both choices of treatment 
should be offered, patients who have larger tumors may subjectively believe that their 
breast cancer is more advanced, subsequently influencing their decision-making towards 
mastectomy. Additionally, larger tumors can result in worse cosmetic outcomes, and the 
breast-tumor ratio has been reported to affect treatment choice.(86) Larger tumors may 
also bias the physician towards recommending mastectomy, as they have been associated 
with higher re-excision and local recurrence rates.(23,77–79) 
 An interesting finding from our study was the effect modification that clinical stage 
had on the subjective ‘tumor size’. When considering the impact of tumor size on treatment 
choice, a smaller tumor might be expected to influence towards BCT choice and a larger 
tumor to influence towards mastectomy. This was true for women who had stage one 
disease, among whom the value placed on tumor size significantly influenced their 
treatment towards BCT, but for women who had stage two disease, the value placed on 
tumor size did not have a significantly influence on therapy choice. These findings suggest 
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that tumor size, especially of smaller tumors, is an important reason women choose BCT 
but is less important for women who undergo mastectomy.  
Socioeconomic status (SES), or indicators of SES, has been associated with increased 
likelihood of BCT, although most research is U.S.-based and thus has insurance as a 
complicating factor.(121) Considering that our study was conducted in a universal 
healthcare system, we did not expect to find this association. SES indicators including 
employment status, relationship status, children, urban versus rural residence, and highest 
level of education were not different between groups in our study. There was a discrepancy 
in income between the BCT and mastectomy groups in univariate analysis, with the middle-
income range being more likely to have undergone BCT, but income was not significant in 
the multivariate analysis when controlling for disease stage. This finding suggests that 
differences in income between groups were incidental findings or reflect a lack of power. 
An alternate explanation is that groups having differing SES also have differences in health 
literacy or cultural norms, leading to differences in personal beliefs that were not captured 
by our survey questions. 
There have been mixed results in the literature regarding the effect of rural 
residence and travel distance to radiation facilities on mastectomy rates, but more studies 
have shown decreasing BCT rates with increasing distance to treatment centres.(121) In 
our study, distance to treatment centres and urban versus rural residence did not affect 
treatment choice except for the subset of participants who rated travel distance as an 
important factor influencing mastectomy choice. Their mean travel distance to surgical and 
radiation facilities was significantly farther than for other mastectomy participants, 
indicating that although distance to treatment centre does not affect most individuals’ 
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treatment choice, distance is a concern for a subset of. We have identified and mapped 
(Figure 8.7) the postal code regions of these patients are have fed this information back to 
the SCA and breast units. It is important to identify these individuals and emphasize the 
local supports in place to address geographical barriers. Locally, our cancer centre offers 
lodging during radiation treatments and shorter-course radiotherapy regimes. All efforts 
should be made to provide these supports to patients so that geographical constraints do 
not limit implementation of patients’ therapy choice.  
In our final model, patients who rated ‘worry about cancer recurrence’ and ‘total 
treatment time’ as important had increased odds of undergoing mastectomy. Worry about 
cancer recurrence has consistently been reported in the literature as the most common 
belief factor influencing the choice of mastectomy.(121) Our previous qualitative study also 
found it to be a primary theme motivating mastectomy choice, always for a secondary 
underlying reason: family history of breast cancer, prior observation of a poor BCT 
outcome, or desire to avoid follow-up imaging.(86) Interestingly, follow-up questions about 
why women rated worry about cancer recurrence as important indicated that family 
history was the most common reason. Patients who exhibit increased concern about 
recurrence because of family history are justified in doing so, as risk of developing a second 
breast cancer is increased in such instances(127). Health care providers must focus on 
appropriate education and counselling regarding relative risks and treatment options for 
these patients. 
For belief factors influencing the choice of BCT, ‘tumor size’, ‘surgeon’s opinion’, and 
‘wanting to keep breast tissue’ were significant in our multivariate model. As noted in the 
earlier discussion, the effect of the tumor size on BCT choice is predominantly when the 
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tumor is small; this is logical as a small tumor may convey to the patient a sense that the 
disease is caught early and does not require a more extensive operation. Wanting to keep 
breast tissue was the strongest associated belief factor with undergoing BCT in our study 
(OR, 0.17; 95% CI, 0.10 – 0.30), in line with previous literature demonstrating breast tissue, 
body image concerns, and / or feminine identity as being the most important belief factors 
influencing BCT.(121) 
Previous literature on physician-related factors has largely focused on physician 
demographics such as gender, age, type of training, and practice pattern.(121) Evaluating 
these factors was impractical in our study, which involved more than twenty surgeons from 
eight different surgical centres in Saskatchewan. Instead, we focused on the patients’ 
perceptions of their interactions with their physician and their perceived influence on 
therapy decision-making. In our survey, those rating ‘surgeon’s opinion’ highly had 
significantly increased odds of having BCT. This same relationship has also been 
demonstrated by local and other research.(86,121,128) The resulting directional 
relationship likely indicates that BCT, when possible, is thought by physicians to be better 
for the patient and is thus promoted as such. Some authors have even suggested that the 
use of mastectomy rates as a quality indicator may actually bias the physician treatment 
against patients’ wishes.(88) In our own study, decision conflict scores were lower in the 
mastectomy group (19.8 versus 25.2; p = 0.02). Additionally, when participants were asked 
to reflect on their involvement in the treatment decision-making process (Table 8.5), 
women who made the treatment decision completely on their own were more likely to 
undergo mastectomy. Conversely, when the decision was shared or mostly the physician’s 
choice, participants were significantly more likely to undergo BCT. These findings indicate 
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that patients undergoing mastectomy are more confident of their treatment choice and less 
likely to involve the physician’s opinion. 
Another interesting result from our study was the effect modification that clinical 
stage had on the ‘surgeon’s opinion’ as an influential factor. For women who had stage one 
disease, the value placed on the surgeon’s opinion significantly influenced their treatment 
decision towards BCT. However, for women who had stage two disease, value placed on the 
surgeon’s opinion did not significantly influence on therapy choice. These findings suggest 
that the physician is more likely to influence the patient towards choice of BCT in cases of 
stage one disease but is less likely to be a significant influence in therapy choice in cases of 
stage two disease.  
A limitation of our study is that most of our survey participants were Caucasian 
females. Approximately 16% of Saskatchewan’s population who identifies as Indigenous 
(First Nations, Metis, or Inuit).(129) Our survey did not adequately sample this group; 
future targeted research strategies will be required to understand decision-making 
amongst this ethnic group. What’s more, the response population did not reach our goal 
sample size, which could affect the reliability and generalizability of our results. A strength 
of our study was the grounding of the survey in a clinical framework to help guide and 
organize the study design and analysis. To the authors’ knowledge, no previous studies on 
decision-making for ESBC have done so. We believe that organizing our survey around this 
framework allowed us to more holistically examine the factors influencing therapy choice 
than we could have done by simply investigating a subset of these domains. Furthermore, 
questionnaire development was, in part, directly informed by a previous exploratory work 
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within the province, which improved the relevance and depth of understanding of the 





The choice of mastectomy versus BCT in ESBC is a complicated decision-making 
process that is influenced by a wide array of factors. As research evaluating this topic grows 
in its comprehensiveness, we are gaining a better understanding of the importance of many 
individual belief factors driving therapy choice. If patients are choosing mastectomy 
predominantly because of values they hold and out of individual preference, a lower rate of 
BCT should not be of concern. We would advise against the use of mastectomy or BCT rates 
as an indicator of quality of care in the future. Instead, attention should be shifted towards 
care that is patient-centered. For physicians, this means patient education, understanding 
patients’ views and preferences towards treatment, understanding their own treatment 
biases, engaging in a shared decision-making process, and facilitating the patient’s 
treatment goals. From a quality improvement viewpoint, attention should be focused on 
identifying and limiting barriers to treatment options, including by identifying patients who 
have travel barriers and ensuring that they are aware of local supports or by ensuring that 
therapy choices are offered to patients. 
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CHAPTER 9: DISCUSSION AND CONCLUSIONS 
9.1 Introduction 
 The general aim of this thesis was to better understand the choice of treatment 
between breast conservation therapy and mastectomy in the setting of early stage breast 
cancer in Saskatchewan. More specifically, this thesis is rooted in two questions. Why are 
Canadian interprovincial mastectomy rates are so different, to the degree that 
Saskatchewan’s mastectomy rate is consistently 20% higher than the national average? 
More importantly, does this difference reflect discrepancies in quality of care relating to 
treatment or how women are exercising their therapy choices? 
Broadly, this research improved our understandings of this complicated decision-
making process, led to the creation of a conceptual framework that better organizes a wide 
array of influencing factors, and has identified the ways in which many of these factors can 
interact with one another. In answering the specific questions that inspired this research, 
this work has produced important results, making Saskatchewan one of only two provinces 
in the nation to have been the subject of in-depth research investigating the factors 
underlying the choice between mastectomy and BCT. Concisely, choice of therapy was 
primarily influenced by disease stage and individual belief factors, which is in line with 
viewing this decision-making process as preference-sensitive care. These results also 
suggest that the mastectomy rate in Saskatchewan does not reflect a quality of care issue. 
Furthermore, with increasing research into and more in-depth understanding of this 
complicated decision-making process, we can better appreciate the importance of different 
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individual belief factors driving patients’ therapy choice. These findings suggest that the use 
of BCT or mastectomy rates as quality of care indicators should be avoided and the focus 
shifted instead towards care that is more patient-centred. 
9.2 Using a Framework to Guide Clinical Research 
 When the topic of research is complicated and influenced by multiple factors, such as 
when seeking to understand why women choose mastectomy compared to BCT, study 
design and results can vary greatly in the literature. This is not surprising, for researchers 
seek to integrate social, psychological, biological, and individual factors, as well as their 
interactions with the physicians and health care systems, in an attempt to understand how 
individuals make their therapy choice. A large body of literature has explored these factors 
for decision making in ESBC, but rarely has the research holistically incorporated the 
various factors. In fact, most individual studies have focused on a single set of factors such 
as tumor or geographical factors without considering other important influences, such as 
individual patient preferences.  
One of the valuable contributions of this thesis has been the creation of a conceptual 
framework, as well as the emphasis that placed on such framework’s importance for 
guiding research, especially when the topic of inquiry is complex. Compared with other 
fields, clinical medicine has lagged behind both in understanding the value of frameworks 
to guide inquiries and in using them to improve the quality of research. The primary 
purpose of a framework is to understand the phenomenon of interest in a more complete 
fashion by identifying and organizing important constructs logically.(110) If more clinical 
research were grounded in a framework, results would be less likely to overlook potentially 
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significant confounding factors, allowing for better interpretation and integration of results 
across the field of health care. 
Chapter 6 presents the development of our conceptual framework, illustrating the 
central domains that influence women’s choice between mastectomy and BCT in cases of 
ESBC (Figure 6.1). These have been organized into three broad constructs: 
clinicopathological factors, physician factors, and individual factors with subgroups of 
sociodemographic, geographic, and individual belief factors.  Although this framework was 
developed specifically to examine the factors influencing a patient’s therapy choice in the 
setting of ESBC, it amply demonstrates the benefits of using a framework to guide clinical 
investigation for any field. 
Our framework was used to organize the literature review –the first and only 
published systematic review to have examined why women who have ESBC chose 
mastectomy compared with BCT. Full details of this review are presented in Chapter 3. The 
framework also provided the foundation of how we developed our survey; the key 
constructs were used to organize all stages of the survey study including conceptual 
development and specific ordering of survey items, guiding the analysis, and enriching the 
interpretation and discussion. Full details of the surveys’ development are presented in 
Chapter 7 and the results of the survey are presented in Chapter 8. 
 In reflection, creation and use of our conceptual framework has greatly benefited 
the quality of the systematic review and the survey phase of this research. It aided in 
organizing the multiple influencing factors into key underlying constructs, and in doing so, 
allowing us to conduct research in a more complete fashion. Furthermore, it provided a 
consistent and logical basis of thinking for critically reviewing a complex topic – that of why 
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women choose mastectomy compared with BCT. This benefited and improved our research 
not only in one manuscript but throughout the thesis itself. 
9.2.1 Reflection on the Theory of Planned Behavior 
 Chapter 2.4 introduces the TPB and presents its’ application to conceptualizing the 
choice between mastectomy versus BCT as a planned behavior. At a theoretical level, 
potential decision-making factors can be applied to one or more of the key TPB constructs – 
attitude towards the behavior, subjective norm, or perceived behavioral control. For 
example, fear of cancer recurrence can be explained by behavioral beliefs and surgeons’ 
influence or recommendations can be explained by individual norms. The application of the 
TPB to these factors, along with other influences on decision-making, is presented in Figure 
2.7. 
Certainly the TPB was important in guiding the thematic analysis of my qualitative 
research. This theory provided a basis for conceptualizing and organizing codes into initial 
candidate themes and candidate concept maps. These maps subsequently provided the 
basis for refining themes and evaluating their associations to produce the final thematic 
maps. Full description of this process is detailed in chapters 4.2.2 and 5.5. 
 Although the TPB is logically sound and is useful for conceptualizing decision-
making influences at an individual level, there is a gap in translating findings when applying 
the TPB to broader clinical investigations. It is impractical for most clinicians to view 
factors theoretically as subjective norms or perceived behavioral control. Recognizing the 
incongruence between theory and clinical application was a significant motivator for 
creation of our own framework that would better fit the research goals. In summary, the 
TPB was useful in my initial research and played an important role in leading up to creation 
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of the framework but in this research context has limited clinical application at a broader 
level. 
9.3 Strengths and Limitations 
Overall, the strength of our research lies in the multiple methodologies employed 
and in how each phase complements another to support our pursuit of research objectives. 
Chapter 9.2 details how the creation, publication, and emphasis of the clinical framework 
we developed was a strength of our research.  
The absence of any previous systematic reviews on this topic motivated our group to 
conduct the first systematic review of why women who have ESBC choose mastectomy 
compared with breast conservation therapy. This review provided a rigorous synthesis of 
factors that was not previously available in the literature. It was also a foundation for 
assessing the current state of knowledge relating to our research topic and thus benefited 
the other phases of study.  
Our research followed an exploratory sequential mixed methods design, which is 
another strength of our investigations. A primary goal of our research was to identify 
factors that influenced Saskatchewan women’s decision-making and to understand how 
these factors influenced their therapy choice. We understood by reviewing the literature 
and conducting a systematic review that this was a complicated topic and that many 
previous publications had inadequately studied treatment decision-making by missing 
large categories of influencing factors. Although doing so would be more time and resource 
intensive, we felt using a combination of qualitative and quantitative approaches as better 
enabling us to investigate and understand the full extent of factors that influence therapy 
choice than with any single approach alone could. 
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No previous research evaluating why women who had ESBC chose mastectomy 
compared with BCT had been conducted in Saskatchewan in the past. We were thus not 
sure whether the same factors noted in the literature applied to Saskatchewan women. The 
initial qualitative study was aimed at identifying factors that influenced therapy choice 
within our population of interest. These findings subsequently directly guided the creation 
of our questionnaire, which targeted individual preferences and values. Because the 
questions were grounded on the Saskatchewan patients and their perspectives, specific 
questions, terminology, wording, and follow-up questions were based on our initial 
qualitative study. The use on an in-depth questionnaire design and specific response 
options is a strength of our study. 
Another strength of our survey was its design to capture all major influencing 
constructs: clinicopathological, physician, and individual with subgroups of 
sociodemographic, geographical, and personal belief factors. As previously discussed, this 
has rarely been featured in the literature – not entirely surprisingly, as capturing factors 
from all three constructs is both resource-intensive and procedurally complicated. 
Nevertheless, it seemed important, when interpreting results of a study, to consider the 
potential for significant confounding were a construct to be ignored altogether.  
Limitations of our research include capturing a representative sample of our target 
population, being retrospective in design, the response rate, and response bias. 
Approximately 16% of Saskatchewan’s population identifies as Indigenous (First Nations, 
Metis, or Inuit).(129) Unfortunately, we did not adequately sample this population in our 
qualitative study or our survey. In our qualitative study and survey, we had 1(4%) and 
4(1.5%) Indigenous participants respectively. Most participants in our research were 
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Caucasian females – 92% in the qualitative study and 95.6% in our survey. Future dedicated 
research strategies will be required to understand why women of Indigenous ethnicity 
make their treatment choices. 
Another limitation was the response population not reaching our intended sample 
size, potentially affecting the reliability and generalizability of our results. Another 
limitation of our research is the retrospective design, which included the potential for recall 
bias’s and post-treatment experiences’ affecting participant responses. It is possible that 
patients reported their decisions based on post hoc justification instead of citing the 
reasons important at the time of decision-making. This also poses a potential problem for 
recalling the details of information presented around the time of treatment choice, for 
research has previously identified that patients’ recall of events surrounding cancer 
diagnosis can be problematic.(108,109) 
Our final survey included 276 participants, for a 26.1% response rate – lower than 
our initial goal of 45%. This shortfall gives rise to potential study limitations, including the 
generalizability of our results to the larger Saskatchewan population. We must also 
consider how potential nonresponse bias could affect our outcomes. Although we would 
like to believe that the general findings from our study are likely to remain the same with 
improved recruitment, differences in outcome would certainly be possible with improved 
response.  
There are multiple potential reasons for the low response rate in our study. 
Invitations to participate were mailed out from December 2017 to April 2018, but patients’ 
cancer treatments had been between 2014 to 2015. This potential four-year gap between 
diagnosis and recruitment might have seen patients move out of province or suffer an 
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adverse event that rendered them unable to respond. What’s more, the invitation period 
came during a time of year when many Saskatchewan residents act as ‘snowbirds’. 
Limitations of technology and computer literacy could also to be to blame. The primary 
modality of survey response was via an online survey and although we offered a phone-
interview option, the mere presence of an online-survey option might have been enough to 
deter some participants. 
Future research with more prospective methods may be warranted to address some 
of the limitations of our current research. For example, all patients in Saskatchewan who 
were diagnosed with ESBC could be prospectively tracked over a one- year period for 
potential study recruitment. These patients could be invited to participate during their 
cancer clinic visits and could be provided with options for computer, tablet, or paper survey 
responses. This would likely improve recruitment of a representative population, alleviate 
the potential limitations of recall bias, and improve the study’s response rate.   
9.4 Other Research Within Canada  
9.4.1 Newfoundland and Labrador 
As far I am are aware, only one other Canadian province, Newfoundland and 
Labrador, has been the site of research into why women choose mastectomy compared 
with breast conservation therapy.(130) It is interesting to note that in the latest 2015 CPAC 
report, Saskatchewan’s mastectomy rate has been second to only that of Newfoundland, 
which has had the nation’s highest final mastectomy rate of 68.3%.(27) Their research team 
has conducted parallel qualitative and quantitative studies.(131,132) 
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The quantitative study by McCrate et al was published in October of 2018 in the 
Canadian Journal of Surgery and entitled ‘Surgical treatment choices for breast cancer in 
Newfoundland and Labrador: a retrospective cohort study’.(131) This is a retrospective 
cohort examined all women diagnosed with breast cancer over a six-year period from 
January 2009 to December 2014. Included participants were not only those who had ESBC, 
stage one and two breast cancer, but also those who had pre-invasive cancer, stage 0 or 
ductal carcinoma in situ, or advanced breast cancer, stage three or four breast cancer. 
Diagnostic data from the Newfoundland and Labrador provincial tumor registry were 
linked with surgery data from the Discharge Abstract Database of the CIHI. The variables 
included in the study were: year of diagnosis, age at diagnosis, stage at diagnosis, 
geographic code of residence, health regions at diagnosis, and surgical procedure 
performed. Driving time between patient residence to the radiation centre in St. John’s was 
calculated using the road distance database maintained by the Economic and Statistics 
Branch of the government. Statistical analysis was performed using univariate and logistic 
regression modelling. 
Their final study cohort included 2,346 cases, in 1,605 (68.4%) of which the patient 
underwent mastectomy. Patients’ mean age of diagnosis was 61 years. Distribution of 
disease by stage was as follows: stage zero (13.9%), stage one (40.5%), stage two (30.6%), 
stage three (11.8%), and stage four (2.9%). In their final multivariate model, the two 
significant predictors of mastectomy were stage at diagnosis and driving time. Women were 
1.82 times [95% CI, 1.64-2.02] more likely to have mastectomy for every unit increase in 
stage from 0 to 4 and 1.15 times [95% CI, 1.11-1.21] more likely to have mastectomy for 
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every unit of driving time increase. Driving units or 30 minutes were divided into eight 
categories, from 30 minutes or shorter to 540 minutes or more. 
A qualitative study by Dicks et al. was published in April of 2019 in Current Oncology, 
and entitled ‘Factors influencing surgical treatment decisions for breast cancer: a 
qualitative exploration of surgeon and patient perspectives.’(132) This study followed a 
descriptive qualitative design focused on better explicating the factors influencing breast 
cancer surgical decision-making. Data collection included interviews and focus groups with 
thirteen surgeons and thirty-five women who were offered the choice of BCT or 
mastectomy. Their analysis using qualitative description to summarize the data pertaining 
to surgical decisions. 
The researchers’ final sample of women included four women who had BCT as their 
final treatment, and thirty-one patients who had mastectomy has their final treatment. In 
their descriptive findings, the authors noted that both physicians and patients recounted 
numerous factors influencing their decisions including clinical, demographic, psychosocial, 
education-related, and cultural.(132) Surgeons in particular recognized the high rate of 
mastectomy in the province and this was in keeping with a rising rate of CPM. For women, 
they found a key factor was fear of recurrence and a need to ‘just get rid of it’, but other 
experiences also influenced their decision. Other important influences noted included body 
image, life stage and family considerations. 
9.4.2 Comparison of Newfoundland and Labrador with Saskatchewan  
 We first compare and contrast the quantitative study by McCrate et al. with 
ours.(131) Broadly, there are some important differences in study design compared with 
our own research. A major difference is the inclusion of all types of breast cancer, including 
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DCIS, which is non-invasive breast cancer, and advanced breast cancer, stage three and four 
cancer, while our study focused only on stage one and two disease. A second major 
difference is their study used database and registry information, which limited the variables 
they were able to collect. Of the clinicopathological factors, only stage was reported. Of the 
individual factors, only age and geographical factors were reported. There were no 
physician factor data. 
 The province of Newfoundland has only one radiation treatment facility located in 
St. John’s. As with much of Canada, the landmass-to-population ratio presents challenges in 
having advanced facilities without some geographical limitations for those living in rural 
communities. In Saskatchewan, when we examined our cohort as a whole, we found no 
significant geographical factors affecting treatment choice including urban versus rural 
residence, city of surgery, and average distance from surgical centre. Only when we further 
examined the participants who valued ‘travel distance’ as an influential factor did the 
seventeen (11.3%) mastectomy and six (4.7%) BCT participants demonstrate a significant 
difference in mean travel distance between groups. In Newfoundland, they reported 
increasing likelihood of undergoing mastectomy with each fourty-minute increase in 
driving time. However, the manuscript did no provide important pieces of information, 
including whether there are any supports in place to aid patients who have long travel 
distances, such as subsidized lodging or variations in radiation regimens. It would also be 
important to know how this information is being offered to the patients, and what is being 
done to maximize patients’ ability to have the treatment option of their choice. 
Another significant predictor in the Newfoundland study was increasing stage of 
disease. However, Newfoundland’s rate of mastectomy for stage one and stage two disease 
 
 182 
was quite high compared with Saskatchewan’s – 64% for stage one disease, compared with 
44.8% in Saskatchewan, and 73.5% for stage two disease, compared with 66.4% in 
Saskatchewan. Potential explanations afforded in their discussion were tumor 
characteristics factors and the potential for their province to have a higher incidence of 
inherited disorders. Considering that the stage incorporates tumor factors, unaccounted for 
tumor characteristics are an unlikely explanation for the mastectomy rate. It is possible, 
however, that Newfoundland has higher rates of BRCA – but if so, this information should 
be incorporated into their research, for management for BRCA differs from that of regular-
risk ESBC.(25) In the 2015 CPAC report, Newfoundland also had the nation’s largest change 
from index to final mastectomy rate at 54.2% to 68.3%.(27) Although this could be related 
to higher rates of open biopsy, assessment of positive margin rates after lumpectomy would 
be important to evaluate so as to ensure a high standard of surgical care.(133) 
Overall, our main caution in interpreting results from McCrate et al. is the lack of 
consideration for other important influencing factors affecting patients’ therapy choice, 
especially personal preference and physician factors. Our study in Saskatchewan also found 
that stage of disease was an important factor in increasing the likelihood of undergoing 
mastectomy, but the majority of significant influencing factors were personal preference 
factors – worry about cancer recurrence, total treatment time, wanting to keep own breast 
tissue, and surgeon’s opinion. We recognize that capturing personal preference factors is 
logistically more challenging and resource-intensive, but it is becoming clear that these are 
important influences that must be evaluated when seeking to understand the ‘surgical 
treatment choices’ that patients are making. We would also suggest using a framework to 
guide future research, as doing so has greatly aided us in our own work. 
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In comparing and contrasting the qualitative study by Dicks et al with our own, the 
major differences are inclusion of physicians in their working group as well as a large 
discrepancy of mastectomy to BCT participants sampled in their study.(132) Dicks et al. 
reported that physicians in Newfoundland were specifically aware of the high rate in the 
province – potentially, the researchers noted, in conjunction with rising CPM rates. We are 
aware of other Canadian literature that has demonstrated increasing CPM rates,(134) but 
did not find this to be a significant factor in choice of therapy in our province. CPM seems 
more likely to be related to the underlying influence of choice of mastectomy rather than to 
be the source of influence for women’s choice of mastectomy. There is some concern in 
interpreting the influences of women undergoing BCT, as only four participants were 
included who had BCT as their final procedure – which poses a risk of under sampling. 
Interestingly, when considering geographical influences on therapy in Newfoundland, it is 
interesting that the qualitative and quantitative results were discordant. The qualitative 
study found that travel distance was problematic if related to life circumstances such as 
having school-aged children and not necessarily related just to resident location from the 
radiation treatment facilitates. This is in contrast to the quantitative study, in which 
distance from radiation treatment facility was one of the only two significant factors to 
influence the likelihood of undergoing mastectomy. Certainly this would be an important 
area of further research. 
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9.5 Should Mastectomy and BCT Rates Be Used as a Quality Indicator? 
9.5.1 Past and Present Use of Mastectomy and BCT Rates as a Quality Indicator 
An important part of modern cancer care is ensuring quality of care, so that patients 
have access to services that are tailored to their needs and preferences, with practice 
patterns following the latest evidence-based medicine to ensure the best outcomes with 
appropriate use of resources. The Canadian Partnership Against Cancer (135) defines 
quality of care as ‘an all-encompassing’ dimension of performance that can be interpreted 
in many ways. In general, quality of care can be defined as ‘the degree to which health 
services for individuals and populations increase the likelihood of desired health outcomes 
and are consistent with current professional knowledge’. (p.4) 
 The use of mastectomy or BCT rates as a quality indicator has been proposed and 
used in the past. In Canada, the 2012 CPAC report on ‘Breast Cancer Control in Canada: A 
system performance special focus report’ specifically uses mastectomy compared with BCT 
in the surgical treatment of breast cancer as the first set of breast cancer treatment 
indicators.(11) Although the report also discusses associated factors such as age, 
neighborhood income quintile, and travel time, the focus of that chapter is on the 
interprovincial mastectomy rates themselves.  
 In Europe, a non-profit group called the European Society of Breast Cancer 
Specialists (EUSOMA) was commissioned to create quality indicators guidelines for breast 
cancer care as part of the European Union’s goal of improving cancer care goals.(122,123) 
These guidelines are intended to provide breast cancer units across the continent with a 
defined set of quality indicators that can be used for certification and ongoing quality 
assessment. These guidelines are comprehensive in breast cancer care, including diagnosis, 
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treatment and follow-up; each of the quality indicators is labelled as either mandatory or 
recommended. Drawing attention to their recommendations for BCT rates, both the original 
position paper in 2010 and the 2017 update have a minimum standard BCT rate of 70% and 
a suggested target rate of 80%. Specifically, the indicator is stated as follows: ‘Proportion of 
patients (BRCA1 and BRCA2 patients excluded) with invasive breast cancer not greater 
than 3cm (total size, including DCIS component) who underwent BCT as primary 
treatment’.(123) This indicator is mandatory and the level of evidence displayed is I, which 
is the highest level of evidence. 
 Explanation of the motivation behind this mandatory quality indicator, however, is 
poor: ‘to conserve the organ with related effects … .The rate is related to a large number of 
factors including (expected) cosmetic outcome, patient preference and access to radiation 
therapy’.(123) If the rate and choice of therapy are related to patient preference, then a 
recommending a BCT rate of 80% seems contradictory unless the patient preferences 
themselves are evaluated. Furthermore, the justification of this indicator with level one 
evidence is also concerning. The guideline authors support this by citing the equivalence of 
treatment between BCT and mastectomy for ESBC, which is widely accepted. However, the 
equivalence of treatment itself does not relate or justify the use of a high BCT rate as a 
quality indicator. They go on to say ‘preservation of the breast has an important impact on 
life quality’ but fail to support this with any cited literature.(123) 
 The use of BCT rate as quality indicator has also been proposed in individual 
countries’ quality assurance guidelines. In Belgium, Stordeur et al published an article in 
2012, ‘Developing and measuring a set of process and outcome indicators for breast cancer’, 
that proposed a set of thirty-two quality of care indicators for their nation’s breast cancer 
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care.(124) Once again, the use of the proportion of women with ESBC who undergo BCT, a 
goal of 70-80%, is used as a quality indicator. This is again supported by level A evidence, 
the highest level of evidence in their report. As with the EUSOMA guidelines, there are 
persistent concerns associated with this indicator and the supporting evidence. What is 
interesting in this report is the focus on indicators that are measurable within the current 
Belgium data system. – but even when data are available, scrutiny is required to evaluate 
the meaning and purpose of the data prior to use.  
9.5.2 Is BCT a Superior Treatment to Mastectomy? 
Many individual institutions that promote BCT as the ‘superior’ therapeutic course 
for patients.(125,136) One American author states that ‘breast conservation is considered 
by many to be the standard of care. With this in mind, a surgeon’s, practice’s or hospital’s 
breast conservation rate … has become a marker of appropriate care’. (125) (p.37) This 
view of the treatment preferences for ESBC is a clear example of the biased belief that BCT 
is the better treatment among many clinicians – a view that has also been reported by other 
authors in the literature.(64) It is also often suggested that BCT is ‘underused’ or 
mastectomy ‘overused’.(137,138) The most radical view we have observed in the literature 
is by Johns et al., who conclude that ‘it no longer seems logical to offer all patients with early 
stage breast cancer, who are not gene carriers, the option of BCT or mastectomy. Such 
patients should be advised that BCT is their optimal treatment’.(136) (p.1,639) 
 The belief that BCT is the ‘preferable’ treatment over mastectomy stemmed from the 
landmark 1991 National Institute of Health Consensus Conference on the treatment of 
ESBC.(10) The specific recommendation states: ‘Breast conservation treatment is an 
appropriate method of primary therapy for the majority of women with stage I and II breast 
 
 187 
cancer and is preferable because it provides survival rate equivalent to those of total 
mastectomy axillary dissection while preserving the breast’.(10) (p. 394) The focus of the 
report is affirming that BCT is an equivalent treatment to mastectomy in terms of survival 
and outlining oncological principles of BCT. Looking closer at the discussion around therapy 
choice, cosmetic result is emphasized as a primary goal along with local-regional 
oncological control. They go on to suggest the patient should make an informed decision 
and that ‘a woman’s body image and her beliefs and concerns may determine her 
preference for breast conservation treatment or mastectomy’.(10) (p. 392) 
 At the time of the conference, significantly less was known about influencing factors 
on women’s choices between mastectomy compared with BCT. It is logical that physicians 
would assume that preservation of breast tissue and cosmetic outcome is a priority for 
female patients; such a belief appears to have led to identifying BCT as the ‘preferable’ 
treatment. Although cosmetic result and preservation of breast tissue are important factors 
that influence treatment choice, we now know that a number of other important personal 
preference factors influence decision-making.(121) Influences such as worry about cancer 
recurrence, desire to avoid radiation, and physician influences, to name a few, were likely 
not recognized as important influences or were underappreciated at the time of the 
conference. Furthermore, medical practices have continued to shift from a more 
paternalistic model in the past to one that is patient-centered and that encourages shared-
decision-making.(43,139–141) 
9.5.3 The Current Management of Early Stage Breast Cancer in Canada 
In North American, major treatment guidelines support offering patients choice of 
mastectomy versus BCT. The National Comprehensive Cancer Network (NCCN), which is 
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the resource most frequently referred to by physicians for cancer treatment algorithms, 
displays both mastectomy or BCT as treatment options for patients; conveying no specific 
recommendation of or preference for one treatment over the other.(25) In Canada, Cancer 
Care Ontario is another frequently used resource for cancer treatment guidelines. These 
guidelines specifically recommend offering patients who have ESBC the choice of BCT or 
mastectomy, and stating that the treatment ‘should be dependent upon patient preference 
where appropriate’.(142) 
9.5.4 A Shift in Philosophy Beyond the Mastectomy Rate 
Previous sections of this chapter have highlighted what I believe to be the 
inappropriate use of mastectomy rates as a quality of care indicator, along with some of the 
bias in the medical field towards viewing BCT as a superior treatment for ESBC. However, I 
believe that BCT and mastectomy are both valid treatments for ESBC and should thus be 
offered to patients with full explanations of each therapy’s risks and benefits. As more 
understanding is gained of how complex and varied individual decision-making can be, the 
literature is also showing an increasing recognition and advocacy against the use of 
mastectomy or BCT rates as a quality indicator.(128,137,143)  
Equipped with an improved understanding of the complexities behind patient 
therapy choice and the shift away from many health care systems’ previous bias towards 
BCT as the ‘preferred’ therapy, we recommend that the use of mastectomy or BCT rates 
should be discontinued. Looking at mastectomy rates alone is not in line with viewing both 
therapy choices as equal. In fact, continued focus and reporting on mastectomy rates will 
likely perpetuate pre-existing biases towards BCT as ‘preferable’ therapy among health care 
professionals. Even worse is the use of BCT rate as a quality indicator target. Both practices 
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may influence health care professionals, and subsequently the health care systems, to 
deliver care that is biased. A biased physician’s overemphasis of BCT can be detrimental to 
patient-physician communication, ultimately leading to treatment that is not actually in line 
with patient preferences and wishes.  
9.5.5 The Future of Evaluating Treatment Decision-Making in ESBC 
Although we oppose the use of mastectomy rates as a quality indicator, we 
emphasize the importance of continued efforts to improve the quality of cancer care 
delivery, as well as the use of auditing practices to ensure that outcomes align with 
treatment goals.(135) If decision-making between mastectomy versus BCT in cases of ESBC 
is still to be used as a quality indicator, then a shift is needed to align quality indicators with 
modern treatment goals, the most important of which is to identify and minimize 
inequalities related to access of treatment for patients, to the best of our ability. Close after 
is finding out whether patients are being offered treatment choices and if the treatment 
they receive is in line with their wishes. 
From the standpoint of inequality, two potentially concerning elements reported in 
some of the literature are the association of low SES or income and geographic distance to 
radiation centre.(121) Although income is generally less a concern in Canada than in the 
United States, as the direct costs of healthcare insurance are universal, indirect costs and 
life circumstances for individuals of lower SES may affect their ability to comply with the 
BCT treatment time length. From a quality assurance viewpoint, it may be difficult to 
measure at an individual level how income and SES directly influence therapy choice. 
However, checkpoints can be put place at a breast unit level. For example, although the 
standard radiation timeframe is 5 weeks, the local radiation oncologist can offer a shorter 
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course therapy to certain individuals that takes 3.5 weeks. A quality indicator can be 
created to measure whether all of the breast unit surgeons and nurse navigators are aware 
of this option and whether this option is made evident in informational pamphlets. From a 
geographical and standpoint, Canada has a large landmass-to-population ratio, and the 
national reports have shown increased mastectomy rates with increasing distance to 
radiation treatment centre.(1) Because increasing the number of rural radiation treatment 
centres is not a feasible solution, we need to develop other solutions are needed to ensure 
that patients have access to all treatment options. For example, the SCA offers subsidized 
lodging to cancer patients, and delivery of this information can be used as a quality 
indicator. Additionally, these patients should also be informed of the potential shorter 
course radiation treatments.   
If we believe that treatment for ESBC is truly ‘preference-sensitive care’ that should 
thus depend on patient preference factors, then ensuring proper deliver of treatment 
options to the patient is critical. This can be measured at the individual level through 
occasional audits asking patients what therapy choices they were offered. At a breast unit 
level, availability of informational pamphlets or handouts bearing a detailed explanation of 
treatment choices and their associated risks and benefits could also be a quality indicator. 
Measurement of the interaction between the physician-patient dyad is more 
complicated. The most commonly accepted models of decision-making are presented in 
Charles et al and include the paternalistic, shared, and informed models.(40,41) Full 
explanations of these are explained in Chapter 2.5. Multiple studies have demonstrated that 
involvement in the decision-making process to be associated with better mental health and 
quality of life.(144–148) However, level of involvement in the decision-making process 
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appears to vary among individuals. Role congruence, which is the preferred level of 
involvement compared with the actual level of involvement in the decision-making process, 
has also been associated with treatment satisfaction and quality of life, and in some studies, 
has been more important than shared decision-making itself.(148–150) 
Ireland provides an excellent example of incorporating patient choice into their 
breast cancer quality indicators. Ireland’s National Quality Assurance Standards for breast 
cancer care specifically require that the consulting surgeon discuss all treatment options 
with the patient with a target goal of 90%.(151) As a second indicator in the decision-
making process, they ask that the patient be actively involved in the decisions concerning 
their treatment, with a target goal of 95%. These are excellent examples of quality 
indicators that promote an informed patient-oriented treatment decision that can also be 
measurable. We suggest that other breast units consider incorporating these measures 
when evaluating patient care outcomes. 
9.6. Conclusion  
 The choice of mastectomy versus BCT in ESBC is a complicated decision-making 
process that is influenced by a wide array of factors. Organizing these factors using a 
framework is important in understanding their relationships and future research 
endeavors. In Saskatchewan, the choice of therapy was primarily influenced by disease 
stage and individual belief factors, suggesting that the mastectomy rate in Saskatchewan 
does not reflect a quality of care issue. We advise administrators against using mastectomy 
or BCT rates as an indicator of quality of care in the future. Instead, attention should be 
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Appendix A – Methods used to define patient treatment episode in CIHI / CPAC report  
 
(12) 
Index surgical interventions and subsequent one-year treatment episodes were constructed using the 
following steps: 
 
1. Select all inpatient and day surgery records from 2006-2007 to 2010-2011 meeting the following 
inclusion/exclusion criteria for surgical treatment of breast cancer: 
Inclusion Criteria 
- Gender = female 
- Age ≥ 18 years 
- Discharged rom acute care or day surgery facility 
- Breast cancer surgical intervention coded anywhere in the abstract and location attribute in right, 
left, bilateral 
- Breast cancer or ductal carcinoma in situ (DCIS) diagnosis code coded as most responsible diagnosis 
(MRDx) 
Exclusion Criteria 
- Potential duplicate records removed from analysis 
- Invalid Health Card Number 
- Health Province Code = CA 
- Invalid postal code 
- Procedures coded as abandoned 
- Newborns, stillbirths and cadaveric donors 
- Invalid episode date 
 
2. Link records to identify all inpatient and day surgery records associated with individual patients. 
a. Construct unique patient ID based on encrypted health card number and person’s birth 
3. Identify patient’s index surgery.  Sort records by procedure, location of care (inpatient versus day 
surgery), admission date and discharge date. 
a. When multiple procedures are coded in the same record, prioritize mastectomy over BCS. 
b. When multiple procedures of the same type occurred on the same day in different locations 
of care, prioritize inpatient records over day surgery records 
4. Remove patients who do not meet the criteria for first treatment. 
a. Exclude patients with a discharge in 2006-2007. 
b. Exclude patients whose first discharge indicates a past history of breast cancer. 
5. Select all index records from the treatment episodes. 
a. The index record contains each patient’s first surgical intervention for breast cancer. 
6. Extract all records linked to index patient that include admission dates on or after the date of the 
index surgery. 






Appendix B – Literature search strategy for Medline  
1. Choice Behavior/ 
2. Decision Making/ 
3. shared decision*.ab,ti. 
4. sharing decision*.ab,ti. 
5. informed decision*.ab,ti. 
6. informed choice*.ab,ti. 
7. decision aid*.ab,ti. 
8. ((share* or sharing* or inform*) and (decision* or deciding or choice*)).ti. 
9. decision support techniques/ 
10. Decision Support Systems, Clinical/ 
11. decision mak*.ab,ti. 
12. decision support*.ab,ti. 
13. choice behaviour*.ab,ti. 
14. choice behavior*.ab,ti. 
15. ((decision* or choice*) and (making* or support* or behaviour* or behavior*)).ti. 
16. decid*.ab,ti. 
17. choos*.ab,ti. 
18. consumer participation/ or patient participation/ 
19. patient participation*.ab,ti. 
20. consumer participation*.ab,ti. 
21. patient involvement*.ab,ti. 
22. consumer involvement*.ab,ti. 
23. ((patient* or consumer*) and (involvement* or involving* or participat*)).ti. 
24. ((treatment* or surg*) adj3 choice*).ab,ti. 
25. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 
18 or 19 or 20 or 21 or 22 or 23 or 24 
26. mastectomy/ or mastectomy, simple/ or mastectomy, subcutaneous/ 
27. mastectom*.ab,ti. 
28. 26 or 27 
29. Mastectomy, Segmental/ 
30. breast conserv*.ab,ti. 
31. lumpect*.ab,ti. 
32. radiotherapy/ or radiotherapy, adjuvant/ 
33. (radiotherap* or radiation*).ti. 
34. ((segmental or resection or "local excision") adj mastectom*).ab,ti. 
35. 29 or 30 or 31 or 32 or 33 
36. breast neoplasms/ or carcinoma, ductal, breast/ 
37. Breast cancer*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
38. Breast Neoplasm*.mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
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39. Ductal Carcinoma*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
40. Lobular Carcinoma*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
41. (breast adj25 neoplasm$).ti,ab,sh. 
42. (breast adj25 cancer$).ti,ab,sh. 
43. (breast adj25 tumour$).ti,ab,sh. 
44. (breast adj25 tumor$).ti,ab,sh. 
45. (breast adj25 carcinoma$).ti,ab,sh. 
46. (breast adj25 adenocarcinoma$).ti,ab,sh. 
47. (breast adj25 ductal).ti,ab,sh. 
48. (breast adj25 infiltrating).ti,ab,sh. 
49. (breast adj25 intraductal).ti,ab,sh. 
50. (breast adj25 lobular).ti,ab,sh. 
51. (breast adj25 medullary).ti,ab,sh. 
52. "neoplasms, ductal, lobular, and medullary"/ or carcinoma, ductal/ or carcinoma, ductal, 
breast/ or carcinoma, lobular/ or carcinoma, medullary/ 
53. (breast adj25 tubular).ti,ab,sh. 
54. (breast adj25 mucinous).ti,ab,sh. 
55. (breast adj25 papillary).ti,ab,sh. 
56. (breast adj25 tubulolobular).ti,ab,sh. 
57. (breast adj25 metaplastic).ti,ab,sh. 
58. (breast adj25 "adenoid cystic").ti,ab,sh. 
59. 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 
51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 
60. 25 and 28 and 35 and 59 






Appendix C – Systematic review screening questions and forms 
Title Screening 


















3. Does this article represent a primary study or a review? (i.e., No letters to the 












6. Is the geography and culture of a comparable health care system?  (i.e., North 
America, Europe, Australia, New Zealand) 
a. Yes 
b. No  
c. Uncertain 
7. Does the study look at traditional Stage I/II breast cancer?  i.e., Not any of the 




If “No”, which of the following does the study include: 
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a.  Benign Breast Disease 
b. DCIS 
c. Stage 3/4 Breast Cancer 
d. BRCA 
e. Male Breast Cancer 
f. Inflammatory Breast Cancer 









10. Is the focus of the study on factors that influence ‘decision making’ for the 
patient?  (ie. Not measuring a decision aid, not measuring an education process, 






1. Does this article represent a primary study or a review? (i.e., No letters to the 




2. Is this article a full length journal article? (i.e., Not an abstract) 
a. Yes 
b. No 








5. Is the geography and culture of a comparable health care system?  (i.e., North 
America, Europe, Australia, New Zealand) 
a. Yes 
b. No  
c. Uncertain 
6. Does the study look at traditional Stage I/II breast cancer?  i.e., Not any of the 






If “No” , which of the following does the study include: 
i.  Benign Breast Disease 
ii. DCIS 
iii. Stage 3/4 Breast Cancer 
iv. BRCA 
v. Male Breast Cancer 
vi. Inflammatory Breast Cancer 





8. Is the focus of the study on factors that influence ‘decision making’ for the 
patient?  (ie. Not measuring a decision aid, not measuring an education process, 








10. What is the study design of this article? 
a. Quantitative 


















Appendix E – Candidate concept map for mastectomy participants
 
 211 




Appendix G – Qualitative study interview guide 
 
1. Can you tell me about your breast cancer diagnosis? (Follow-up questions to elicit 
details regarding events leading up to and during diagnosis).   
 
2. What were the treatment options suggested to you and what surgical intervention 
did you choose? 
 
3. What factors contributed to your decision to have __________?  
 
a. Did you have past experiences with breast cancer or cancer of any type and 
did this influence your treatment choice? 
b. Did a friend or family’s experience with breast cancer factor into your choice 
of therapy? 
c. What therapy did your surgeon suggest and how did this contribute to your 
decision? 
d. How did employment effect your decision? 
e. How did your living distance to the treatment center effect your decision? 
f. Did you think one treatment was superior to the alternative/s? Why? 
g. Did breast reconstruction factor into your decision? 
h. What role did radiation therapy have on your decision (5 week process of 
radiation, potential side-effects of radiation) 
i. Do you think your health or other medical conditions at the time influence 
your decision? 
 
4. Were there specific personal values that contributed to your decision regarding your 
therapy choice? 
a. Retaining your breast/s 
b. Minimized chance of cancer reoccurrence 
c. Avoiding radiation 
d. Wanting to do everything possible to get well 
e. Minimize the length of treatment 
f. To do what the doctor thinks is best 
g. Remove the breast/s for peace of mind.  
 
5. Do you feel that your therapy choice was in line with your personal values? If no, 
why? 
 
6. (if not already mentioned) During your decision-making regarding your surgery 
what resources did you seek? (other physicians’ opinions, literature, internet, family, 
friends, etc.)  
 
7.  (if not already mentioned) Tell me a little about your personal/home/family life and 
how these contributed to your decision making? (Follow-up questions to elicit 
details regarding children, ages, working outside the home, employment and 
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sick/disability leave, spouse, stability of household income, religious affiliations, 
distance from the hospital etc.) 
 
8. (if not already mentioned) Do you know someone close to you who had/has an 
intimate experience with breast cancer and how did that play into your decision 
making ? 
 
9. (if not already mentioned) Do you feel that you were adequately informed and had 
sufficient information to make the decision of which surgery to choose and if not 
what else would you have liked to know? 
 




11. Did your decision regarding therapy choice change after you spoke with the 
surgeon? Please explain.  
 
 
12. How did you make your decision regarding treatment? 
i. Made the decision yourself after listening to the options 
ii. Sharing the decision 








Appendix H – Full Survey: “An Examination of Why Saskatchewan Women Choose 
Mastectomy Versus Breast Conservation Therapy in Early Stage Breast Cancer” 
 
“An Examination of Why Saskatchewan Women Choose Mastectomy Versus Breast 
Conservation Therapy in Early Stage Breast Cancer” 
Participation in this research is voluntary, and you can stop your participation at any time. 
After completion of the survey, certain pre-defined data items about your pathology and 
from your chart will be disclosed in a de-identified manner by the Saskatchewan Cancer 
Agency and linked to your survey results. Please know you cannot be personally identified 
based on the data we collect. This research project has been approved on ethical grounds by 
the University of Saskatchewan Behavioural Research Ethics Board.  Any questions 
regarding your rights as a participant may be addressed to that committee through the 
Research Ethics Office ethics.office@usask.ca (306) 966-2975. Out of town participants may 
call toll free (888) 966-2975. 
For more information on the study itself please contact by email or phone Dr. Jeffrey Gu 
(jeg998@mail.usask.ca, (306) 262-3537) or Dr. Gary Groot (garygroot@gmail.com, (306) 
653-3366). For study results, please contact the researchers in January 2018. If you do not 
want to participate in this project or if you want to be removed from our mailing list, please 
contact Serena Kozie at the Saskatchewan Cancer Agency at (639) 625-2045 or by email at 
serena.kozie@saskcancer.ca 
There are no known risks to participating in this survey; however, as with any online 
related activity the risk of breach of confidentiality is possible. If you decide not to 
participate or withdraw from the study, your treatment and medical care will not be 
affected. 
This survey is hosted by Voxco, a Canadian-owned and managed company whose data is 
securely stored in Canada. Consider printing this page for your records. 
In order to complete this survey, you may be required to answer certain questions; 
however, you are never obligated to respond and you may withdraw from the survey at any 
time by closing your internet browser. 
By completing and submitting the questionnaire, YOUR FREE AND INFORMED CONSENT IS 
IMPLIED and indicates that you understand the above conditions of participation in this 
study. 
 
 I consent 
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 [Linking Variable]  
Please type the identification code you were provided in your recruitment letter.  
 
Q.1 [Screener]  
What was your initial treatment choice? 
1. Mastectomy 
2. Breast conservation therapy (lumpectomy and radiation) 
 
Q2. [High Level Questions about personal values and beliefs] 
[All items under question 2 will be randomized for each participant] 
[All items under question 2 will be presented 1 at a time] 
[All items under question 2 will be presented a 5-point likert scale from strongly 
disagree to strongly agree] 
 [All items under questions 2 will have the following pre-amble] 
 
 “Taking your time to think through each question, please indicate the extent to which you 
agree with the following statements. Please think back to when you made your initial 
treatment choice. Keep in mind that there are no right or wrong answers.” 
  
 
- My worry about cancer recurrence influenced my choice of therapy 
- My age influenced my choice of therapy 
- Other individual medical or health concerns influenced my choice of therapy 
- My family history of breast cancer influenced my choice of therapy 
- My previous experience with breast cancer or breast disease influenced my choice of 
therapy 
- My breast size influenced my choice of therapy 
- The tumor size influenced my choice of therapy 
- The travel distance to the treatment center (for surgery or radiation) influenced my 
choice of therapy 
- My surgeon’s opinion influenced my choice of therapy 
- My feminine identity influenced my choice of therapy. 
- My sexuality influenced my choice of therapy 
- Wanting to keep my own breast tissue influenced my choice of therapy 
- Incorporating reconstruction influenced my choice of therapy 
- The total time required to treat my breast cancer influenced my choice of therapy 
 
Q2A1. These questions will be displayed for those selecting mastectomy only. 
  (Items still included in the randomization) 
- Wanting to avoid the potential for requiring further surgery influenced my choice of 
mastectomy 
- The length of radiation treatments required for breast conservation therapy 
influenced my choice of mastectomy 
- Lodging or housing required in order to undergo radiation treatments influenced my 
choice of mastectomy 
- Wanting to avoid radiation treatments influenced my choice of mastectomy 
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- Wanting to remove my other breast without cancer (prophylactic mastectomy) 
influenced my choice of mastectomy 
 
Q2A2.   (Items not included in the randomization) 
- Did your doctors discuss that breast conservation therapy was a possible treatment 
option for you? 
o Yes 
o No 
o Do not remember 
- In your decision to undergo mastectomy, please indicate your involvement in the 
decision-making process: 
o Completely your choice, no physician input 
o Mostly your choice, minimal physician input 
o A shared decision-between you and your physician 
o Mostly your physician’s choice 
o Completely your physician’s choice, no individual input 
 
Q2B1. These questions will be displayed for those selecting breast conservation therapy 
only. 
  (Items still included in the randomization) 
- The recovery time for undergoing mastectomy influenced my choice of breast 
conservation therapy  
- Feeling that mastectomy was too radical or extreme of a procedure influenced my 
choice of breast conservation therapy 
 
Q2B2.   (Items not included in the randomization) 
- Did your doctors discuss that mastectomy was a possible treatment option for you? 
o Yes 
o No 
o Do not remember 
- In your decision to undergo breast conservation therapy, please indicate your 
involvement in the decision-making process: 
o Completely your choice, no physician input 
o Mostly your choice, minimal physician input 
o A shared decision-between you and your physician 
o Mostly your physician’s choice 
o Completely your physician’s choice, no individual input 
- Did you require further surgical procedures beyond your initial lumpectomy? 
o No 
o Yes 
▪ Re-excision for a positive margin with lumpectomy 
▪ Re-excision for a positive margin with mastectomy 
▪ Re-excision for local recurrence with lumpectomy 
▪ Re-excision for local recurrence with mastectomy 




Q3. [Follow-up / Secondary questions for personal values and beliefs] 
[All items under question 3 will use display logic for relevant questions] 
[All items under question 3 will use the following pre-amble:] 
  
“You indicated BLANK was important in choosing breast conservation 
therapy/mastectomy.” 
 
i. If worry about cancer recurrence is selected, display: 
 
Do any of the following impact your worry about cancer recurrence? Please 
select all that apply.     [USE SELECT ALL THAT APPLY OR RATE THEM 
INDIVIDUALLY AGAIN] 
a. Someone close to you had a negative outcome with breast conservation 
therapy  
b. Someone close to you had a positive outcome with mastectomy 
c. You would like to avoid follow-up imaging 
d. You have a family history of breast cancer 
e. Your age 
f. Other, please specify:  
 
ii. If breast size is selected, display: Since you selected breast size was an impacting 
factor on your choice of therapy. Which of the following options related to this 
decision. 
a. Large breast size 
b. Small breast size 
 
iii. If tumor size is selected, display: Since you selected tumor size was an impacting 
factor on your choice of therapy. Which of the following options related to this 
decision. 
a. Large tumor size 
b. Small tumor size 
 
iv. If travel distance selected, display:  Since you selected travel distance was an 
impacting factor on your choice of therapy. Please explain how travel distance 
was an impacting factor in your choice of therapy?  
a. Open-ended answer space 
 
v. If surgeon influence selected, display: Since you indicated surgeon influence was 
an impacting factor on your choice of therapy, could you please explain why the 
surgeon suggested this option for you?  
a. Open-ended answer space 
 
vi. If feminine identity/feeling whole as a woman selected, display: Please explain 
how feminine identify impacted your choice of therapy.  




vii. If sexuality selected, display: Please explain how feminine identify impacted your 
choice of therapy.  
a. Open-ended answer space 
 
viii. If mastectomy is too radical or extreme selected, display: Since you indicated 
feeling that mastectomy is radical or extreme, were any of the following options 
related to this decision? Please select all that apply: 
a. Your confidence in breast conservation therapy 
b. Survival is equivalent between breast conservation therapy and mastectomy 
c. Small tumor size 
d. Recovery time would be shorter with breast conservation therapy compared 
with mastectomy 
e. Other, please specify:  
 
ix. If length of radiation treatments selected, display: You indicated length of 
radiation treatments required for breast conservation therapy influenced your 
choice of mastectomy. What options were offered to you in regards to length of 
radiation treatments? 
a. 25 fractions taking 5 weeks 
b. 16 fractions taking 3.5 weeks 
c. The choice of 5 or 3.5 weeks 
d. Do not remember 
 
x. If lodging or housing required selected, display: You indicated lodging or 
housing required for radiation treatments influenced your choice of mastectomy. 
Were you informed that there was lodging available to you across from the 
cancer centre? 
a. Yes 
b. No  
xi. If total time of treatment selected [for mastectomy patients] display: You 
indicated total time of treatment was important in choosing mastectomy. Please 
explain why. 
a. Open ended answer 
xii. If total time of treatment selected [for breast conservation therapy patients] 
display: You indicated total time of treatment was important in choosing 
mastectomy. Which of the following impact this choice? Please select all that 
apply 
a. Time away from work 
b. Time away from family 
c. Time away from leisure activities 
d. Other, please specify: 
 
Q4. [Ranking for most influential factors of therapy] 
[Please select up to five factors that most influenced your choice of therapy. Please 
drag and drop your choices into the selection box.] 
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[Please take your time to think through each option, keeping in mind that there are 
no right or wrong answers.] 







Q.5. [Decisional Conflict Scale] 
[All items under question 5 will be presented in order] 
[All items under question 5 will be presented in 1 table] 
[All items under question 5 will be presented a 5-item likert scale from strongly 
disagree to strongly agree] 
 [All items under questions 5 will have the following pre-amble] 
Please think back to the time you made your choice of therapy and indicate the level to 
which you agree with the following statement.  
 
Informed Subscale: 
 I knew which options were available to me. 
 I knew the benefits of each option. 
 I knew the risks and side effects of each option. 
 
Values Clarity Subscale: 
 I was clear which benefits mattered most to me. 
 I was clear about which risks and side effects mattered most. 




 I had enough support from others to make a choice 
 I was choosing without pressure from others 
 I had enough advice to make a choice 
 
Uncertainty Subscale: 
 It was clear from me what was the best choice was 
 I felt sure about what to choose 
 The decision was easy for me to make 
 
Effective Decision Subscale 
 I felt I made an informed choice 
 My decision showed what was important to me 
 I expected to stick with my decision 
I was satisfied with my decision 
 
Q.5b. [Decisional Conflict Scale Addendums] 
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[All items under question 5 will be presented in order] 
 [All items under questions 5 will have the following pre-amble] 
Please think back to the time you made your choice of therapy and indicate the level to 
which you agree, disagree, or unsure with the following statements.  
 
 Overall survival is the same between mastectomy and breast conservation therapy 
 Overall survival is higher with mastectomy 
 Overall survival is higher with breast conservation therapy 
 Local recurrence rate is the same between mastectomy and breast conservation 
therapy 
 Local recurrence rate is higher with mastectomy 
 Local recurrence rate is higher with breast conservation therapy 
 
Please indicate where most of your support came from during your treatment decision-
making process. Please select all that apply. 
 Family members 
 Friends 
 Physician 
 Nursing support 
 Social media 
 Other, please specify: 
 
 
Finally, we would like to ask some questions about yourself.  
 
Q6. Demographic Factors 
1. Please provide your age at the time of surgery – [Numerical] 
2. Please provide the first 3 characters of your postal code only. Your postal code will 
only be used to report travel-related difference by region/geography and will not be 
used to identify you in any way. Please use the format ‘S7N’ 
3. Which best describes the area where you live? 
a. Urban, please specify the city you live in: 
b. Rural 
4. Approximately how many kilometers (km) is your home away from the surgical 
centre? 
5. Approximately how many kilometers (km) is your home away from the radiation 
centre? 
6. Which city did you have your surgery in? 
a. Saskatoon 
b. Regina 
c. Moose Jaw 
d. Prince Albert 
e. Lloydminster 
f. North Battleford 




7. Will you be staying at home or your primary residence during radiation treatments? 
a. Yes 
b. No, please specify where you will be staying: 
c. Don’t know/undecided 
d. Not applicable 
8. Weight + Height [for BMI] 
a. [Weight → Space for lbs or kg] 
b. [Height → space for cm and ft+inches] 









10. Did you have pre-operative breast MRI? 
a. Yes 
b. No 
11. Were you offered reconstruction? (JUST MASTECTOMY) 
a. Yes 
i. Were you offered immediate reconstruction 
ii. Were you offered delayed reconstruction 
iii. Were you offered both? 
b. No 
12. Please list all medical conditions you have: 
13. What was your total annual household income in 2015? 
a. Less than  $20,000 
b. $20,000 - $39,999 
c. $40,000 - $59,999 
d. $60,000 - $79,999 
e. $80,000 - $99,999 
f. $100,000 - $120,000 
g. Greater than $120,000 
h. Prefer not to disclose 




[display logic → only display if they are employed] 
a. [Open ended] 
16. What is the highest level of formal education you have received? 
a. Less than high school 
b. Completed high school 
c. Some technical or community college 
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d. Completed technical or community college 
e. Some university 
f. Bachelor’s degree 
g. Master’s degree 
h. Professional degree or doctorate 
17. Were you in a relationship around the time of decision-making? 
a. Yes, I was in a relationship 
b. No, I was not in a relationship 
18. Do you have children? 
a. Yes 
i. Please indicate how many children you have in the space provided: 
b. No 
19. Please indicate your smoking status 
a. I have never smoked cigarettes 
b. I used to smoke cigarettes, but have quit 
c. I currently smoke cigarettes 
20. What ethnicity do you identify with? 
a. Caucasian 
b. First Nation, Métis or Inuit? 
c. Asian 
d. African American 
e. Hispanic 
f. West Indian/Caribbean 
g. Other 
21. At the time of your diagnoses, are you pre or post menopausal? Menopause is 
defined as one full year with no menses) 
a. Pre-menopause 
b. Post-menopause 
22. If post menopausal, did you go through menopause because of surgical removal of 
your uterus or ovaries (hysterectomy or oophorectomy) 
a. Yes 
b. No 














Data items not in the questionnaire. Information from the SCA: 
- C-code      (C-code = breast, and location – quadrant) 
- C-code English description 
- Morphology    (Gross Histology) 
- Morphology English description   (ie. Ductal carcinoma) 
- Behavior    (All would be 3 = malignant (not in situ) 
- Grade     (Value of 1-4, or 9=unknown) 
o 1 = Well differentiated 
o 2 = Moderately differentiated 
o 3 = Poorly differentiated 
o 4 = Undifferentiated / anaplastic 
o 9 = Unknown 
- Laterality 
- Multiplicity Counter  (Number of tumors, ie. 1 or 2, 3.)  
o Most patients with multiple tumors have the ‘North American Multiple 
Primary and Histology Rule’ – from SEER 
o See below from more details →  
- Tumor Size 
- Regional Nodes Positive  
- Regional Nodes Examined 
- SSF 1 – ER Assay  (010 = Positive or Negative or Not Done or Unknown 
[treated in different province]) 
- SSF 2 – PR Assay   
- SSF 14- HER2: Result of Other or Unknown Test 
- SSF 16 – Combination ER, PR & HER2 
- Overall Stage, T, N and M stage values  (JCC 7th Edition) 
- Surgery Date 
- Radiation therapy 
- Chemo therapy 









Appendix I – Clinicopathological Data legend from the Saskatchewan Cancer Agency 
1. C-code – the topographical code, which describes the anatomical code, which 
describes the anatomical site of origin (or organ system) of the tumour 
a. C50.0 – Nipple 
b. C50.1 – Central portion of breast 
c. C50.2 – Upper-inner quadrant of breast 
d. C50.3 – Lower-inner quadrant of breast 
e. C50.4 – Upper-outer quadrant of breast 
f. C50.5 – Lower-outer quadrant of breast 
g. C50.6 – Axillary tail of breast 
h. C50.8 – Overlapping lesion of breast 
i. C50.2 – Breast, NOS 
2. C-code English description  
3. Morphology – the morphological code, which describes the cell type (or 
histology) of the tumour, together with the behavior 
4. Morphology English description 
5. Behavior 
a. 0 (benign) 
b. 1 (uncertain behavior) 
c. 2 (carcinoma in situ) 
d. 3 (malignant) {Results for your research project will all be /3 – malignant 
as per data selection} 
6. Grade 
a. Grade 1 – Well differentiated, differentiated NOS, low grade 
b. Grade 2 – Moderately differentiated, moderately well differentiated, 
intermediate differentiation, intermediate grade 
c. Grade 3 – Poorly differentiated, high grade 
d. Grade 4 – Undifferentiated, anaplastic 
e. Grade 9 – grade or differentiation not determined, not stated or not 
applicable 
7. Laterality – right, left, paired no info (means breast is a paired site (right or left) 
but we didn’t know which side the breast cancer/primary occurred on or we 
didn’t know which side the breast cancer/primary occurred on or we didn’t have 
enough information to capture laterality 
8. Multiplicity Counter – used to count the number of tumors (multiplicity) 
reported as a single primary 
9. Tumor Size 
a. 000 – No mass/tumor found 
b. 001-988 – 001 – 0988 millimeters (mm) (Code exact size in mm) 
c. 989 – 989mm or larger 
d. 990 – Microinvasion, microscopic focus or foci only and no size given, 
described as “less than 1 mm”, Stated as T1mi with no other information 
on tumor size 
e. 991 – Described as “less than 1 centimeter (cm)”, States as T1b with no 
other information on tumor size 
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f. 992 – Described as “less than 2 cm,” or “greater than 1 cm,” or “between 1 
cm and 2 cm”, Stated as T1 [NOS] or T1c [NOS] with no other information 
on tumor size 
g. 993 – Described as “less than 3 cm,” or “greater than 2 cm,” or “between 2 
cm and 3 cm” 
h. 994 – Described as “less than 4 cm,” or “greater than 3 cm,” or “between 3 
cm and 4 cm” 
i. 995 – Described as “less than 5 cm,” or “greater than 4 cm,” or “between 4 
cm and 5 cm”, Stated as T2 with no other information on tumor size 
j. 996 – Mammographic/xerographic diagnosis only, no size given; clinically 
not palpable 
k. 997 – Pagets disease of nipple with no demonstrable tumor 
l. 998 – Diffuse 
m. 999 – Unknown; size not stated, Size of tumor cannot be assessed, not 
documented in patient record 
10. Regional Nodes Positive 
a. 00 – All nodes examined negative 
b. 01-89 – 1-89 nodes positive (code exact number of nodes positive) 
c. 90 – 90 or more nodes positive 
d. 95 – Positive aspiration or core biopsy of lymph node(s) 
e. 97 – Positive nodes – number unspecified 
f. 98 – No nodes examined 
g. 99 – Unknown if nodes are positive; not applicable, Not documented in 
patient record 
11. Regional Nodes Examined 
a. 00 – No nodes examined 
b. 01-89 – 1-89 nodes examined (code exact number of regional lymph 
nodes examined) 
c. 90 – 90 or more nodes examined 
d. 95 – No regional nodes removed, but aspiration or core biopsy of regional 
nodes performed 
e. 96 – Regional lymph node removal documented as sampling and number 
of nodes unknown/not stated 
f. 97 – Regional lymph node removal documented as dissection and number 
of nodes unknown/not stated 
g. 98 – Regional lymph nodes surgically removed but number of lymph 
nodes unknown/not stated and not documented as sampling or 
dissection; nodes examined, but number unknown 
h. 99 – Unknown if nodes were examined; not applicable or negative, Not 
documented in patient record 
12. SSF 1 – ER Assay 
a. 010 – Positive/elevated 
b. 020 – Negative/normal; within normal limits 
c. 030 – Borderline; undetermined whether positive or negative 
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d. 988 – Not applicable: Information not collected for this case (if this item is 
required by your standard settler, use of code 988 will result in an edit 
error.) 
e. 996 – Test ordered, results not interpretable 
f. 997 – Test ordered, not in chart 
g. 998 – Test not done (test not ordered and not performed) 
h. 999 – Unknown or no information, Not documented in patient record 
13. SSF 2 – PR Assay 
a. 010 – Positive/elevated 
b. 020 – Negative/normal; within normal limits 
c. 030 – Borderline; undetermined whether positive or negative 
d. 988 – Not applicable: Information not collected for this case (if this item is 
required by your standard settler, use of code 988 will result in an edit 
error.) 
e. 996 – Test ordered, results not interpretable 
f. 997 – Test ordered, not in chart 
g. 998 – Test not done (test not ordered and not performed) 
h. 999 – Unknown or no information, Not documented in patient record 
14. SSF 14- HER2: Result of Other or Unknown Test 
a. 010 – Positive/elevated; amplified 
b. 020 – Negative/normal; within normal limits; not amplified 
c. 030 – Borderline; equivocal; indeterminate; undetermined whether 
positive or negative 
d. 988 – Not applicable: Information not collected for this case (if this item is 
required by your standard settler, use of code 988 will result in an edit 
error.) 
e. 997 – Test ordered, not in chart 
f. 998 – Test not done (test not ordered and not performed) 
g. 999 – Unknown or no information, Not documented in patient record 
15. SSF 16 – Combination ER, PR & HER2 
a. 000 – ER Negative, PR Negative, HER2 Negative (Triple Negative) 
b. 001 – ER Negative, PR Negative, HER2 Positive 
c. 010 – ER Negative, PR Positive, HER2 Negative 
d. 011 – ER Negative, PR Positive, HER2 Positive 
e. 100 – ER Positive, PR Negative, HER2 Negative 
f. 101 – ER Positive, PR Negative, HER2 Positive 
g. 110 – ER Positive, PR Positive, HER2 Negative 
h. 111 – ER Positive, PR Positive, HER2 Positive 
i. 988 – Not applicable: Information not collected for this case (if this 
information is required by your standard settler, use of code 988 may 
result in an edit error.) 
j. 999 – One or more tests not performed, One or more tests unknown if 
performed, One or more test with unknown or borderline results, 
Unknown or no informatio 
16. Overall Stage, T, N and M stage values  
17. Surgery Date 
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18. Radiation therapy 
a. 1 = Received therapy 
b. 0 = Did not receive therapy 
19. Chemo therapy 
a. 1 = Received therapy 
b. 0 = Did not receive therapy 
20. Hormone therapy 
a. 1 = Received therapy 










Are you eligible? 
 
 Are you a female diagnosed with 
early stage breast cancer (Stage 1 
or 2) 
 Entering treatment for the first 
time (not recurrent cancer or 
entering followup treatment) 
 Being treated for their breast 
cancer in Saskatchewan 
Then you may be eligible! 
   
 
Contact us 
If you want more information about 
the study, or wish to participate in 
this survey, please contact the study 
investigator: 
 
Jeffrey Gu, MD 








This study is funded by: 
 
And has been approved by the 
University of Saskatchewan Research 





Breast Cancer Therapy 
Decision Making 
Research Study 
A Research Survey for 
Women with Early Stage 
Breast Cancer  
 
Why is this study 
being done? 
 
Breast cancer in North America is 
the most commonly diagnosed 
cancer and the second most 
common cause of cancer death in 
women. 
For early stage breast cancer it is 
well established that breast 
conservation therapy and 
mastectomy offer equivalent 
survival. 
However, Saskatchewan 
women have the second 
highest mastectomy rate in 
Canada 
Between 2007 and 2010, 65% of all 
Saskatchewan patients with newly 





   
To understand this difference 
researchers at the U of S and the 
Saskatchewan Cancer Agency are 
conducting a research survey to 
explore: 
 What factors influence 
Saskatchewan women's 
choice of treatment for early 
stage breast cancer 
 
 Identify potential gaps in 
provisions of care or 
delivery of information 
 
 Identify avenues to improve 
delivery of care for patients 
with early stage breast 
cancer 
 
 How Saskatchewan 
women’s health treatment 
choices align with those in 
other provinces 
  
What does participation 
include? 
We are recruiting participants to 
take part in a survey 
The survey will ask for details about: 
• Your cancer diagnosis and 
treatment choices 
• Your opinions and preferences 
regarding your treatment 
• Your healthcare providers and 
relationships with them  
• Your demographics 
 
The survey can be filled in online or 












Appendix K – Sample size outputs 
Tumor Size Sample Size Calculation 
Tests for Two Proportions 
 
Numeric Results for Testing Two Proportions using the Z-Test with Unpooled Variance 
H0: O1/O2 = 1 vs. H1: O1/O2 = OR1 ≠ 1. 
 
Target Actual      O.R.   
Power Power* N1 N2 N P1 P2 OR1 Alpha  
0.80 0.80509 51 51 102 0.5878 0.3200 3.030 0.0500  
 
1. Power was computed using the normal approximation method. 
 
Surgeon Sex Sample Size Calculation 
Tests for Two Proportions 
 
Numeric Results for Testing Two Proportions using the Z-Test with Unpooled Variance 
H0: O1/O2 = 1 vs. H1: O1/O2 = OR1 ≠ 1. 
 
Target Actual      O.R.   
Power Power* N1 N2 N P1 P2 OR1 Alpha  
0.80 0.80884 39 39 78 0.7897 0.4970 3.800 0.0500  
 
* Power was computed using the normal approximation method. 
 
 
Travel Distance Sample Size Calculation 
Tests for Two Proportions 
 
Numeric Results for Testing Two Proportions using the Z-Test with Unpooled Variance 
H0: O1/O2 = 1 vs. H1: O1/O2 = OR1 ≠ 1. 
 
Target Actual      O.R.   
Power Power* N1 N2 N P1 P2 OR1 Alpha  
0.80 0.80255 46 46 92 0.2887 0.5670 0.310 0.0500  
 
* Power was computed using the normal approximation method. 
 
Peace of Mind Size Calculation 
Tests for Two Proportions 
 
Numeric Results for Testing Two Proportions using the Z-Test with Unpooled Variance 
H0: O1/O2 = 1 vs. H1: O1/O2 = OR1 ≠ 1. 
 
Target Actual      O.R.   
Power Power* N1 N2 N P1 P2 OR1 Alpha  
0.80 0.80006 160 160 320 0.5031 0.3500 1.880 0.0500  
0.80 0.80103 157 157 314 0.5562 0.4000 1.880 0.0500  
0.80 0.80051 157 157 314 0.6060 0.4500 1.880 0.0500  
 
* Power was computed using the normal approximation method. 
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Report Definitions 
Target Power is the desired power value (or values) entered in the procedure. Power is the probability of 
   rejecting a false null hypothesis. 
Actual Power is the power obtained in this scenario. Because N1 and N2 are discrete, this value is often 
   (slightly) larger than the target power. 
N1 and N2 are the number of items sampled from each population. 
N is the total sample size, N1 + N2. 
P1 is the proportion for Group 1 at which power and sample size calculations are made. This is the treatment 
   or experimental group. 
P2 is the proportion for Group 2. This is the standard, reference, or control group. 
OR1 is the odds ratio [P1/(1-P1)] / [P2/(1-P2)] assumed for power and sample size calculations. 
Alpha is the probability of rejecting a true null hypothesis. 
 
Summary Statements 
Group sample sizes of 171 in group 1 and 171 in group 2 achieve 80.207% power to detect an odds 
ratio of the group proportions of 1.880. The proportion in group 1 (the treatment group) is 
assumed to be 0.2900 under the null hypothesis and 0.4344 under the alternative hypothesis. The 
proportion in group 2 (the control group) is 0.2900. The test statistic used is the two-sided 













I am writing to invite you to participate in a research study that has been funded by the University of 
Saskatchewan. The goal of this study is to understand why Saskatchewan women choose mastectomy 
versus breast conserving therapy, thus we are looking for women who have been recently diagnosed and 
treated for early stage breast cancer to be a part of our study. We hope together the information we gain 
will provide surgeons, administrators, and patients with the knowledge they need to optimize and 
improve this process in the future.  
 
We are looking for approximately 400 people like you to participate. Participation in this study is 
voluntary, and you can decide not to participate at any time by closing your browser, or choose not to 
answer any questions you don’t feel comfortable with. If you decide not to participate or withdraw from 
the study, treatment and medical care will not be effected. 
 
As with any online related activity, the risk of breach of confidentiality is possible. Strategies are in place 
to mitigate this risk including passcode secured storage and transfer of data. If you do not want to 
participate in this project or if you want to be removed from our mailing list, please contact Serena Kozie 
at the Saskatchewan Cancer Agency at (639) 625-2045 or by email at serena.kozie@saskcancer.ca 
Completion of the survey should take 10-15 minutes. 
 
Project Title: An Examination of Why Saskatchewan Women Choose Mastectomy Versus Breast 
Conservation Therapy in Early Stage Breast Cancer 
 
Researcher: Jeffrey Gu (MD, PhD Candidate), Community Health & Epidemiology, University of 
Saskatchewan, jeg998@mail.usask.ca  
Supervisor: Gary Groot (MD, FRCP, PhD) Community Health & Epidemiology, University of 
Saskatchewan, (306) 653-3366, garygroot@gmail.com 
Rachel Engler-Stringer (PhD) Community Health & Epidemiology, University of 
Saskatchewan, (306) 966-7839, Rachel.engler-string@usask.ca 
 
Participant Code – [insert 8 digit participation code] 
This 8-digit participation code is required to gain access to the survey. Please enter this 8-digit participation 
code online to access the survey. 
 
To participate: 
1. Online link / url to the study: http://tiny.cc/fq6sky  
 
2. Alternatively, if you do not have access to a computer we can administer the study via a 
phone-interview. Please email or call Dr. Gu, jeg998@mail.usask.ca, (306)-262-3537 
for more information and to volunteer to be a participant.   
 








Jeffrey Gu, MD PhD Candidate 
Department of General Surgery, Community Health and Epidemiology 






Appendix M – Consent form oral telephone script 
Consent Form Oral Telephone Script 
 
 
“An Examination of Why Saskatchewan Women Choose Mastectomy Versus Breast 
Conservation Therapy in Early Stage Breast Cancer” 
 
Assistant Researcher: Hello, my name is ___________, and I am a research assisting helping 
with the study ‘an examination of why Saskatchewan women choose mastectomy versus 




 [If participant states no → Conversation related to the study will end.] 
 [If participant wants more information related to the study → they will be directed 
to contact Jeffrey Gu or Gary Groot] 
 
Assistant Researcher: Before commencing with the study, I would like to go over the 
consent to participate and make sure you understand everything. Can we do that now? 
 
Participant: Yes 
 [If other response, refer to above responses] 
 
Assistant Researcher: 
Participation in this survey is voluntary, and you can decide not to participate at any 
time, or choose not to answer any questions you don’t feel comfortable with. After 
completion of the survey, certain pre-defined data items about your pathology and 
from your chart will be disclosed in a de-identified manner by the Saskatchewan 
Cancer Agency and linked to your survey results. Also know that you cannot be 
personally identified based on the data we collect. This research project has been 
approved on ethical grounds by the University of Saskatchewan Behavioural 
Research Ethics Board.  Any questions regarding your rights as a participant may be 
addressed to that committee through the Research Ethics Office 
ethics.office@usask.ca (306) 966-2975. Out of town participants may call toll free 
(888) 966-2975. 
For more information on the study itself please contact by email or phone Dr. Jeffrey 
Gu (jeg998@mail.usask.ca, (306) 262-3537) or Dr. Gary Groot 
(garygroot@gmail.com, (306) 653-3366). For study results, please contact the 
researchers in January 2018. If you do not want to participate in this project or if you 
want to be removed from our mailing list, please contact Serena Kozie at the 




There are no known risks to participating in this survey; however, as with any online 
related activity the risk of breach of confidentiality is possible. If you decide not to 
participate or withdraw from the study, your treatment and medical care will not be 
affected. Survey responses will remain anonymous. Since the survey is anonymous, 
once it’s submitted it cannot be removed. 
This survey is hosted by Voxco, a Canadian-owned and managed company whose 
data is securely stored in Canada.  
This survey will take approximately 10-15 minutes. If you would like a copy of this 
consent form for your own records, we can mail it to you. 
Do you understand and give consent to participate in this study? 
Participant: Yes [Continue onto survey] 
 [If participant states no → Conversation related to the study will end.] 
 [If participant wants more information related to the study → they will be directed 
to contact Jeffrey Gu or Gary Groot] 
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Correlational mapping was performed for individual belief factors asked of both BCT 
and mastectomy participants using R Studio. 
There exists a debate for how to statistically treat Likert scales, categorical versus 
ordinal. We have performed a sensitivity analysis for the individual belief factors items 
which utilized a 5 point Likert scale (Table N1). Logistic regression was performed treating 
these items as ordinal, categorical with 3 categories, and categorical with 2 categories 
(Table 8.3). The 3 categories include combined strongly disagree and disagree, neither 
agree nor disagree, and combined agree and strongly agree (Table N2). The 2 categories 
include combining strongly disagree, disagree, and neither agree nor disagree and 
combined agree and strongly agree (Table N3). 
Table N1: Sensitivity Analysis for Significance of Personal Belief Factors – Ordinal versus 3 
Group Categorical versus 2 Group Categorical  
 Ordinal (1, 2, 3, 4, 5) Categorical 
(1+2, 3, 4+5) 
Categorical 
(1+2+3, 4+5) 
Worry About Cancer 
Recurrence 
Significant Significant Significant 
Age  Not Significant Significant Significant 
Other Individual Medical 
History 
Not Significant Not Significant Not Significant 
Family History of Breast 
Cancer 
Significant Significant Significant 
Previous Breast Disease Not Significant Not Significant Not Significant 
Breast Size Not Significant Not Significant Not Significant 
Tumor Size Significant Significant Significant 
Travel Distance Not Significant Not Significant Significant 
Surgeon’s Opinion Significant Significant Significant 
Feminine Identity Significant Significant Significant 
Sexuality Significant Significant Significant 
Wanting to Keep Breast Tissue Significant Significant Significant 
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Incorporating Reconstruction Not Significant Significant Significant 
Total Treatment Time Significant Significant Significant 
1 = Strongly Disagree 
2 = Disagree 
3 = Neither Agree nor disagree 
4 = Agree 
5 = Strongly Agree 
 
Table N2: Personal Belief and Preference Factors for Mastectomy versus BCT Participants – 
3 Group Categorical Logistic Regression 
 Odds 
Ratio 
95% C.I. p-value 
Worry About Cancer Recurrence     
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 1.51 0.65 – 3.49 0.33 
Agree and strongly agree 14.7 7.28 – 29.80 <0.01 
Age     
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.65 0.32 – 1.32 0.24 
Agree and strongly agree 1.94 1.14 – 3.29 <0.01 
Other Individual Medical History    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.82 0.44 – 1.54 0.54 
Agree and strongly agree 1.56 0.89 – 2.73 0.12 
Family History of Breast Cancer    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.84 0.48 – 1.49 0.556 
Agree and strongly agree 2.22 1.21 – 4.08 <0.01 
Previous Breast Disease    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 1.00 0.58 – 1.72 0.99 
Agree and strongly agree 1.66 0/85 – 3.22 0.14 
Breast Size    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.77 0.42 – 1.44 0.42 
Agree and strongly agree 1.28 0.65 – 2.52 0.48 
Tumor Size    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.92 0.35 – 2.39 0.86 
Agree and strongly agree 0.25 0.14 – 0.44 <0.01 
Travel Distance    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 1.20 0.60 – 2.39 0.60 
Agree and strongly agree 2.63 1.00 – 6.92 0.05 
Surgeon’s Opinion    
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Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.55 0.24 – 1.27 0.16 
Agree and strongly agree 0.28 0.15 – 0.52 <0.01 
Feminine Identity    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 1.21 0.61 – 2.38 0.59 
Agree and strongly agree 0.25 0.13 – 0.47 <0.01 
Sexuality    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.78 0.40 – 1.48 0.44 
Agree and strongly agree 0.19 0.08 – 0.43 <0.01 
Wanting to Keep Breast Tissue    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.34 0.18 – 0.66 0.01 
Agree and strongly agree 0.03 0.01 – 0.08 <0.01 
Incorporating Reconstruction    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 0.68 0.38 – 1.23 0.20 
Agree and strongly agree 1.97 1.05 – 3.71 <0.01 
Total Treatment Time    
Strongly disagree and disagree 1.00 Referent  
Neither agree nor disagree 1.18 0.64 – 2.17 0.59 
Agree and strongly agree 2.35 1.23 – 4.49 <0.01 
Note: denominators may vary depending on response rate for each questionnaire item.  
Univariate logistic regression was used to evaluate likelihood of mastectomy versus BCT. Higher odds favours mastectomy.  
p-values listed used significance level of 0.05. 
 
Table N3: Personal Belief and Preference Factors for Mastectomy versus BCT Participants – 
2 Group Categorical Logistic Regression 
 Odds 
Ratio 
95% C.I. p-value 
Worry About Cancer Recurrence     
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 12.16 6.87 – 21.5 <0.01 
Age     
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 2.18 1.33 – 3.57 <0.01 
Other Individual Medical History    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 1.65 0.97 – 2.80 0.07 
Family History of Breast Cancer    
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Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 2.37 1.35 – 4.17 <0.01 
Previous Breast Disease    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 1.66 0.88 – 3.12 0.12 
Breast Size    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 1.35 0.70 – 2.63 0.37 
Tumor Size    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 0.25 0.15 – 0.42 <0.01 
Travel Distance    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 2.56 0.97 – 6.70 0.06 
Surgeon’s Opinion    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 0.35 0.21 – 0.58 <0.01 
Feminine Identity    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 0.24 0.12 – 0.45 <0.01 
Sexuality    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 0.20 0.09 – 0.45 <0.01 
Wanting to Keep Breast Tissue    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 0.04 0.16 – 0.11 <0.01 
Incorporating Reconstruction    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 2.22 1.21 – 4.06 0.01 
Total Treatment Time    
Strongly disagree, disagree, and 
neither agree nor disagree 
1.00 Referent  
Agree and strongly agree 2.25 1.20 – 4.22 0.01 
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Note: denominators may vary depending on response rate for each questionnaire item.  
Univariate logistic regression was used to evaluate likelihood of mastectomy versus BCT. Higher odds favours mastectomy.  
p-values listed used significance level of 0.05. 
 
Clinically important effect modifiers were individually tested for potential inclusion 
in the model using an interaction term. These were informed by research team and clinical 
consultation with local experts in the field. The following interaction terms were tested for 
potential inclusion into the model: 
- ‘Wanting to keep my own breast tissue’ by age 
- ‘Incorporating reconstruction’ by age 
- ‘Fear of cancer recurrence’ by ‘family history of breast cancer’  
- ‘Surgeon’s influence’ by age 
- ‘Surgeon’s influence’ by subjective ‘tumor size’ 
- ‘Feminine identity’ by wanting to keep my own breast issue’ 
- Stage of disease by ‘income’ 
- Stage of disease by ‘surgeon’s opinion’ 
- Stage of disease by subjective ‘tumor size’ 
 
Two interaction terms, stage of disease by ‘surgeon’s opinion’ and stage of disease by 
subjective ‘tumor size’, were statistically significant with p-value <0.05 (Chapter 8). All 
other interaction terms were non-significant. 
Results 
 
Personal Belief and Preference Factors 
We asked participants to rate how much each individual preference factor 
influenced their choice of therapy on a 5-point Likert scale. Of the 14 questions asked of 
both groups (Table N4, Figure 8.2), only other medical history, previous breast disease, and 
breast size were not significantly different between groups. The belief factors that were 
rated as significantly (p<0.05) more important for mastectomy patients were worry about 
cancer recurrence, age, family history of breast cancer, travel distance, incorporating 
reconstruction, and total treatment time. The factors that were rated as significantly 
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(p<0.05) more important for BCT patients were tumor size, surgeon opinion, feminine 
identity, sexuality, and keeping one’s own breast tissue. 
 Five other questions were specific for mastectomy participants only (Table N5). Of 
these factors, ‘avoiding the potential for requiring further surgery’ had 71% of mastectomy 
participants rating agree or strongly agree to influencing their therapy choice (Figure 8.3). 
Two other questions were specific for BCT participants only (Table N6). Of these factors, 
‘feeling that mastectomy was too radical or extreme of a procedure’ had 51% of BCT 
participants rating agree or strongly agree to influencing their therapy choice (Figure 8.4).  
 
Correlational maps for mastectomy individual belief factors are presented in Figure 
N1 and Table N4. The correlational coefficient for ‘worry about cancer recurrence’ and 
‘family history of breast cancer’ was 0.34. The correlational coefficient for ‘tumor size’ and 
‘surgeon’s opinion’ was 0.33.  Correlational maps for BCT individual belief factors are 
presented in Figure N2 and Table N5. The correlation coefficient for responses between 
‘feminine identity’ with ‘my sexuality’ and ‘wanting to keep my own breast tissue’ was 0.68 
and 0.65 respectively. The correlation between the factors ‘my sexuality’ and ‘wanting to 
keep my own breast tissue’ was also high at 0.51, suggesting a strong relationship between 
these three factors for women choosing BCT. 











     <0.01 
Mastectomy n (%) 6 (4.0) 8 (5.3) 15 (10.0) 53 (35.6) 67 (45.0)  
BCT n (%) 14 (7.3) 41 (17.8) 39 (19.6) 21 (26.9) 11 (28.4)  
Age       <0.01 
Mastectomy n (%) 26 (17.5) 31 (20.8) 17 (11.4) 57 (38.3) 18 (12.1)  
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BCT n (%) 16 (12.7) 43 (34.1) 27 (21.4) 33 (26.2) 7 (5.6)  
Other Individual 
Medical History 
     0.28 
Mastectomy n (%) 26 (17.3) 47 (31.3) 26 (17.3) 29 (19.3) 22 (14.7)  
BCT n (%) 20 (15.9) 47 (37.3) 29 (23.0) 20 (15.9) 10 (7.9)  
Family History of 
Breast Cancer 
     <0.01 
Mastectomy n (%) 23 (17.4) 38 (28.8) 19 (14.4) 19 (14.4) 33 (25.0)  
BCT n (%) 23 (20.6) 37 (33.0) 29 (19.7) 19 (15.6) 4 (15.2)  
Previous Breast 
Disease 
     0.18 
Mastectomy n (%) 28 (18.9) 45 (30.4) 43 (29.1) 18 (12.2) 14 (9.5)  
BCT n (%) 23 (18.3) 45 (35.7) 40 (31.8) 15 (11.9) 3 (2.4)  
Breast Size      0.32 
Mastectomy n (%) 48 (32.2) 50 (33.6) 25 (16.8) 17 (11.4) 9 (6.0)  
BCT n (%) 32 (25.4) 50 (39.7) 27 (21.4) 14 (11.1) 3 (2.4)  
Tumor Size      <0.01 
Mastectomy n (%) 22 (14.8) 38 (25.5) 21 (14.1) 44 (29.5) 24 (16.1)  
BCT n (%) 7 (5.6) 14 (11.1) 8 (6.4) 61 (48.4) 36 (28.6)  
Travel Distance      <0.01 
Mastectomy n (%) 68 (45.3) 43 (28.7) 22 (14.7) 11 (7.3) 6 (4.0)  
BCT n (%) 44(34.9) 59 (46.8) 17 (13.5) 6 (4.7) 0 (0)  
Surgeon’s Opinion      <0.01 
Mastectomy n (%) 22 (14.9) 31 (21.0) 23 (15.5) 41 (27.7) 31 (21.0)  
BCT n (%) 10 (7.9) 9 (7.1) 15 (11.9) 39 (31.0) 53 (42.1)  
Feminine Identity      <0.01 
Mastectomy n (%) 45 (30.0) 59 (39.3) 30 (20.0) 13 (8.7) 3 (2.0)  
BCT n (%) 21 (16.8) 46 (36.8) 16 (12.8) 28 (22.4) 14 (11.2)  
Sexuality      <0.01 
Mastectomy n (%) 49 (32.7) 68 (45.3) 25 (16.7) 7 (4.7) 1 (0.7)  
BCT n (%) 30 (28.7) 46 (41.5) 21 (16.7) 22 (10.6) 6 (2.6)  
Wanting to Keep 
Breast Tissue 
     <0.01 
Mastectomy n (%) 47 (31.3) 74 (49.3) 24 (16.0) 4 (2.7) 1 (0.7)  
BCT n (%) 10 (20.7) 33 (38.3) 25 (17.8) 36 (14.5) 22 (8.3)  
Incorporating 
Reconstruction 
     0.04 
Mastectomy n (%) 30 (20.0) 48 (32.0) 29 (19.3) 32 (21.3) 11 (7.3)  
BCT n (%) 21 (16.9) 47 (37.9) 37 (29.8) 12 (9.7) 7 (5.7)  
Total Treatment 
Time 
     0.01 
Mastectomy n (%) 33 (22.0) 48 (32.0) 30 (20.0) 26 (17.3) 13 (8.7)  
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BCT n (%) 22 (17.5) 61 (48.4) 26 (20.6) 15 (11.9) 2 (1.6)  
Note: denominators may vary depending on response rate. 
Comparison between mastectomy and BCT were made using Pearson’s chi-square test unless otherwise specified. 
p-values listed used significance level of 0.05. 
 








Avoid Further Surgery 
Potential 
     
Mastectomy n (%) 11 (7.4) 22 (14.7) 10 (6.7) 56 (37.6) 50 (33.6) 
Length of Radiation 
Therapy 
     
Mastectomy n (%) 32 (21.3) 50 (33.3) 34 (22.7) 15 (10.0) 19 (12.7) 
Avoiding Radiation 
Therapy 
     
Mastectomy n (%) 24 (16.0) 44 (29.3) 27 (18.0) 27 (18.0) 28 (18.7) 
Lodging For Radiation 
Therapy 
     
Mastectomy n (%) 58 (38.9) 54 (36.2) 21 (14.1) 11 (7.4) 5 (3.4) 
Wanting Prophylactic 
Mastectomy 
     
Mastectomy n (%) 22 (14.9) 34 (23.0) 42 (28.4) 29 (19.6) 21 (14.1) 
Note: denominators may vary depending on response rate. 
Comparison between mastectomy and BCT were made using Pearson’s chi-square test unless otherwise specified. 
p-values listed used significance level of 0.05. 
 








Recovery Time For 
Mastectomy 
     
BCT n (%) 20 (16.1) 54 (43.6) 27 (21.8) 15 (12.1) 8 (6.5) 
Feeling Mastectomy Too 
Radical / Extreme 
     
BCT n (%) 13 (10.3) 28 (22.2) 21 (16.7) 37 (29.4) 27 (21.4) 
Note: denominators may vary depending on response rate. 
Comparison between mastectomy and BCT were made using Pearson’s chi-square test unless otherwise specified. 
p-values listed used significance level of 0.05. 
 










Table N4: Correlation Coefficients of Mastectomy Responses for Individual Belief Factors 
 
 




Participants were also asked if the alternative treatment option was discussed with 
them (Table N7). There was no significant difference in self-reported discussion between 
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mastectomy and BCT groups, 67% and 71% respectively. However, when separated by 
treatment type and city of surgery, women undergoing mastectomy in Regina were less 
likely to have self-reported discussion of BCT as a possible treatment option, 52% 
compared with 75% in Saskatoon and 91% in smaller surgical centers.  
Table N7: Discussion of other treatment options and distribution by city 
 Yes n (%) No n (%) Do Not 
Remember n (%) 
p-value 
Discussion of Other Treatment 
Option 
   0.31 
Mastectomy (n = 150) 100 (66.7) 39 (26.0) 11 (7.33)  
BCT (n = 126) 89 (70.6) 33 (26.2) 4 (3.2)  
City of Surgery (Mastectomy)    <0.01 
Saskatoon (n = 79) 59 (74.7) 15 (19.0) 5 (6.3)  
Regina (n = 60) 31 (51.7) 24 (40.0) 5 (8.3)  
Other (n = 11) 10 (90.9) 0 (0.0) 1 (9.1)  
City of Surgery (BCT)    0.26 
Saskatoon (n = 79) 47 (75.8) 13 (21.0) 2 (3.2)  
Regina (n = 79) 35 (71.4) 13 (26.5) 1 (2.0)  
Other (n = 79) 7 (46.7) 7 (46.7) 1 (6.7)  
Comparison between mastectomy and BCT were made using Pearson’s chi-square test. 
p-values listed used significance level of 0.05. 
 
